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Summary
Each year close to 9 million cases of tuberculosis (TB) are caused by bacteria of the My-
cobacterium tuberculosis complex (MTBC). The genetic and phenotypic diversity of the
pathogen has been underestimated for a long time. Recently, large-scale whole genome
sequencing (WGS) became available and has revealed thousands of single nucleotide poly-
morphisms (SNPs). In contrast to other molecular markers, these SNPs can be used to
construct robust phylogenies and to characterize the population structure of MTBC. WGS
also shows great promise as the new method of choice for molecular epidemiology of TB.
WGS has a higher discriminatory power than classical genotyping methods, and addition-
ally allows for the studying of MTBC micro-evolution during chains of TB transmission.
However, for both research and clinical applications, the costs of WGS are still high
and the analytical challenges numerous. Routine application of WGS to large collections
of MTBC isolates is not yet feasible. Particularly in settings where the burden of TB is
highest, the capacities to generate and analyse WGS data are limited. Hence, innovative
approaches are needed to identify the subset of MTBC isolates for which WGS brings the
highest level of added value. Due to the strictly clonal nature of the MTBC, we can often
use single mutations (i.e. SNPs) to identify isolates of a specific genotype.
In this thesis, we first aimed at developing new, cost-effective strategies for MTBC
strain classification based on SNP-typing. We then aimed at applying a combination
of SNP-screening and targeted WGS to study the transmission and micro-evolution of
MTBC in a local TB outbreak during 20 years. Third, we aimed at using a similar combi-
nation of SNP-typing and WGS to infer the global evolutionary scenario of one particular
lineage of MTBC, Lineage 4, during historical times.
The first three chapters of this thesis introduce the current knowledge in MTBC research
and the objectives of this thesis, and the following four chapters represent primary research
work.
In Chapter 1, the global burden of TB, the species concept, the genetic diversity and
the genotyping methods of MTBC are introduced. Chapter 2 lists the objectives of this
thesis. In Chapter 3, we reviewed the nature and consequences of SNPs in MTBC and the
iv
SNP-discovery by WGS. Also, we discuss the potential of SNPs to serve as phylogenetic
markers and the use of SNPs for the detection of antibiotic resistance.
In Chapter 4, we developed two new SNP-typing assays for cost-effective classification of
clinical MTBC isolates into the main phylogenetic lineages. These assays provide a solid
basis to study phenotypical and clinically relevant differences between MTBC lineages.
In Chapter 5, a new, user-friendly tool for in silico SNP-genotyping in MTBC is de-
scribed. We developed the open-source software KvarQ to scan raw WGS reads in fastq-
format. Drug resistance, phylogenetic, or any other allelic information can be obtained
in a matter of minutes. Using a large set of 880 bacterial genome sequences, we showed
the high accuracy of the software.
In Chapter 6, we aimed at resolving the dynamics of a TB outbreak in the Canton of
Bern, Switzerland. This outbreak was caused by an MTBC strain initially described in
1993, and that is still circulating today. Using WGS data generated from three historical
“Bernese outbreak” isolates, we developed a strain-specific SNP-genotyping assay to screen
1642 isolates from between 1991 and 2011. We identified 68 patients with the same MTBC
strain. The majority of patients were from a social “milieu” of homeless and substance
abusers. We then applied WGS to all isolates of the “Bernese outbreak” and resolved
transmission events to the single patient level. Simultaneously, we also revealed the limits
of WGS.
In Chapter 7 we zoomed out of the micro-evolutionary level and looked at the macro-
evolutionary level. We used a combination of SNP-typing and WGS to track the global
dispersal of the “Euro-American” lineage of MTBC (Lineage 4). Using WGS data of
72 MTBC isolates, we defined 10 Lineage 4 sublineages. We screened more than 3,000
clinical isolates with sublineage-specific markers and mapped sublineage proportions to
countries. Five sublineages were restricted to specific geographical areas, indicating a
clonal expansion outside of Europe. Three sublineages were observed frequently among
patient isolates born in Europe and were also found globally distributed. Focusing on one
of the “global” sublineages, the “Latin-American Mediterranean” strain family, we found
evidence that the hypothetical origin of the “LAM” sublineage was in Europe.
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1. Introduction
Tuberculosis is driven by interacting environmental, host and pathogen factors (Comas
et al., 2009a). This thesis is focused on understanding the pathogen, members of the
Mycobacterium tuberculosis complex (MTBC). The origin, the species concept and the
diversity of the pathogen are presented in this introductory chapter. First, however, the
importance of the disease and the global burden of TB are introduced.
1.1. The global burden of tuberculosis
The World Health Organization (WHO) estimated that there were 8.6 million cases and
1.3 million deaths caused by tuberculosis (TB) in 2012, making TB (together with HIV
and malaria) one of the top three global killers among infectious diseases (WHO, 2013).
For a long time dangerously neglected, TB came into the focus of the WHO in the
beginning of the 1990s, when it was recognized as a re-emerging disease (Dye et al.,
2010). Since 1990, TB mortality has dropped by 45% thanks to the renewed efforts in TB
control and research. After peaking between 2000 and 2005, the global TB incidence rate
has now also started to slowly decrease (WHO, 2013). However, in at least five of the 22
high-burden countries that carry 80% of the TB burden (WHO, 2013), the incidence is
not decreasing. In South Africa, as a particular case, the incidence rate has more than
doubled in the last 15 years, and South Africa has now, together with Swaziland, the
highest yearly incidence in the world with over 1,000 new cases per 100,000 population
(WHO, 2013). Indeed, a large number of the countries with the highest incidence rates
are in sub-Saharan Africa (Figure 1.1).
The largest absolute numbers of TB cases occur in Asian countries, with India and
China together carrying more than a third of the global burden (2.2 million and 1 million
cases, respectively, in 2012) (WHO, 2013). The Central Asian region also has the highest
number of drug-resistant TB cases, with more than 18% of new TB cases and 50% of
previously treated TB cases having multi-drug resistant TB (MDR-TB) in some countries.
The Central Asian region is followed by Eastern Europe with between 10% and 20% MDR-
TB cases among new cases.
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TB is a poverty disease, reflected in the large majority of cases in developing coun-
tries and in the poor population of newly industrialized countries (Figure 1.1). Although
in high-income countries, particularly in Northern America, Europe and Australia / New
Zealand, the incidence and mortality of TB could be massively reduced in the last decades,
elimination of the disease is in no reach, and likewise, no country has ever eliminated
TB (WHO, 2013). In Europe, the remaining cases are mainly found in immigrants (in
Switzerland as an example, approximately 75% of cases) and in populations of home-
less, drug addicts and alcoholics, who share some of the strongest risk factors for TB.
These include bad living and housing conditions, malnutrition, smoking and often HIV
co-infection (Palomino et al., 2007).
In 1999, WHO has estimated that nearly one third of the world population is latently
infected with bacteria of the MTBC (Figure 1.2) (Dye C et al., 1999). This population
represents a huge reservoir for the disease, and around 5-10% of these persons will progress
to active disease at any point in their life (Barry et al., 2009). However, the risk of
progressing to active TB, the infectious form of the disease, depends on host factors, which
have been well established and include immunological factors (e.g. immunosuppression),
co-infections (e.g. HIV, diabetes), physical condition and other factors (Barry et al., 2009).
The role of the causative agent of the disease, MTBC, is less well understood. In
particular, the diversity of the pathogen has been underestimated for a long time (Her-
shberg et al., 2008). In the last two decades, molecular methods have revealed genetic
diversity within the MTBC, phenotypic differences between MTBC strains, and the role
of co-evolution with humans (Gagneux, 2012). In the next sections, the origin of the
pathogen, the genetic and phenotypic diversity and the genotyping methods of MTBC
are introduced.
1.2. TB is an ancient disease
Tuberculosis has co-evolved with humans for thousands of years (Donoghue, 2011). Ev-
idence for TB being an ancient disease includes morphological changes associated with
TB in skeletal remains, molecular data from ancient DNA, and phylogenetic data from
contemporary isolates.
In 2005, Gutierrez et al. (2005) proposed that a progenitor species, ancestral to today’s
MTBC, could have caused a form of TB as early as 3 million years ago. The oldest mor-
phological indications of TB were found in a 500,000 year old remains of Homo erectus
in Turkey (Kappelman et al., 2008), but are controversially discussed. Later indications
date back to Neolithic times (Donoghue, 2011). Molecular studies using ancient DNA
3Estimated new TB 
cases (all forms) per 
100 000 population 
per year
0–9.9
10–19
20–49
50–124
125–299
300–499
≥500
No data
Not applicable
Figure 1.1.: TB incidence rates per country in 2012 as estimated by WHO. Figure from WHO
(2013).
Figure 1.2.: The global burden of TB as estimated by WHO (Dye C et al., 1999). Each section
of the triangle is roughly in scale. Figure from Rustad et al. (2009).
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(aDNA) were then able to demonstrate the presence of MTBC DNA in bones of mum-
mified humans, and even to uncover the MTBC genotypes of the historic MTBC strains
(Donoghue, 2009). Hershkovitz et al. (2008) found DNA in bodies of a woman and an
infant in the region of today’s Haifa (Israel), dating to 9250 to 8150 BP, for which spolig-
otyping revealed a pattern consistent with contemporary Lineage 4, the “Euro-American”
lineage (see below) (Hershkovitz et al., 2008). Zink et al. (2003) investigated Egyptian
mummies from 2500 to 500 BC, and found spoligotypes also consistent with contemporary
Lineage 4. Ancient DNA was also isolated from several locations in Europe, reflecting
the large burden of TB during the last centuries. This is discussed later in this thesis
(Chapter 7). Recently, the first whole genome sequences of historic isolates were reported
(Bouwman et al., 2012; Chan et al., 2013).
The question as to which genotypes of Mycobacteria caused TB in the pre-Columbian
times in the Americas is debated. The fact that “European” genotypes, i.e. MTBC Lin-
eage 4 strains, are pre-dominant from North to South America indicates a (recent) intro-
duction from Europe. Molecular evidence, however, has indicated the presence of MTBC
DNA in much older mummified remains. The first molecular evidence of MTBC in the
Americas was found in a mummified Bison from 17,870 BP inWyoming. The spoligotyping
pattern however, was inconclusive and only allowed the exclusion of M. bovis (Rothschild
et al., 2001). Salo et al. (1994) and Arriaza et al. (1995) had identified MTBC DNA in
mummies before, from 1000-1300 AD in Peru and from 1000 AD in Chile, but did not
report genotypic data.
The evolutionary age calculated with molecular data is the subject of ongoing dis-
cussions. For a long time, it was thought that during the Neolithic Revolution (10,000
years BP), human TB emerged as a zoonosis with the advent of domestication of animals
(Daniel, 2006). But using population genetic methods, Wirth et al. (2008) and Comas
et al. (2013) suggested an origin of the MTBC as early as 40,000 years and 70,000 years
ago, respectively. Pepperell et al. (2013) recently estimated a much higher evolutionary
mutation rate, and less than 5,000 years for the origin of the MTBC. The divergence
might result from different calibration points to estimate mutation rates.
Despite the increasing knowledge about the origin of the MTBC and the proposed
“out-of-and-back-to-Africa” scenario (see also below) (Hershberg et al., 2008), no studies
have used robust genomic data to address the question as to how the “modern” MTBC
Lineage 4 evolved to be globally dispersed. This will be discussed in Chapter 7.
51.3. Current genetic diversity in the MTBC
Tuberculosis is today caused by closely related members of the MTBC. The MTBC rep-
resents a group of species or ecotypes (Smith et al., 2006) within the genus of Mycobac-
terium (Figure 1.3) (Brosch et al., 2002; Achtman, 2008). M. tuberculosis sensu stricto
(s.s.) and M. africanum are responsible for the large majority of human TB cases. The
MTBC further includes the animal-associated pathogens M. bovis (infecting and causing
disease mainly in cows), M. caprae (goats), M. microti (voles) and M. pinnipedii (seals)
(Palomino et al., 2007) (Figure 1.5). On a side note, M. bovis was an important cause of
TB in humans before the introduction of milk pasteurization, but the cases have since de-
creased to low numbers, in particular where bovine TB incidence is low or pasteurization
is standard (Müller et al., 2013). Additional members of the MTBC include the “dassie
bacillus” (Mostowy et al., 2004), M. mungi (infecting mongoose) (Alexander et al., 2010),
M. orygis (antelopes) (Gey van Pittius et al., 2012) and the chimp bacillus (Coscolla
et al., 2013), all of which have only been described anecdotally. The “smooth tubercle
bacteria”, including M. canettii, are traditionally also considered part of the MTBC and
cause sporadic cases of TB, but are only isolated from patients from the Horn of Africa
(or with a connection to the Horn of Africa). These microbes are much more diverse than
the other members of the MTBC, have a larger genome size, and show a clear evidence of
ongoing horizontal gene exchange (Supply et al., 2013). The categories and species names
within the MTBC were originally assigned based on biochemical characteristics (Collins
et al., 1982). The differentiation between M. bovis and M. tuberculosis was mainly based
on the presence of nitrate reductase and the production of niacin. The identification of M.
africanum based on the chemical tests is ambiguous, but colony morphology resembles M.
bovis (Jong et al., 2010). Brosch et al. (2002) then provided a comprehensive classification
scheme based on large sequence polymorphism.
Until the 1990s, MTBC was considered as genetically uniform. First genotyping meth-
ods, including IS6110-RFLP (see below) and spoligotyping (Kamerbeek et al., 1997)
revealed major global families (Embden et al., 1993; Brudey et al., 2006; Demay et al.,
2012) (methods see below). However, these genotyping methods based on repetitive or
mobile elements (rather than DNA sequencing data) both had limitations for evolutionary
inference (Comas et al., 2009b). Sequencing of the genes katG and gyrA identified “prin-
cipal genetic groups” with two polymorphisms (Sreevatsan et al., 1997). Only multi-locus
sequence typing (MLST) (Maiden et al., 1998), i.e. the sequencing of a small number
of housekeeping genes (traditionally by Sanger sequencing) revealed robust lineages (115
polymorphic positions in seven genes) (Baker et al., 2004), but could not resolve all
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phylogenetic lineages known today. The first complete genome sequence (H37Rv) (Cole
et al., 1998) and three additional genome sequences enabled various SNP-typing stud-
ies (Gutacker et al., 2002; Filliol et al., 2006; Gutacker et al., 2006) and allowed robust
groupings (further discussed in Chapter 3). Gagneux et al. (2006b) used microarrays to
identify main phylogenetic lineages based on large deletions, and showed an association
of these lineages with human populations. Hershberg et al. (2008) found 488 SNP by
sequencing 1.5% of the 4.4 Mb genome in 108 MTBC strains, and not only confirmed the
phylogenetic lineages, but in particular discovered a strikingly reduced purifying selection
and likely a large part of polymorphisms having functional consequences (Hershberg et
al., 2008). The data was also consistent with an “out-of-and-back-to-Africa” evolutionary
scenario of the MTBC. Wirth et al. (2008) proposed a similar grouping of strains and
a congruent evolutionary scenario using MIRU-VNTR, and dated the age of the MTBC
to around 40,000 years. Population genomic analyses using whole genome sequences (see
below) proposed 70,000 years for the origin of the MTBC, and found a striking congruence
of co-evolution between humans and the MTBC (Comas et al., 2013). The seven main
phylogenetic lineages (Figure 1.4) are being confirmed repeatedly (Casali et al., 2014;
Farhat et al., 2013). However, a confusing of genetic groupings within these lineages and
a number of not necessarily overlapping definitions is complicating the situation. A com-
prehensive nomenclature, including main phylogenetic lineages and (what we refer to as)
“sublineages” is now needed, which ideally should be based on whole genome data.
“Zooming” to the tips of the phylogeny, i.e. MTBC genotypes isolated from individ-
ual patients, WGS has also reaveled new diversity. Recent studies have applied WGS to
MTBC isolates in transmission chains that were indistinguishable by classical genotyping
methods (IS6110-RFLP, MIRU-VNTR, spoligotyping) (Schürch et al., 2010; Gardy et al.,
2011; Walker et al., 2013b; Roetzer et al., 2013; Bryant et al., 2013b; Walker et al., 2014).
SNP-analyses showed that a considerable number of SNPs are found between isolates
from different patients, and even within patients. These aspects are further discussed
below and in Chapter 6. First, however, the different genotyping methods for MTBC are
introduced in chronological order.
1.4. Genotyping and molecular markers of MTBC
Strain classification and nomenclature within the MTBC has a long history (Schürch et al.,
2012). After the discovery of the aetiological agent in 1882 (Koch, 1932), the bacterium
7Figure 1.3.: Phylogeny of the genus Mycobacterium using 16S rRNA sequences. Unrooted
neighbor-joining tree using 1,325 nucleotides. The blue triangle corresponds to Mycobac-
terium tuberculosis and the smooth tubercle bacilli, which are identical or differing by only
one single nucleotide. Figure from Gutierrez et al. (2005).
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Figure 1.5.: Proposed evolutionary pathway of the tubercle bacilli using Regions of Difference
(RD). Figure from Brosch et al. (2002).
was named M. tuberculosis (Lehmann et al., 1896), but it was not until 1976 that the
“TB complex” was defined (Tsukamura, 1976). At this time, M. bovis and M. africanum
were recognized as closely related species (Castets et al., 1969; Collins et al., 1982). The
three species could be differentiated by biochemical tests (Collins et al., 1982). Some of
these tests are still performed today, but have limitations (Jong et al., 2010). With the
availability of DNA- and especially PCR-based methods, genotyping became the new gold
standard for species and strain differentiation.
1.4.1. IS6110 RFLP
The first genotyping method to be used was a restriction fragment length polymorphism
(RFLP) method based on insertion sequence IS6110 (Embden et al., 1993). RFLP has
routinely been used in molecular epidemiology of TB to identify outbreaks and chains of
transmission (Small et al., 1994). IS6110-RFLP has a high discriminatory power, but is
labour-intensive, time consuming and needs a lot of high-quality DNA. The results are
difficult to compare between laboratories (Comas et al., 2009b). Nevertheless, IS6110-
RFLP paved the way for large epidemiologic and phylogenetic studies and revolutionized
the understanding of the transmission of the disease. Chains of transmission were identi-
fied (same IS6110-RFLP pattern), re-infection could be discriminated from relapse, and
contaminations could be detected (Barnes et al., 2003; Genewein et al., 1993). On the
9other hand, IS6110-RFLP was not ideally suited for strain classification, and also lacked
a format to be easily exchanged between laboratories.
1.4.2. Spoligotyping
Kamerbeek et al. then developed a CRISPR-based (Clustered Regularly Interspaced
Short Palindromic Repeats) method and named it “spoligotyping” (Kamerbeek et al.,
1997). Spoligotyping takes advantage of the Direct Repeat (DR) locus of the MTBC
genome, a region consisting of identical 36 bp direct repeats, interspersed with unique
35-41 bp spacer sequences. The latter are amplified and visualized on a membrane, which
allows testing for the presence or absence of each of the spacers (usually, a set of 43
spacers is used). Strains have different patterns of absence and presence of these spacers,
and common patterns among clades can be found. However, this method has limited
value for constructing phylogenies, as convergent evolution among strains from different
lineages can occur. Low statistical support for phylogenetic groupings is usually obtained,
and not all lineages can be detected that are found with other methods (Comas et al.,
2009b). Nevertheless, spoligotyping has been an invaluable tool for the TB research
community to identify genotyping families and phylogeographical distributions, and also
paved the way for the next generation of molecular markers. Thanks to its ease of use and
high portability, spoligotyping is still used extensively in many laboratories. The largest
database of MTBC genotyping data is based on spoligotyping (SITVITWEB, formerly
SpolDB4) (Demay et al., 2012), and tools to extract spoligotyping patterns from WGS
data have been developed (Coll et al., 2012) (and Chapter 5).
1.4.3. MIRU-VNTR
The first complete whole genome sequence, generated in 1998 with Sanger-sequencing
(Cole et al., 1998), allowed the development of whole genome-based methods. Mycobac-
terial Interspersed Repetitive Units (MIRU) - Multiple Loci Variable Number of Tandem
Repeats (VNTR) Analysis (MLVA) is today’s accepted gold standard for molecular epi-
demiology of TB (Supply et al., 2006). MIRUs are tandemly repeated DNA elements
which are dispersed in inter- and intragenic regions of the genome. The number of tan-
dem repeats per locus varies from strain to strain, and can be presented in a numeric
way (as number of copies per locus). MIRU-VNTR can be automatized with capillary
electrophoresis, but is still labour-intensive due to a high number of individual PCRs
required. A database was introduced for MIRU-VNTR, known as MIRU-VNTRplus, to
globally compare among samples (Allix-Béguec et al., 2008; Weniger et al., 2010; Weniger
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et al., 2012). In addition to epidemiological applications, MIRU-VNTR data have been
used for the definition of MTBC clades and for the dating of the MTBC phylogeny (Wirth
et al., 2008).
1.4.4. Large Sequence Polymorphisms (LSP)
Due to the limitations of spoligotyping and MIRU-VNTR, robust alternatives were needed
as markers for phylogenetic applications. Large sequence polymorphisms (LSP) and single
nucleotide polymorphisms (SNPs) were proposed as robust phylogenetic markers. LSPs in
form of deletions in mycobacteria represent unidirectional events, i.e. they are irreversible,
as ongoing horizontal gene transfer does not occur in MTBC (Gagneux et al., 2006b).
One of the first deletion analyses was performed on different strains of the vaccine strain
BCG (Behr, 2001). Hirsh et al. (2004) identified 68 genomic regions that were present
in H37Rv but absent in other strains. Gagneux et al. (2006b) later identified six main
lineages of MTBC based on LSPs, also known as regions of difference (RD). Tsolaki et al.
(2004) and Gagneux et al. (2006a) have used these robust markers to assess phenotypic
differences between genotypes. In the study by Gagneux et al. (2006b), each MTBC
lineage was associated with specific, sympatric human populations, i.e. humans from a
certain geographic region were more likely to be infected with a strain phylogeographically
associated with this region. RD deletions have also unravelled the evolutionary scenario
of the animal-associated species or ecotypes of MTBC (Figure 1.5, Brosch et al. (2002)).
1.4.5. Single Nucleotide Polymorphisms (SNP)
The large deletions discussed above reflect unidirectional events and are therefore not
prone to homoplasy. However, they do not allow the calculation of genetic distances and
also cannot completely resolve all deep-rooting branches of the MTBC phylogeny, and
are therefore of limited phylogenetic value (Comas et al., 2009a). With the availability
of sequencing technologies, large numbers of SNPs have been discovered in MTBC and
have been questioning the notion of MTBC as a pathogen with very restricted genetic
diversity (Achtman, 2008). Because of the absence of recombination and lateral gene
transfer, SNPs are perfect phylogenetic and epidemiological markers. They are unique
events and show almost no homoplasy. The discovery of SNPs in MTBC, as well as the
SNP-genotyping past and present, are discussed in more detail in Chapter 3.
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1.4.6. Whole genome sequencing as a typing method
SNPs are nowadays discovered by sequencing the complete genome of MTBC isolates.
WGS has become increasingly available, and prices have exponentially decreased in the
last years. Barcoded DNA sequencing libraries for pooled sequencing of up to 96 isolates,
as well as new benchtop DNA sequencing devices have lead to a free fall of sequenc-
ing costs in the last decade (although slowing down recently, http://www.genome.gov/
sequencingcosts/). It can be foreseen that WGS will be implemented in daily research
and routine clinical work and replace previous genotyping methods as well as genotypic
drug resistance testing. The first researchers to use WGS to investigate a chain of trans-
mission in the Netherlands (the infamous Haarlem cluster) were Schürch et al. (2010) that
resolved three isolates indistinguishable by classical DNA fingerprinting. They found 8
polymorphic positions. The first comprehensive study using WGS for molecular epidemi-
ology was published in 2011 (Gardy et al., 2011). The authors sequenced 32 recent and
4 historical isolates of a MIRU-VNTR cluster and combined the SNP-data with social
network analysis. Two distinct lineages, a superspreader behaviour, and a correlation
with crack cocaine use were identified. In a landmark study, Walker et al. (2013b) se-
quenced 390 MTBC isolates, estimated a mutation rate of 0.5 SNPs/genome/year in
longitudinal isolates, and found usually five or fewer SNPs between epidemiologically
linked cases. A study by Bryant et al. (2013b) found a comparable mutation rate (0.3
SNPs/genome/year), but a large variability and no clear SNP-threshold for linked cases.
Roetzer et al. (2013) used WGS to decipher an outbreak of 86 patients in Germany, and
found again a similar mutation of 0.4 SNPs/genome/year and several subclusters, i.e. dis-
tinct clades in the genomic network. Ford et al. (2011) used WGS of MTBC from infected
macaques and inferred MTBC mutation rates comparable between latent infection and
active disease. Several studies have applied large-scale WGS to identify drug-resistance
associated mutations (drug resistance in TB is discussed below). Comas et al. (2011a),
Casali et al. (2012) and Casali et al. (2014) have found mutations compensating for the
fitness defect associated with rifampicin resistance. Köser et al. (2013) report the use of
WGS to rapidly identify drug resistance mutations of an XDR-TB patient.
These studies demonstrate the potential for future routine applications of WGS in re-
search and molecular epidemiology. However, large-scale applications are not yet possible
as cost and the analyses remain important hurdles (also discussed in Chapter 3). Targeted
sequencing of selected isolates, on the other hand, is feasible in many settings. Hence,
innovative solutions are needed to identify subsets of MTBC isolates for which targeted
WGS can be applied. The subsets would consist of the isolates where the benefit of
WGS is highest compared to other molecular markers. For molecular epidemiology, these
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subsets would be molecular clusters, which classical markers can not resolve due to the
lack of discriminatory power (Niemann et al., 2009) (see Chapter 6). For evolutionary
applications, genotypes of MTBC can be identified with clade-specific SNPs, and only the
uncategorised samples subjected to WGS. This approach is further elaborated in Chapter
7.
1.5. Phenotypic consequences of genetic diversity
The genetic diversity of MTBC identified in the last 20 years has also lead to increased
efforts to study phenotypic consequences of this genetic diversity. However, already in
the 1960s, studies in guinea pigs found differences in virulence between MTBC isolates
from India and from the UK (Mitchison et al., 1960). Since then, many studies have
sought associations between genotype and phenotype (Homolka et al., 2010). They were
recently reviewed by Coscolla et al. (2010). MTBC Lineage 2 strains (in particular the
“Beijing” sublineage) have repeatly been associated with increased virulence and drug
resistance (Hanekom et al., 2011). For example, Lan et al. (2003) found an association of
Beijing strains with treatment failure and disease relapse, Caws et al. (2006) found Beijing
strains associated with HIV co-infection, resistance to any drug and multi drug-resistance
in TB meningitis cases, and Hanekom et al. (2007) found one specific Beijing sublineage
more abundant than other MTBC strains in Cape Town, South Africa. Strikingly, a
higher mutation rate towards antibiotic resistance of MTBC Lineage 2 strains compared to
MTBC Lineage 4 was recently found by Ford et al. (2013). However, results are not always
congruent (Yuan et al., 2014), and might also depend on the geographical region (i.e.
the human population). Furthermore, not only lineage-specific, but also strain-specific
characteristics influence the phenotypic differences and need to be considered (Reiling
et al., 2013).
Many of these phenotypic differences have been observed between main phylogenetic
lineages (as defined by LSPs or SNP data). However, it is also increasingly appreciated
that there is diversity within these main lineages. We refer to sub-clades of the 7 main
human-associated MTBC lineages as “sublineages”. In the last years, a few studies have
looked at phenotypic differences between isolates of sublineages. In fact, the “Beijing”
clade is a sublineage of Lineage 2 (defined by RD207), and has recently been associated
with a higher pathogenicity than other Lineage 2 strains in guinea-pigs (Kato-Maeda et
al., 2012). Nahid et al. (2010) have found Lineage 4 sublineage RD724 (see also Chapter
7) associated with more severe disease of TB at baseline compared to non-RD724 strains.
Anderson et al. (2013) have compared isolates from the RD-defined sublineages of Gag-
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neux et al. (2006a) in an epidemiological study, and found one sublineage, defined by
RD183-deleted, associated with clustering and homelessness. However, the comparison of
these sublineage-definitions between studies is often difficult. Various, often incompati-
ble markers and typing schemes are used, and groupings are not always based on robust
markers. For the future analysis of genotype-phenotype associations between sublineages
(and main lineages), a classification based on WGS data is needed (see also Chapter 7).
The population structure based on robust groupings can then to be considered for the
development of new diagnostic methods and new treatment options. Specific members of
the MTBC could be naturally resistant to new antituberculosis drugs (such as M. bovis
to pyrazinamide), or genetic background mutations could lead to false-positive results in
genotypic drug resistance diagnostic assays (Köser et al., 2012a; Feuerriegel et al., 2014).
1.6. Treatment of TB and drug resistance
TB can be treated with antituberculosis drugs since the 1940s, when Streptomycin and
para-aminosalicylic acid were discovered (Schatz et al., 1944; Lehmann, 1946). Several
other drugs have become available since then (Zhang et al., 2009). Today, the standard
TB treatment regimen is defined by the WHO (WHO, 2010). It is part of the DOTS strat-
egy (Direct Observed Treatment, Short-course) that was launched in 1994. The standard
regimen for new cases of TB consists of 2 months of isoniazid, rifampicin, pyrazinamid and
ethambutol, followed by 4 months of isoniazid and rifampicin (WHO, 2010). In the case of
drug resistance, the WHO defined multidrug-resistant strains (MDR) as strains resistant
to at least the two major first line drugs, isoniazid and rifampicin. Further drugs are avail-
able for MDR-TB, categorized in five groups; 1) pyrazinamide, ethambutol and rifabutin
(as first-line oral agents); 2) kanamycin, amikacin, capreomycin and streptomycin (injecta-
bles/aminoglycosides); 3) levofloxacin, moxifloxacin and ofloxacin (fluoroquinolones); 4)
para-aminosalicylic acid, cycloserine, terizidone, ethionamide and prototionamide (oral
bacteriostatic second-line agents) 5) clofazimine, linezolid, amoxicillin/clavulanate, thiac-
etazone, imipenem/cilastatin, high-dose isoniazid and carithromycin (with unclear role).
Drug resistance to these second-line drugs can also occur. The definition of extensively
drug resistant strains (XDR) is defined as MDR plus the resistance to any fluoroquinolone
and to at least one of the injectable second-line drugs. XDR strains represent a major
concern for global TB control, but other drug resistances and combinations can occur as
well, and reports of totally drug resistant strains (TDR) have been published (Migliori
et al., 2007).
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Resistance to all the available antituberculosis drugs can occur. To a large part, re-
sistance is conferred by single nucleotide mutations in the chromosome of MTBC. No
resistance plasmids exist in MTBC and, as mentioned above, horizontal gene transfer
does not occur. Due to the clonal nature of MTBC, single SNPs can therefore be used
as resistance markers. This is discussed in the following chapter (Chapter 3). In Chapter
5, we make use of the most important drug resistance markers in the software KvarQ to
rapidly identify drug resistance patterns from WGS data. A list of the currently known
most important drug resistance mutations in MTBC is found in Table A.2 in Appendix
A.1. A public database, TBDReaMDB serves as an (unofficial) reference for known drug
resistance associated mutations (Sandgren et al., 2009).
2. Objectives and outline
2.1. Aims of this thesis
The overarching aims of this thesis were i) to develop a framework for WGS- and SNP-
based classification of MTBC isolates into main phylogenetic lineages and sublineages, ii)
to study the transmission and micro-evolution of MTBC in a local outbreak, and iii) to
infer the global evolutionary scenario of MTBC Lineage 4.
2.2. Specific objectives
The corresponding six specific objectives were:
• Objective 1. To review the knowledge about SNPs in MTBC and to identify the
needs of the community (Chapter 3).
• Objective 2. To extract MTBC lineage-specific SNPs from WGS data and to
develop two laboratory SNP-typing assays (Chapter 4).
• Objective 3. To develop a software tool for rapid in silico SNP-typing of MTBC
raw genome sequencing data (Chapter 5).
• Objective 4. To study the transmission of a specific MTBC strain in an outbreak
in Switzerland (Chapter 6).
• Objective 5. To define sublineages of MTBC Lineage 4 using WGS data and to
develop a SNP-based classification scheme for Lineage 4 sublineages (Chapter 7).
• Objective 6. To study the evolutionary trajectory of MTBC Lineage 4 on a global
scale (Chapter 7).
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2.3. Outline
In the following chapter (Chapter 3), we reviewed the current knowledge about SNPs
in MTBC. We summarized how SNPs in MTBC are identified, how they are used as
molecular markers for genotyping, and what we would need to sustainably store SNP
information in the public domain.
In Chapter 4, we developed two new laboratory SNP-typing assays to unambiguously
classify clinical isolates into the main phylogenetic lineages of MTBC.
To facilitate the analysis of WGS data, we also developed a software for in silico SNP-
typing. The new software KvarQ allows the targeted extraction of phylogenetically infor-
mative SNPs and drug resistance mutations from raw genome sequencing data. KvarQ is
described in Chapter 5.
In Chapter 6, we describe the application of combined SNP-typing and WGS to identify
a large TB outbreak in Switzerland during 21 years. We tracked the transmission with
WGS and social network analysis.
In Chapter 7, we expanded our focus to the macro-evolutionary scale. We aimed at in-
ferring the historical dispersal of MTBC Lineage 4 (previously called the “Euro-American”
lineage). To that end, we again applied a combination of SNP-typing and targeted WGS
to a collection of more than 3,000 clinical isolates to generate a phylogeographical distri-
bution. Focusing on one of the globally most frequent genotypes, the “Latin American
Mediterranean” (LAM) family, we studied the global spread with phylogenetic and pop-
ulation genomic methods.
In Chapter 8 the key findings are summarized, and general points addressed that not
were discussed in the individual chapters.
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3.1. Summary
Recent advances in DNA sequencing have lead to the discovery of thousands of single nu-
cleotide polymorphisms (SNPs) in clinical isolates of Mycobacterium tuberculosis complex
(MTBC). This genetic variation has changed our understanding of the differences and
phylogenetic relationships between strains. Many of these mutations can serve as phy-
logenetic markers for strain classification, while others cause drug resistance. Moreover,
SNPs can affect the bacterial phenotype in various ways, which may have an impact on
the outcome of tuberculosis (TB) infection and disease. Despite the importance of SNPs
for our understanding of the diversity of MTBC populations, the research community is
currently lacking a comprehensive, well-curated and user-friendly database dedicated to
SNP data. First attempts to catalogue and annotate SNPs in MTBC have been made,
but more work is needed. In this review, we discuss the biological and epidemiological
relevance of SNPs in MTBC. We then review some of the analytical challenges involved
in processing SNP data, and end with a list of features, which should be included in a
new SNP database for MTBC.
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3.2. Why are SNPs important for our understanding of
TB?
The declaration of tuberculosis (TB) as a global public health emergency in 1993 (WHO,
2011) lead to renewed efforts to study the biology of the Mycobacterium tuberculosis com-
plex (MTBC). For many years, the main research focus was on individual genes and
proteins, but the generation of the first M. tuberculosis genome sequence in 1998 (Cole
et al., 1998) opened the door for more comprehensive approaches. In particular, compar-
ative genomics studies have helped us gain a better insight into the genetic diversity and
phylogenetic relationships in MTBC (Mostowy et al., 2002; Comas et al., 2010; Brosch
et al., 2002). These studies showed that the different members of MTBC primarily asso-
ciated with human disease (i.e. M. tuberculosis sensu stricto and M. africanum) are more
genetically diverse than previously appreciated (Hershberg et al., 2008; Bentley et al.,
2012). Increasingly, various “omics” approaches in TB research are being combined into
what is generally known as Systems Biology (Comas et al., 2011b). Systems Biology tries
to understand complex biological systems by integrating data from various disciplines; in
TB for example the comprehensive data from human, animal, and computational model
systems (Breitling, 2010; Kirschner et al., 2010). There is increasing evidence that, in
addition to environmental factors and human genetics, strain variation in MTBC plays a
role in the outcome of TB infection and disease (Coscolla et al., 2010). Hence, there is a
need to better understand the global diversity of MTBC, and determine if and how this
diversity has relevance for global TB control (Gagneux et al., 2007; Comas et al., 2009a).
The advent of next-generation DNA sequencing (NGS) methods is likely to facilitate this
task, and indeed, many genome-sequencing projects of MTBC clinical isolates are cur-
rently underway (Sanger Institute, 2012a). More than 3,800 raw genome sequences of
MTBC strains have already been deposited on public sequence read archives (Figure 3.1),
and it is safe to assume that this number will continue to grow rapidly as sequencing costs
keep decreasing (Stein, 2010; Wetterstrand, 2012).
In contrast to the relative ease with which DNA sequencing data can be generated
today, extracting useful information and compiling these in a user-friendly manner is less
straightforward. In particular, thousands of genetic polymorphisms have been extracted
from whole genome sequences, but the TB research community currently lacks a cen-
tralized database, which would allow accessing and handling these data more efficiently.
Several TB-specific databases have been created over the last years, including genome
browsers, genotyping- and drug resistance databases (Sharma et al., 2011), but despite
these existing platforms, we lack a centralized and comprehensive repository for data on
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Figure 3.1.: Number of MTBC samples with raw genome sequences available in the Sequence
Read Archive of the National Center for Biotechnology Information (NCBI
SRA). Search query was “Mycobacterium tuberculosis complex” in the NCBI Biosample
database, and results were extracted from filter “Used in SRA”. Y-axis represents cumulative
numbers of entries on October 15 of each year.
strain-specific genetic variation in MTBC. Particularly, the field would benefit greatly
from a new database compiling all known single nucleotide polymorphisms (SNPs) in
MTBC. Ideally, such a database should include proper annotation of these SNPs as well
as all relevant metadata. Considering the increasing number of MTBC genomes becoming
available, the number of MTBC SNPs identified in the coming years will surely increase
by one or more orders of magnitude.
In this review, we start by summarizing the nature of SNPs in MTBC, how SNPs can
be used to define phylogenetic relationships between strains, and how they might impact
on the phenotype of particular MTBC variants. We then elaborate on how new SNP data
can be obtained with NGS technologies, and discuss some of the analytical challenges
involved. We end by advocating for a new, user-friendly SNP database for MTBC.
3.3. What are SNPs and how many do we observe?
SNPs are the most common form of genetic variation in MTBC, after insertions and dele-
tions (InDels). A total of 9,037 SNPs were discovered by sequencing 21 clinical strains
of MTBC (Comas et al., 2010). Generally, SNPs represent single nucleotide differences
between at least two DNA sequences. The term “SNP” is often used interchangeably with
“mutation”, “polymorphism“ or “substitution”. Strictly speaking, a change in a single base
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pair is generally referred to as a (point) mutation, and happens through errors during
DNA replication or as a consequence of DNA damage. Such a mutation represents a
relatively rare change from the “normal” base to a mutant form, and is most likely to be
neutral or (slightly) deleterious; beneficial mutations can of course occur, but they are
generally much less likely. Mutations that are highly deleterious will be rapidly removed
by purifying selection, whereas beneficial mutations will increase because of positive se-
lection. In addition, any mutation can increase in frequency as a consequence of random
genetic drift. When an allele reaches a certain frequency in the population, we refer to it
as a polymorphism (i.e. the co-existence at a specific locus of two or more alleles in a given
population). The threshold for defining a new variant as a “polymorphism” as opposed
to a “mutation” is arbitrary, and e.g. is set at 1% for human variants (i.e. the minority
allele has to be present at a frequency of at least 1% in a given human population for the
corresponding nucleotide position to be referred to as “polymorphic”). Below this thresh-
old frequency, this new variant would be referred to as a single nucleotide “mutation”. If
a new variant becomes fixed in a given population (i.e. 100% of the members of a given
population have the new variant), this variant will be referred to as a “substitution” rather
than a “polymorphism” (Hartl et al., 2007).
In addition to the difference between single nucleotide mutation, polymorphism, and
substitution, biologist often differentiate between “natural polymorphisms” and “adap-
tive mutations” such as those conferring drug resistance. Natural polymorphisms can be
thought of pre-existing variation which defines the overall genomic diversity of a pop-
ulation or a particular strain background, while adaptive mutations represent de novo
acquired changes driven by a particular selective force (e.g. exposure to antibiotics, fur-
ther discussed below). However, it is not always straightforward to discriminate between
these different types of mutations. For example, the intrinsic resistance of Mycobacterium
bovis to pyrazinamide is due to an amino acid change in pncA (Rv2043c) (Huard et
al., 2006). This drug resistance-conferring mutation clearly predates the introduction of
pyrazinamide and can therefore be considered a natural polymorphism. Moreover, as all
strains of the classical M. bovis clade harbour this mutation, one could also refer to this
mutation as a natural substitution when comparing all classical M. bovis to the rest of
MTBC. For the sake of simplicity, we will use the term “SNP” for the remainder of this
article when referring to any form of single nucleotide variant.
Depending on their position in the genome, SNPs can be either coding or non-coding.
With a coding density of 90-96% (Namouchi et al., 2012), most of the SNPs in MTBC are
in coding regions of the genome. Coding SNPs can be further divided into synonymous
(sSNP) and non-synonymous (nSNP) depending on whether they lead to changes in the
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corresponding amino acid sequence. While in average nSNPs are likely to have a stronger
effect on the organism’s fitness (either beneficial or deleterious), and will therefore be
under a stronger selective pressure than sSNPs, the latter are not necessarily selectively
neutral. Phenomena such as the codon bias in MTBC and the general mutational bias in
bacteria (Hershberg et al., 2010; Namouchi et al., 2012) suggest that sSNPs, too, can be
affected by natural selection. Similarly, non-coding SNPs are often considered selectively
“neutral”, but increasingly the importance of non-coding (i.e. un-translated) regions of the
bacterial genome for gene regulation is becoming evident (Arnvig et al., 2011).
SNPs are relatively rare events in MTBC. They occur approximately every 3 kb of DNA
sequence (Comas et al., 2010). Hence, there is about three times less genetic variation in
MTBC than in humans (Wheeler et al., 2008). Together with other bacterial pathogens
such as Yersinia pestis, Bacillus anthracis, Mycobacterium leprae or Salmonella enterica
serovar Typhi, MTBC has been referred to as “genetically monomorphic”, even though
MTBC harbours significantly more variation than other monomorphic bacteria (Achtman,
2008). One interesting observation is that the large majority of SNPs in MTBC occur
as singletons (variants that only occur in a single strain). No clear explanation currently
exists for this phenomenon, but a possible effect of background selection has been proposed
(Hershberg et al., 2008; Pepperell et al., 2010).
3.4. SNPs are phylogenetically informative in MTBC
The comparably low frequency of SNPs and limited ongoing horizontal gene transfer in
MTBC result in low levels of homoplasy (i.e. the independent occurrence of the same
SNP in phylogenetically unrelated strains) (Hershberg et al., 2008; Comas et al., 2010).
Hence, SNPs represent robust markers for inferring phylogenies and for strain classification
(Gagneux et al., 2007). SNPs can also be used to measure evolutionary distances between
strains, i.e. to estimate the time of divergence of strains from their genetic distance, if a
mutation rate is known (Ford et al., 2011).
The first step in generating SNP data is referred to as SNP discovery and usually
involves comparative sequencing of multiple genes or whole genomes in two or more strains
of interest. Once a set of SNPs has been identified, these can then be used to screen
additional strains using one of many available SNP-typing platforms (Kim et al., 2007;
Wang et al., 2007). Importantly, the usefulness of a given SNP-set is dependent on the
amount of effort put into the initial identification of these SNPs, in particular on the
number of strains included at the discovery stage. Poor representation of the relevant
strain diversity during the discovery process will result in a biased set of SNPs which
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can lead to erroneous phylogenetic inferences; this phenomenon is known as “phylogenetic
discovery bias” and has been discussed in detail elsewhere (Pearson et al., 2004; Alland
et al., 2003; Achtman, 2008; Smith et al., 2009).
In 1997, Sreevatsan and colleagues sequenced 26 drug resistance-associated genes in 842
clinical isolates and identified two nSNPs which were unrelated to drug resistance (Sree-
vatsan et al., 1997). Based on these two SNPs, a classification scheme into three Principle
Genetic Groups was developed, which has been widely used in the past. The whole
genome sequence of H37Rv published in 1998 (Cole et al., 1998) established a first refer-
ence against which other genomes could be compared. In 2002, CDC1551 was sequenced
(Fleischmann et al., 2002) allowing for a first insight into the genome-wide SNP-diversity
in M. tuberculosis; 1,075 SNP differences were found between the two strains. The whole
genome sequence of Mycobacterium bovis AF2122/97 (Garnier et al., 2003) and the par-
tial genome of the “Beijing” strain 210 became available shortly thereafter, generating an
increased collection of SNPs for genotyping purposes. Two studies took advantage of the
availability of these four genome sequences and indentified phylogenetically informative
SNPs to genotype large strain collections and identify phylogenetic groups within MTBC.
However, as outlined above, both of these studies suffered from a phylogenetic discovery
bias due to the low number of genomes used for SNP discovery. Hence, the resulting
phylogenies presented by these groups were similarly affected by this problem (Achtman,
2008; Smith et al., 2009). By contrast, three other studies used de novo sequencing of
six genes (Baker et al., 2004), 56 genes (Dos Vultos et al., 2008) and 89 genes (Hershberg
et al., 2008), respectively, in large strain collections and produced unbiased phylogenies
which were more congruent with those inferred using other methods, i.e. genomic dele-
tions (Gagneux et al., 2006b). However, even the phylogeny by Hershberg et al. based
on 89 whole gene sequences was unable to completely resolve all the branches within the
tree. In 2010, Comas et al. published the first whole-genome based global phylogeny of
human-associated MTBC (Comas et al., 2010). As expected given MTBC’s largely clonal
population structure, this genome-based phylogeny was highly congruent with those pub-
lished previously, but all main lineages were now clearly resolved (Figure 3.2). This
phylogeny has since then been used as a reference for phylogenetic studies including an
increasing number of MTBC strains (Bentley et al., 2012; Firdessa et al., 2013).
The growing number of individual gene sequences and whole genomes in MTBC has
already resulted in the identification of thousands of SNPs, which in recent years have
been incorporated into various SNP-typing schemes. Because MTBC is largely clonal, for
each of the main lineages “diagnostic” or “canonical” SNPs can be extracted and used as
markers to assign unknown isolates to a particular phylogenetic group or lineage. Various
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Figure 3.2.: Phylogenetic tree of 22 whole genome sequences of MTBC and M. canettii used
as the outgroup. Modified from (Stucki et al., 2012; Bentley et al., 2012).
SNP-typing assays have been developed on different platforms (Sreevatsan et al., 1997;
Baker et al., 2004; Filliol et al., 2006; Gutacker et al., 2006; Bergval et al., 2008; Abadia
et al., 2010; Bouakaze et al., 2010; Bouakaze et al., 2011; Bergval et al., 2012; Stucki et al.,
2012), and the latest assays can interrogate multiple SNPs simultaneously in one reaction.
Examples include assays designed for the MassArray and the Luminex platform (Bouakaze
et al., 2011; Stucki et al., 2012; Bergval et al., 2012). These methods provide the robust
phylogenetic framework necessary for genotype-phenotype- and other association studies
(Comas et al., 2009a). For example, there is increasing evidence for phenotypic differences
between strains, and studies need to be conducted to assess if these differences are due to
genetic differences between MTBC clades (Coscolla et al., 2010).
Even though a lot of progress has been made in our understanding of the global phy-
logenetic diversity of MTBC, much remains unknown with respect to both human- and
animal-associated MTBC diversity (Gagneux, 2012). For example, in addition to the six
main human-associated MTBC lineages, a seventh lineage was recently discovered in TB
patients from Ethiopia (Firdessa et al., 2013). Similarly, new animal-associated lineages
have been identified in several African mammal species, indicating that more MTBC di-
versity exists (Mostowy et al., 2004; Alexander et al., 2010). Moreover, in addition to
focusing on differences between the main lineages of MTBC, we also need to look deeper
into the diversity within individual lineages. For example, the Beijing family of strains is
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a sublineage of Lineage 2 (Figure 3.2) and is currently a strong focus of research because
of its association with drug resistance (Borrell et al., 2009), hypervirulence in animal
models (Caws et al., 2006; Parwati et al., 2010), and recent expansion in human popula-
tions (Cowley et al., 2008; Spuy et al., 2009). Moreover, even though phenotypic diversity
has been associated with the different MTBC lineages (e.g. in the elicited innate immune
responses), individual strains within these lineages exhibit a wide range of phenotypes
(Portevin et al., 2011), suggesting that in addition to strain-specific effects, sub-lineage
structure should also be considered (Schürch et al., 2011; Wada et al., 2012). Only with a
full understanding of the nature and phenotypic consequence of MTBC diversity will we
be able to properly evaluate new diagnostics, vaccines and treatment options (Gagneux
et al., 2007).
To achieve a more comprehensive view of the global diversity of MTBC, we propose
an iterative process, in which, first, genome sequencing of the most diverse strains is
performed to identify new phylogenetically informative SNPs. These SNPs are then used
to genotype large collections of strains, whereby some strains will be classified into known
lineages and others identified as novel. Genome sequencing of these unclassified strains
will then define their phylogenetic positions, identify new lineages and corresponding
signature SNPs, which can be used in a following round of genotyping.
In the future, genome sequencing is likely to replace any sort of genotyping in MTBC,
including SNP-typing. While SNP-typing is an ideal tool for phylogenetic strain clas-
sification in MTBC, it does not have the necessary resolution for standard molecular
epidemiological investigation such as defining chains of transmission or differentiating
cases of relapse from re-infection; MIRU-VNTR in combination with spoligotyping is
still the gold standard for these applications (Supply et al., 2006). Genome sequencing,
on the other hand, generates a complete “barcode” of a strain, including the evolutionary
background, drug resistance mutations or virulence-associated polymorphisms, and at the
same time provides high resolution for transmission studies (Schürch et al., 2010; Gardy
et al., 2011). Yet, until large-scale genome-sequencing becomes more readily available in
standard laboratories, SNP-typing in MTBC will continue to play an important role in
TB research and control.
3.5. The functional consequences of SNPs
In addition to being useful phylogenetic markers, SNPs carry functional information. The
best-characterized “SNPs”‘ in MTBC are drug resistance-conferring mutations. Drug re-
sistance in MTBC is largely caused by single nucleotide mutations (Musser, 1995; Telenti,
27
1997; Ramaswamy et al., 1998; Riska et al., 2000). Many drug resistance-conferring mu-
tations have been identified, and are publicly available in the TBDReamDB database
(Sandgren et al., 2009) (currently containing information on 1447 mutations relevant for
most anti-TB drugs (Table 3.1). This kind of molecular information is crucial for the de-
velopment of new and faster diagnostic methods to detect drug resistance. While for the
first-line anti-TB drugs, the most important drug resistance-conferring mutations have
been identified and incorporated into promising new diagnostic tools (Hillemann et al.,
2005; Boehme et al., 2010; Hain Lifescience - Mycobacteria 2012), many mutations re-
main unknown, including many of those causing resistance to the 2nd-line drugs. Besides
the mutations causing drug resistance, other associated mutations could also be targeted
in the future. For example, two recent studies have shown that compensatory mutations
in the RNA polymerase of MTBC can contribute to the fitness of rifampicin-resistant
strains (Comas et al., 2011a; Casali et al., 2012). While the molecular mechanisms in-
volved remain to be determined, other mutations associated with drug resistance (e.g.
compensatory mutations) could be used for molecular diagnostics even if they are not
directly responsible for the drug resistance phenotype.
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Although drug resistance-conferring mutations are most important as far as TB control
is concerned, most SNPs in MTBC are unrelated to drug resistance. Indeed, thousands of
SNPs have already been identified across MTBC strains and lineages. Many of these might
translate into cellular and/or clinically relevant phenotypic changes. This is particularly
true given the fact that up to two thirds of SNPs in MTBC are non-synonymous, which
is unlike most other organisms in which sSNPs predominate (Hershberg et al., 2008).
The reason for the high proportion of nSNPs in MTBC is unclear but has been proposed
to be the consequence of the relatively short evolutionary age of MTBC (i.e. purifying
selection has not had time to remove nSNPs which on average are slightly deleterious)
(Rocha et al., 2006). Alternatively, it might reflect a reduction in the efficacy of purifying
selection as a consequence of increased genetic drift in MTBC (Hershberg et al., 2008).
While intragenic and sSNPs are not necessarily neutral (e.g. they can affect regulatory
regions), the effect of nSNPs is likely to be more pronounced. Yet, in contrast to drug
resistance-conferring mutations, the effects of these nSNPs are less evident and likely to
be more subtle, rendering the study of the biological and epidemiological consequences of
these SNPs difficult.
One possible way forward is to use in silico predictions of the effects of SNPs. There are
a number of freely available tools that can be used for this purpose. A prominent example
is Sorting Intolerant From Tolerant (SIFT), a tool that, based on sequence homology and
amino acid properties, predicts how much a given polymorphism might affect the function
of the corresponding protein (Kumar et al., 2009). Other tools include ANNOVAR (Wang
et al., 2010) and SVA (http://www.svaproject.org). In MTBC, such an approach has
recently been used to look at variation in mammalian cell entry (mce) operons (Pasricha
et al., 2011). Ultimately however, polymorphisms predicted to effect protein function will
have to be experimentally confirmed using other tools (Lamrabet et al., 2012).
Adding another level of complexity, which so far has been largely ignored, are the possi-
ble epistatic interactions between SNPs in the same genome. A good example of this phe-
nomenon are compensatory mutations that interact with corresponding drug resistance-
conferring mutations (Comas et al., 2011a; Casali et al., 2012). Similar effects might be
occurring among other mutations (Borrell et al., 2011). Hence, the phenotypic character-
istics of a given strain genetic background will depend on both the individual mutations as
well as on the interactions between these mutations. Another important characteristic of
MTBC is the fact that horizontal gene exchange is comparably rare and as a consequence,
MTBC exhibits a largely clonal population structure (Supply et al., 2003; Liu et al., 2006;
Hirsh et al., 2004). Hence, all SNPs in a particular strain’s genome are linked (i.e. they
are in linkage disequilibrium), which makes attributing the phenotypic behaviour of a
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given strain to a particular mutation non-trivial.
In summary, thousands of SNPs are being identified in MTBC thanks to the new DNA
sequencing technologies. We can use these SNPs for phylogenetic and population genetic
analyses and to study drug resistance. As for the large majority of SNPs, we do not
know what their functional impact might be (partially also because we do not know
the functions of the relevant genes). The functional consequences of these SNPs, and
their potential for driving phenotypic differences between strains should be studied in the
future. In the meantime, most ongoing SNP work in MTBC largely consists of discovering
and cataloguing new SNPs. Let us now discuss some of the technicalities involved in these
processes.
3.6. How do we discover new SNPs in MTBC?
In the upcoming years, we expect whole genome sequencing to at least partially replace all
previous genotyping methods for MTBC. So far, large-scale DNA sequencing projects have
usually been performed by specialized Sequencing Centres, but new benchtop sequenc-
ing devices increasingly allow for “do-it-yourself” approaches in the standard laboratory
(Köser et al., 2012b). In this section, we elaborate on some of the technical aspects of
NGS genome analysis, with a particular focus on the workflow during the bioinformat-
ics analysis. The DNA sequencing technologies themselves have been covered by several
recent reviews (Ansorge, 2009; Metzker, 2010; Lee et al., 2012).
Panel A of Figure 3.3 shows one possible data analysis pipeline for Illumina short read
data, as currently used in our laboratory (Comas et al., 2010; Comas et al., 2011a).
Starting with a fastq file with millions of short sequence reads (50-200 bp in length),
different software tools are used to align each read to a reference genome and to call
variant positions (Maq 2012; Li et al., 2009; Sanger Institute, 2012b; Samtools 2012). As
a reference genome we generally use the H37Rv genome with all known variant positions
replaced by the hypothetical ancestral allelic states, representing a putative reconstructed
ancestor of all MTBC (Comas et al., 2010). Each nucleotide position differing from the
reference, i.e. each SNP, can be annotated with gene, amino acid change and several other
features (Wang et al., 2010). Throughout the workflow, a number of filtering steps are
used to remove SNPs showing low confidence. These include SNPs in repetitive regions of
the genome, including PE/PPE genes and insertion sequences (panel B in Figure 3.3). A
list of SNPs per strain is given as an output. Similar to single nucleotide variants, other
polymorphisms such as small insertions and deletions can be analyzed, but will not be
further discussed here.
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Figure 3.3.: Example of a genome (re-) sequencing analysis pipeline for MTBC and reduction
of the number of SNPs due to filtering. A. The whole-genome sequencing data analysis
pipeline for SNP calling as currently used in our laboratory. Input data are Illumina short
reads in fastq-format. Outputs are single nucleotide variants per strain compared to the
hypothetical ancestor of MTBC. B. Schematic illustration of steps where (true or false-
positive) SNPs remain undiscovered or are lost due to filtering.
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The number of called SNPs is therefore a result of combining different algorithms. Panel
B of Figure 3.3 shows schematically where true- or false-positive SNPs are lost in the filter-
ing process (i.e. they are filtered out by the software according to the particular parameter
settings). This particular approach aims at reducing the number of false-positive calls.
Often, the question as to what SNPs are true (as opposed to false-positives) remains, and
ideally, SNPs should be confirmed by other methods such as Sanger sequencing. The issue
of data quality is key in all sequencing projects, and there is a general trade-off between
data quality (i.e. the stringency of filter settings) and the number of true SNPs identified.
Moving forward, there is a need for minimum requirements for SNP data generated by
NGS. One possible approach could be that a particular SNP has to be confirmed by at
least one independent method. However, such an approach might become increasingly
difficult as the number of SNPs increases beyond a few dozen. Also, filtering thresholds
will have to be defined, and difficulties resulting from ambiguous base calls or multiallelic
variants discussed.
The NGS data pipeline shown in Figure 3.3 consists of a combination of several command-
line tools and customized scripts. Even though scripting can automatize the processing
of one or many genomes, running these tools requires a certain level of bioinformatic ex-
pertise. But if whole genome sequencing is to be used more broadly in clinical settings,
we need good software packages with automatic SNP-calling and SNP-annotation (Köser
et al., 2012b). There are several (not MTBC specific) public platforms for customized
and semi-automated NGS data analysis, with the most prominent and feature-rich among
them known as “Galaxy” (Goecks et al., 2010). Galaxy allows graphically guided analysis
of NGS data. The DNA data bank of Japan (DDJB) also features a NGS analysis plat-
form, which is publicly available and makes automatic integration into the DDBJ-archive
possible for publication (http://p.ddbj.nig.ac.jp/pipeline/Login.do). These plat-
forms are designed as customized combinations of tools that can be controlled with a
graphical interface. However, what is actually needed for the TB-community is a “one-
click” tool to upload NGS data in fastq format, and to get a list of polymorphisms as
an output (see Box 1). Moreover, the rapidly increasing amount of SNP data gener-
ated through all the ongoing and future NGS projects should ideally be centralized in a
user-friendly and well-curated database.
3.7. The need for a new SNP database for MTBC
So far, most SNP data in MTBC have been computed and stored on local workstations,
and only made available upon publication. For the raw NGS reads, NCBI, EBI and DDJB
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have created Sequence Read Archives (SRA) where these data can be deposited (http://
www.ncbi.nlm.nih.gov/sra, http://www.ebi.ac.uk/ena/home, http://trace.ddbj.
nig.ac.jp/dra/index_e.shtml). These archives contain the raw sequencing reads in
SRA format, which can be downloaded and converted to fastq files (http://www.ncbi.
nlm.nih.gov/books/NBK47537/). Raw sequence reads are required whenever a re-analyses
of variants (e.g. with new software algorithms) are performed.
Once the polymorphisms have been extracted from the raw NGS data, they have to
be made available upon publication. With previous projects based on classical Sanger
sequencing, it was often possible to present SNP data as tables or spreadsheets, but
the need for an online centralized database becomes obvious when considering the large
amount of SNP- and associated metadata coming out of current and future MTBC NGS
projects. The number of SNPs identified in a particular NGS project will likely be between
several hundreds and several tens of thousands, depending on the number of MTBC
genomes analyzed. This makes the use of lists or spreadsheets problematic and error-
prone. Furthermore, to make use of this SNP information, researchers need to have access
to the biological context, and to be able to interlink SNP data with other metadata as
well as with other databases containing e.g. information on protein structure.
At least five existing databases harbour information on polymorphisms in MTBC (Table
3.1). Four of them were designed to contain data on MTBC SNPs only. The most im-
portant and multifunctional among these is probably the Tuberculosis Database (TBDB)
(Reddy et al., 2009). It currently contains 23,795 SNPs extracted from 25 MTBC genomes
(Table 3.1). These SNPs can be viewed as pair-wise or multiple comparisons of genomes
with a variety of display options. SNPs can also be viewed in form of sequence align-
ments and downloaded as text files. SNPs can be separated by coding- and non-coding
regions, or clustered by functional enrichment (e.g. all polymorphisms per COG-category
gene). Drug resistance mutations can be specifically sought for. Each SNP is linked to
the annotated gene it falls in, which is then linked to other databases. Phylogenetically
relevant SNPs, i.e. potential markers, can be extracted by generating lists of SNPs shared
by members of one lineage, and excluding SNPs shared with members of other lineages.
Another database is TBDReamDB which focuses on drug resistance-conferring muta-
tions (Sandgren et al., 2009). It is probably the most complete repository for drug resis-
tance mutations in MTBC. It currently features 1447 mutations and is regularly updated
with information from new publications. MGDD (Vishnoi et al., 2008) is a database to
compare SNPs across 6 MTBC genomes by gene name, nucleotide position or base change.
MTCID (Bharti et al., 2012) is another database comparable in function to MGDD, and
has in addition geographical mapping of SNPs implemented. Both MGDD and MTCID
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focus on drug resistance-associated mutation, but not exclusively. However, they have
limited search functions and it is unclear if these databases are still being updated. The
SNP database with the largest number of MTBC SNPs is dbSNP of NCBI (Sherry et al.,
2001). Currently about 40,000 SNPs are obtained using the search query “Mycobacterium
tuberculosis”. Unfortunately, these SNPs are not annotated, and the origin of the data is
unclear. But dbSNP is likely to be the most powerful database for SNP data in other or-
ganisms, and serves as reference database for the known genetic variants in Homo sapiens.
Several features of dbSNP established for human variation could inform the establishment
of a new SNP database for MTBC.
Several large databases of human variants are available (Table 3.1). dbSNP comprises
currently 53,558,214 human variants. Most other databases reference their SNPs to
dbSNP by the respective rs# number. This is an established annotation system that
functions as follows: whenever a SNP of any species is uploaded to dbSNP (from pub-
lications or directly from the user) it is assigned a unique and position-independent
submitted SNP ID number (ss#) and mapped to the reference genome (position on
the contig). In a next step, the ss# is linked to a unique new RefSNP ID number
(rs#), or is assigned to an existing rs# if a SNP at this genomic position was found
and uploaded before. An rs# can therefore contain multiple ss# numbers, which are
found in a table shown in each rs# record. The rs# is also position-independent, but
each record contains the genomic position of the SNP. The SNP, i.e. the rs#, is then
fully annotated, and linked to other NCBI resources such as gene context or publica-
tion source. Any attribute field or database can be linked to a specific rs#. In the
next “build” of the database, the SNP is then incorporated (Kitts et al., 2011). Other
databases containing human data can use the dbSNP data to build, link and annotate
their own SNP information. A selection of other large SNP databases potentially rel-
evant for MTBC is listed in Table 3.1. These databases have different contents (i.e.
only a subset of the dbSNP entries or refer to restricted populations as in PASNP or
JSNP), different structures and are tailored to match different requirements, such as the
HapMap genome browser (http://hapmap.ncbi.nlm.nih.gov/whatishapmap.html), or
the topoSNP database (Stitziel et al., 2004), which maps SNPs to protein structures. All
of these databases have specific fields, which could be included in a future MTBC SNP
database. In addition to all the descriptive information of a given SNP, human dbSNP
entries contain data about the frequency of the SNP in different human populations.
Drawing a line to a future MTBC SNP database, frequency data could be important for
drug resistance-conferring mutations, and could be calculated e.g. by lineage (e.g. the
frequency of rpoB mutations in each lineage, calculated and updated automatically). To
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allow calculating frequencies of mutations, a database needs to allow for multiple uploads
of the same SNP. In the final chapter of this review we discuss some other features that
a new MTBC SNP database should include (Box 1).
3.8. Features of a new MTBC SNP database
Given the existing features of TBDB (discussed above), this database represents an ideal
starting point for an extended SNP database for MTBC (Box 1). TBDB already includes
important aspects such as the relational tables and annotations. Unique and highly valu-
able modules such as the phylogenetic context could be extended to deal with larger num-
bers of taxa (strains) and characters (SNPs). So far, SNPs in TBDB are identified based
on their position in the reference genome, but with larger numbers of genome sequences
and characters, as well as alternative reference genomes used by different researchers, a
unique SNP ID will become necessary, similar to what has been implemented in dbSNP.
This would allow for unambiguous communication across the research community, solve
the problem of SNPs whose positions are not found in a particular reference genome (e.g.
in regions where large deletions in H37Rv occur), and allow for specifying a position of
interest on more than one genome (e.g. when referring to the recently finished genome
of Mycobacterium africanum GM041182). Moreover, a new MTBC SNP database should
be frequently updated. Regular builds are also important in case of new annotations in
the reference genome(s). The database should include as many informative fields as pos-
sible, but should not store any redundant information available in other databases. Many
important fields are already present in TBDB and could be adopted into an extended
version (Figure 3.4). These fields include the “standard” data on position, nucleotide
change, gene annotation, and amino acid change (synonymous/non-synonymous). Addi-
tional fields could include “essentiality” of the corresponding gene (based on experimental
evidence (Sassetti et al., 2003a)), validation (methods used to confirm polymorphism and
to exclude sequencing errors), source of data (publication, upload, diversity sequencing
project, etc.), associations with drug resistance, phylogenetic context (e.g. “Lineage 4
marker”), and data quality scores (e.g. phred score or coverage depth from the corre-
sponding sequencing project). Other metadata such as clinical associations (e.g. virulence,
transmission, vaccine efficacy, drug treatment) could be annotated in attribute fields as
they become available. Other fields could be developed based on functional predictions
of SNPs, and experimental confirmation of any phenotypic effects. Here, the SIFT algo-
rithm (see above) and other related approaches could be implemented more widely. The
way by which a particular SNP was discovered has to be defined (sequencing method,
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confirmation by other methods), and the adjacent sequence up- and down-stream of the
SNP position should be shown for unambiguous identification.
Regarding the original source of the SNP data, the ideal database should harbour both
the raw sequencing data and the corresponding polymorphism data. This would allow a
direct link to the source data, and – if needed – the possibility to retrieve the original
sequencing reads for quality assessment or application of alternative mapping algorithms
or other analytical approaches. For example, fastq files could be uploaded by users, with
SNPs called automatically and put into the context of the existing SNP data (see also
Box 1). Following a set of quality criteria, the new SNPs would then be automatically
merged into the main SNP database. SNPs should also be linked to relevant entries in
other databases. There are a variety of databases that store MTBC-specific information
(Sharma et al., 2011), and potential links are shown in Figure 3.4. Some of these databases
include existing and highly accessed databases such as gene annotations on TubercuList or
expression data on TBDB. Others could include new functions such as visualizing the spa-
tial location of a SNP on the corresponding protein structure. Moreover, two large Systems
Biology consortia are currently working on TB (http://www.systemtb.org/ and http:
//www.broadinstitute.org/annotation/tbsysbio/home.html (Aderem et al., 2011)).
Linking MTBC SNP information with transcriptional, proteomic, and metabolomic data
generated through these consortia should allow for a more comprehensive understanding
of TB biology.
As already mentioned, frequency data on SNP distribution should be included. As the
number of available whole-genome sequences increase, we will need sophisticated tools
to visualize allele frequencies in a geography-dependent manner. The high clonality of
MTBC and the strong genome-wide linkage disequilibrium between individual SNPs in
a given genome will have to be considered in this respect. Finally, the SNP database
should be easily searchable by position, reference number, keywords, or free text. All
data contained in the database should also be downloadable as a bulk. In dbSNP, this is
achieved by building a local copy of the database. For MBTC, as the number of SNP will
be considerably smaller, this could be achieved by a bulk download in text format.
The requirements and opportunities for a new SNP database for MTBC are manifold
but will not be easy to implement (Box 1). Ideally, joint efforts between NCBI, TBDB and
PATRIC are needed to achieve this goal. PATRIC (Gillespie et al., 2011) is a platform
for storage and exchange of bacterial data, featuring a variety of tools including genome
browsing, BLAST, comparative pathways, and protein annotations. PATRIC has already
compiled a lot of mycobacterial data, and there are plans to host bacterial SNP data as
well (B. Sobral, personal communication). Thanks to the large amount of information
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Figure 3.4.: A simplified scheme of a future relational SNP-database for MTBC SNPs, in-
cluding links to other databases. “rs” numbers are unique IDs from dbSNP (reference
cluster). This proposal for a new MTBC SNP database is independent of the platform hosting
the central database.
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already included, a joint venture between TBDB and PATRIC seems like an ideal way
forward to establish a new SNP database for MTBC.
Box 1. “Wish list” for a new SNP database for MTBC. A future database for SNP
annotation and genome analysis to serve the needs of the TB research community should
include (amongst other):
• Position-independent reference numbers for SNPs for unambiguous communication
between laboratories and data management. The rs# numbers of NCBI provide a
suitable starting point.
• Implementation of a “one-click” genome analysis pipeline to extract SNPs and indels
from uploaded fastq-files. Fastq file would be automatically processed, all SNPs given
as output, compared with the existing ones in the SNP-database, and annotated. The
phylogenetic position of the user-genome would be given (see below). The SNP data
from the user genome could then be shared with the database to be included in a next
build. Multiple genomes sequences (i.e. multiple fastq-files) can be uploaded.
• Phylogenetic context: MTBC strains harbouring a particular SNP can be shown as a
list. Strains of interest (e.g. all Lineage 4 strains) can be selected and shared SNPs
shown (“SNPs per selected clade”).
• Generation of a phylogenetic tree with all available genomes or SNPs, and possibility
of mapping a genome uploaded by the user.
• Visualization of SNPs as an alignment of all strains piled up (as in TBDB).
• A genome map highlighting SNP positions.
• Visualization of sequence upstream- and downstream of the SNP.
• Genotyping assays for selected SNPs: either published, or automatically calculated
(e.g. primer pairs for PCR amplification of the SNP-relevant genomic region).
3.9. Conclusions
NGS studies of MTBC clinical isolates are discovering thousands of SNPs. Studying the
functional effects of these SNPs and their association with phylogenetic clades should be-
come an increasing part of the research portfolio. MTBC consist of a diverse population of
strains, and this diversity should be considered when developing new tools and strategies
to combat TB. A new, extended, and well-curated database is necessary to accommodate
these rapidly accumulating SNP data in a user-friendly and integrated format. Ideally,
dbSNP/NCBI, TBDB and PATRIC should join forces and play major roles in the devel-
opment of such a database. After establishing the basic framework of such a database,
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specific needs and wishes of the community can be discussed and incorporated (Box 1).
The aim of this review is to contribute to the discussion.
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4.1. Abstract
There is increasing evidence that strain variation in Mycobacterium tuberculosis complex
(MTBC) might influence the outcome of tuberculosis infection and disease. To assess
genotype-phenotype associations, phylogenetically robust molecular markers and appro-
priate genotyping tools are required. Most current genotyping methods for MTBC are
based on mobile or repetitive DNA elements. Because these elements are prone to conver-
gent evolution, the corresponding genotyping techniques are suboptimal for phylogenetic
studies and strain classification. By contrast, single nucleotide polymorphisms (SNP) are
ideal markers for classifying MTBC into phylogenetic lineages, as they exhibit very low de-
grees of homoplasy. In this study, we developed two complementary SNP-based genotyp-
ing methods to classify strains into the six main human-associated lineages of MTBC, the
“Beijing” sublineage, and the clade comprising Mycobacterium bovis and Mycobacterium
caprae. Phylogenetically informative SNPs were obtained from 22 MTBC whole-genome
sequences. The first assay, referred to as MOL-PCR, is a ligation-dependent PCR with
signal detection by fluorescent microspheres and a Luminex flow cytometer, which simul-
taneously interrogates eight SNPs. The second assay is based on six individual TaqMan
real-time PCR assays for singleplex SNP-typing. We compared MOL-PCR and TaqMan
results in two panels of clinical MTBC isolates. Both methods agreed fully when assign-
ing 36 well-characterized strains into the main phylogenetic lineages. The sensitivity in
allele-calling was 98.67% and 98.8% for MOL-PCR and TaqMan, respectively. Typing of
an additional panel of 78 unknown clinical isolates revealed 99.2% and 100% sensitivity
in allele-calling, respectively, and 100% agreement in lineage assignment between both
methods. While MOL-PCR and TaqMan are both highly sensitive and specific, MOL-
PCR is ideal for classification of isolates with no previous information, whereas TaqMan
is faster for confirmation. Furthermore, both methods are rapid, flexible and comparably
inexpensive.
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4.2. Introduction
Genotyping of human-associated Mycobacterium tuberculosis complex (MTBC) plays an
increasing role for understanding the epidemiology and biology of tuberculosis (TB)
(Kato-Maeda et al., 2011b; Coscolla et al., 2010). On the one hand, genotyping techniques
are key for standard molecular epidemiological investigations of TB such as defining chains
of ongoing transmission and differentiating patient relapse from exogenous re-infection
(Kato-Maeda et al., 2011b). On the other hand, strain genotyping in MTBC is important
for defining the evolutionary background of clinical isolates. There is mounting evidence
that the strain genetic background might influence the outcome of TB infection and dis-
ease. Experimental studies have shown that clinical strains differ in immunogenicity and
virulence, but whether this variation translates into comparable clinical phenotypes is
unclear (Caws et al., 2008; Nicol et al., 2008; Thwaites et al., 2008; Jong et al., 2008;
Coscolla et al., 2010; Homolka et al., 2010; Portevin et al., 2011; Click et al., 2012). To
study the effect of strain variation and detect relevant genotype-phenotype associations,
suitable phylogenetic markers and appropriate genotyping methods are required (Comas
et al., 2009b).
Several methods for genotyping of MTBC have been developed over the past years
(Schürch et al., 2012). Two of the most popular methods, spoligotyping (Kamerbeek
et al., 1997) and MIRU-VNTR (Supply et al., 2006), rely on repetitive DNA elements,
and are currently considered the gold standard for TB transmission studies (Kato-Maeda
et al., 2011b; Supply et al., 2006). However, due to their propensity for convergent evolu-
tion and resulting homoplasies (Comas et al., 2009b), inferring robust phylogenies using
these methods can be problematic. Moreover, because of these homoplasies, classification
of MTBC strains into robust phylogenetic lineages is not always possible and misclassifi-
cation can occur (Fenner et al., 2011; Flores et al., 2007). In addition to mobile genetic
elements (e.g. IS6110 (McEvoy et al., 2007)), repetitive DNA (DR region (Groenen et al.,
1993), MIRU-VNTR (Supply et al., 2000)), and large sequence polymorphisms (Tsolaki
et al., 2004; Gagneux et al., 2006b), single nucleotide polymorphisms (SNPs) have become
available as phylogenetic markers for MTBC. SNPs are ideal markers for genotyping of
MTBC, as they represent unique events and show virtually no homoplasy (Comas et al.,
2009b). Several studies have reported the use of SNPs for phylogenetic classification of
MTBC (Sreevatsan et al., 1997; Baker et al., 2004; Filliol et al., 2006; Gutacker et al.,
2006; Bergval et al., 2008; Hershberg et al., 2008; Abadia et al., 2010; Bouakaze et al.,
2010; Bouakaze et al., 2011). However, no consensus has yet been reached as to what set
of SNPs should be used for standard phylotyping of MTBC. Importantly, not all phyloge-
netically informative SNPs will be equally amendable to all possible SNP-typing platforms
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(Wang et al., 2007; Kim et al., 2007). In MTBC, some of the methods that have been
proposed are allele-specific PCR (Espinosa de los Monteros et al., 1998), real-time PCR
(Halse et al., 2011), Sanger sequencing (Mestre et al., 2011), SNaPshot minisequencing
(Bouakaze et al., 2010), iPlex Gold (SEQUENOM Inc.) (Bouakaze et al., 2011) and
MLPA (Bergval et al., 2008). All of these methods differ in their technical requirements.
Hence, depending on the particular technique used, different, but phylogenetically equiv-
alent SNP sets will be required. In addition, these typing methods vary largely in their
throughput, cost, and flexibility. With respect to the latter, we identified a lack of meth-
ods, which are at the same time flexible and rapid (< 1 day / 96 samples), and amendable
to a variable number of strains and a limited number of SNPs (5-50)
Recently, whole genome sequences of a global collection of 21 MTBC strains repre-
senting the six main lineages of human-associated MTBC became available (Comas et
al., 2010). The 9,037 SNPs identified in these genomes represent an ideal starting point
for extracting diagnostic or “canonical” SNPs, which are lineage-specific, to design phy-
logenetically robust genotyping assays (Keim et al., 2004). In this study, we present
two new and complementary SNP-typing methods for MTBC. These methods are based
on two phylogenetically equivalent sets of SNP markers that are specific for the 6 main
human-associated lineages of MTBC. Additionally, we present SNPs specific for the clade
comprising Mycobacterium bovis and Mycobacterium caprae (Hershberg et al., 2008), and
for the “Beijing”-sublineage of Lineage 2 (East-Asian) (Figure 1). “Beijing” strains are of
special epidemiological interest because of their repeated association with drug resistance
and hypervirulence in infection models (Caws et al., 2006; Parwati et al., 2010). The M.
bovis / M. caprae specific SNP does not capture the other animal-associated strains, i.e.
M. pinnipedii, M. microti, M. orygis, M. mungi and the Dassie bacillus.
The first SNP-typing method is MOL-PCR (multiplexed oligonucleotide ligation PCR)
(Deshpande et al., 2010), which uses allele-specific ligation for allele discrimination, sin-
gleplex PCR for signal amplification and fluorescent microspheres (beads) for the signal
detection on a flow cytometer (Figure 2, see Methods). A Luminex device is needed; i.e.
a flow cytometric platform for various nucleic acid and immunological assays (Dunbar,
2006; Lee et al., 2004; Clotilde et al., 2011), which allows for simultaneous interrogation
of 50 biallelic SNPs. MOL-PCR is flexible for both the number of SNPs as well as for
the number of strains tested (individual tubes to 96-well plates). We developed an 8-plex
SNP-typing assay for the identification of the main phylogenetic lineages of MTBC. As a
second method, we present SNP-typing with TaqMan real-time PCR. As a commercially
available system, TaqMan has proved to be sensitive and specific in numerous studies for
various applications and species (Yesilkaya et al., 2006; Ben Shabat et al., 2010; Milner
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Figure 4.1.: Phylogenetic tree of 22 whole genome sequences of MTBC plus Mycobacterium
canettii as outgroup, and canonical SNPs used for MOL-PCR and TaqMan as-
says. Rv-numbers in grey arrows represent SNPs used for MOL-PCR and TaqMan in this
study, respectively, and nucleotide change at the position in the annotated reference sequence
of H37Rv (Cole et al., 1998). The first number indicates the SNP used for MOL-PCR, and
the italic number the SNP used for TaqMan. Assays for the “Beijing” sublineage of Lineage 2
and for M. bovis / M. caprae were developed only for MOL-PCR (modified from (Bentley
et al., 2012)).
et al., 2012; Nübel et al., 2012), and is therefore considered the standard for SNP-typing
in our laboratory (Gagneux et al., 2006b; Fenner et al., 2011). Reactions are performed in
a 96-well format in less than 2 hours. In contrast to MOL-PCR, only one SNP is assessed
per reaction.
4.3. Methods
4.3.1. Ethics statement
All MTBC strains used in this study were from published reference collections (Gagneux
et al., 2006b; Allix-Béguec et al., 2008; Hershberg et al., 2008; Yeboah-Manu et al., 2011;
Fenner et al., 2011; Fenner et al., 2012b) or from an ongoing molecular epidemiology study
on tuberculosis in Nepal. This study was ethically approved by the Nepal Health Research
Council (NHRC), Kathmandu, Nepal, and the Ethics Committee of Basel, Switzerland
(EKBB). Written informed consent was obtained from all Nepalese patients.
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4.3.2. Strain panels
Two different strain panels were used in this study. A “training panel” of 46 MTBC
strains was first chosen for establishing the MOL-PCR and TaqMan assays. These strains
had been characterized previously by spoligotyping and were available as crude lysates
and purified DNA. This training panel contained clinical strains from published reference
collections (Gagneux et al., 2006b; Allix-Béguec et al., 2008; Hershberg et al., 2008;
Yeboah-Manu et al., 2011; Fenner et al., 2011; Fenner et al., 2012b) and some clinical
isolates from Nepal (Malla et al., 2012). The training panel was composed of five to seven
isolates of the 6 main phylogenetic lineage of MTBC, and additionally, Mycobacterium
bovis, Mycobacterium caprae, Mycobacterium pinnipedii and Mycobacterium microti as
controls for the M. bovis / M. caprae-specific SNP in the MOL-PCR assay. For each of
these strains, SNP-typing was done by MOL-PCR and TaqMan for both crude lysates
and purified DNA. Allele calls, i.e. lineage assignments, were obtained for all data points,
and results between the two methods compared. As it was not possible to use the same
SNPs for both MOL-PCR and TaqMan (due to probe design restrictions), we compared
the lineage assignment rather than the locus-specific alleles.
A ”test panel” was then chosen for the validation of MOL-PCR and TaqMan under
“blind” conditions. This test panel consisted of 78 clinical MTBC isolates recently obtained
from a molecular epidemiology study in Nepal. No previous genotyping had been done for
these samples. The samples were cultured on Löwenstein-Jenssen (LJ) medium, frozen
in tryptic soy agar and glycerol, and heat-inactivated for 1 h at 90°C. Purified DNA was
available for fifteen of these strains.
4.3.3. Culturing and DNA extraction
MTBC strains were grown in standard Middlebrook 7H9 medium supplemented with
ADC (Becton Dickinson, Allschwil, Switzerland), Tween80 (Sigma-Aldrich) and glycerol
(Sigma-Aldrich). Liquid medium and agar plates for culturing Mycobacterium africanum
(i.e. MTBC Lineage 5 and 6) were supplemented with 40 mM sodium pyruvate (Sigma-
Aldrich). All bacterial cultures were incubated at 37°C. After two weeks, 500 µL culture
were heat-inactivated (1 hour at 90°C) and centrifuged. The supernatant was used as input
for TaqMan and MOL-PCR. Alternatively, 100 µL of a frozen stock culture was thawed
and heat-inactivated (100 µL culture added to 100 µL TE buffer, 1 hour at 90°C). From
all cultures, purified genomic DNA was extracted with the CTAB method (Embden et al.,
1993). DNA concentration was determined with a Nanodrop ND-1000 device (Thermo
Scientific NanoDrop Products, Wilmington, USA).
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4.3.4. Whole genome sequencing and SNP identification
Informative SNPs were obtained from whole genome sequencing as described before (Co-
mas et al., 2010; Bentley et al., 2012). In brief, short reads from Illumina-sequencing
of 22 MTBC strains were mapped to the reference genome of H37Rv and strain-specific
nucleotide differences were extracted as SNPs. A neighbor-joining phylogenetic tree was
constructed with MEGA (Tamura et al., 2011), and SNPs mapped to the tree using
Mesquite (Maddison et al., 2011). Clade-specific SNPs were compiled in OpenOffice
spreadsheets (openoffice.org). Position in reference to H37Rv, codon change, essen-
tiality (Sassetti et al., 2003a; Sassetti et al., 2003b), and annotated function of the gene
(Cole et al., 1998) were collected for each SNP. This list was used as a starting point
for oligonucleotide design. In the course of the study, 151 additional genome sequences
became available (Comas et al., 2013). With the total of 172 genome sequences represent-
ing the global MTBC diversity, we confirmed that the SNPs chosen were specific for all
members of a lineage. In reference to the first MTBC genome sequenced and annotated
(Cole et al., 1998) (Genbank AL123456.2), every SNP was named with the prefix “Rv”,
followed by 7 digits that represent the position of this SNP in the genome of H37Rv, and
the nucleotide change (i.e. “Rv2154724AC” for the Lineage 4-specific SNP in katG, codon
463).
4.3.5. Assay description Luminex MOL-PCR
The assay described here is conceptually related to Multiplex Ligation-dependent Probe
Amplification (MLPA) that was also described for SNP-typing ofM. tuberculosis (Schouten
et al., 2002; Bergval et al., 2008). MLPA uses allele-specific ligation and stuffer sequences
of variable lengths, which allow multiplexed typing with a capillary electrophoresis device.
The high level of multiplexing is made possible by the PCR-amplification of the ligated
oligonucleotides rather than the amplification of template DNA. This allows the use of
a universal primer-pair for the singleplex-amplification of all ligated oligonucleotides and
avoids multiplex-PCR. Allele-specific ligation was recently combined with the Luminex
platform and named MOL-PCR, and used for pathogen detection and SNP-typing of
Bacillus anthracis, Yersinia pestis, and Francisella tularensis (Deshpande et al., 2010;
Song et al., 2010). MOL-PCR uses fluorescent beads and coupled tag-sequences instead
of stuffer sequences for the multiplexed analysis. This allows the signal detection on a
flow cytometer, i.e. a Luminex device. We adapted and modified MOL-PCR for typing of
an 8-plex set of MTBC lineage-specific SNPs. In our assay, the tag-sequences complemen-
tary to antiTag-sequences on microspheres were included on the left-probe-oligonucleotide
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(LPO), i.e. preceding the 5’-end of the allele-discriminating sequence (left-hybridizing se-
quence, LHS), contrary to the original publication of MOL-PCR (Deshpande et al., 2010),
where tag-sequences were included on the right-probe-oligonucleotide (RPO). With this
modification in oligonucleotide design, two competing LPO could be used, differing only
by the 3’-end (the SNP of interest) and the tag-sequence. This change allowed the calcu-
lation of an allelic ratio rather than a signal-to-noise ratio, and improved the sensitivity
by discriminating background signal from uncalled allele signal. An additional change was
made in separating the hybridization/ligation step from the PCR step. We obtained high
background signal levels when combining these two steps. The assay therefore consisted
of three steps (Figure 2): 1. Competitive hybridization of allele-specific probes and liga-
tion to universal, 3’-adjacent probes. This step provides the allele-specificity of the assay.
2. Signal amplification by PCR and a fluorescently labeled primer, which guarantees the
sensitivity. 3. Detection of allele-specific signals by hybridizing amplicons to allele-specific
beads and read-out by flow cytometry.
4.3.6. SNP selection and MOL-PCR oligonucleotide design
The selection of suitable SNPs is crucial for the success of a typing assay. In MOL-PCR,
probes of 20-45 bp are designed to anneal directly adjacent to the SNP of interest. The
need for a suitable sequence up- and downstream of the SNP requires a number of SNPs to
choose from as a starting point. Eligible SNPs for MOL-PCR were chosen using following
criteria:
1. SNP is specific for the lineage of interest
2. SNP is not in a region where a genomic deletion has been described (to ensure
binding of oligonucleotides and subsequent allele-calls for all strains)
3. No other SNP less than 50 bp up- or downstream (to avoid mismatches in oligonu-
cleotide annealing)
4. SNP is not a transition (i.e. no nucleotide change A>G, G>A, C>T or T>C; lower
unspecific signal because no alternate base pairing possible)
5. SNP is in a coding sequence (deletions or insertions less likely)
6. SNP is in an essential gene (deletions less likely)
7. SNP change is synonymous (no amino acid change; therefore lower selective pressure
acting on SNP compared to nonsynonymous SNP)
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Figure 4.2.: Schematic illustration of MOL-PCR. A. Three oligonucleotides and two fluorescently
labelled beads are used for interrogation of one SNP. B. MOL-PCR consists of three steps.
1. One of two competitive allele-specific left-hand probe oligonucleotides (LPO) and one
universal right-hand probe oligonucleotide (RPO) are hybridized to the template DNA and
ligated. 2. With PCR and a reporter-labelled forward primer, the ligated oligonucleotides
(LPO + RPO) are amplified. 3. After denaturation of the PCR product, allele-specific
fluorescent beads carrying an allele-specific antiTag sequence are hybridized to the amplicons.
This will result in beads carrying reporter fluorescence (bead 1 in example) and beads not
carrying fluorescence (bead 2). Reporter fluorescence (Alexa532) per bead is measured with
a flow cytometric device (Luminex). For the 8-plex assay, a total of 24 oligonucleotides and
16 beads are used in the same reaction.
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For each eligible SNP, 100 bp of enclosing genomic sequence of H37Rv up- and down-
stream of the SNP were obtained using Ugene (Okonechnikov et al., 2012) and saved as
multifasta file. Sequences and SNPs were introduced in AlleleID (Premier Biosoft, Palo
Alto, USA) and suitable oligonucleotides searched using the MLPA module. As MLPA
uses stuffer sequences rather than tag-sequences (for hybridizing to microspheres with
coupled antitag-oligonucleotides), the latter were introduced manually and according to
sequences provided by Luminex Corporation (Austin, USA). We used the following crite-
ria for oligonucleotide search in AlleleID: 1. GC-content between 35% and 65%, 2. Tm
between 72°C and 90°C, 3. Minimum left and right hybridization sequence (LHS and
RHS) length 21 bp. Probes with high scores in AlleleID were exported from AlleleID to
OpenOffice spreadsheets. BLAST search against M. tuberculosis H37Rv was run to ex-
clude cross-homology. The 24 oligonucleotides for each lineage-specific SNP were pooled
(3 oligonucleotides each) and assessed for heterodimer formation with SBEprimer (Kader-
ali et al., 2003), AutoDimer (Vallone et al., 2004) and Oligoanalizer (www.idtdna.com).
Probes with potential dimer formation (dG < -11 kcal/mol) were excluded, a new SNP
chosen and new probes designed, until a compatible set was found. The final set of 24
oligonucleotides was synthesized by Sigma-Aldrich (Buchs, Switzerland). The 5’-end of
each RPO was phosphorylated to enable ligation.
4.3.7. Luminex MOL-PCR procedure
All SNPs were interrogated in one tube (multiplexed). Our modified MOL-PCR assay
consisted of three laboratory steps. 1. Oligonucleotides were hybridized to target DNA
and ligated. 2. The ligation product was amplified by singleplex PCR (one primer pair
for all SNPs). 3. Beads were hybridized to the amplification products and run on a flow
cytometric device.
Hybridization and ligation: In a 10 µL volume with H2O, 0.5 µL of oligonucleotide-mix
(40 nM each oligonucleotide; see Table 4.1) were mixed with 1 µL of ligation buffer (NEB;
New England Biolabs, Ipswich, USA), 0.1 µL of thermostable ligase (NEB) and 3 µL of
pure DNA (10 ng / µL) or 4 µL heat-inactivated, crude extract. In a thermocycler, the
following protocol was run: 4 min 94°C, 30 cycles 25 sec 94°C and 30 sec 50°C.
PCR: In a 10 µL volume, 3 µL of the ligation product was added to the PCRmix of 5.095
µL of H2O, 1 µL PCR buffer without MgCl2 (Roche, Basel, Switzerland), 0.2 µL dNTPs
(10 mM, Sigma-Aldrich), 0.5 µL forward primer (10 µM; Sigma-Aldrich, 5’-Alexa532-
GGGTTCCCTAAGGGTTGGA), 0.125 µL reverse primer (10 µM; Sigma-Aldrich, GT-
GCCAGCAAGATCCAATCTAGA) and 0.08 µL FastStart Taq polymerase (Roche). The
following protocol was run in a thermocycler: 2 min 96°C and 43 cycles of 20 sec 94°C,
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20 sec 58°C, 20 sec 72°C.
Hybridization of beads and signal detection: A bead mix containing 2 µL of beads (16
polystyrene bead regions of MagPlex-Tag beads, Luminex Corp., Austin, USA; Table 4.1)
and 3 µL of buffer (1.33 M NaCl (Merck Chemicals, Darmstadt, Germany), 83.33 mM
MES (Sigma-Aldrich)) was added to the 10 µL PCR product. In a thermocycler, the
following protocol was run to hybridize beads (antiTags) to PCR products (tags): 1 min
94°C, ramp-down 0.1°C / sec decrement to 25°C, 5 min 25°C. 80 µL of running buffer (10
mM Tris-HCl, 0.1 mM EDTA (Sigma-Aldrich), 90 mM NaCl, 0.04% (v/v) Triton X-100
(Sigma-Aldrich), pH 8) were added and the reaction transferred to flat-bottom plates
(BioRad, Hercules, USA). A BioPlex 200 device (BioRad) was used to discriminate beads
and measure reporter fluorescence (Alexa532) for each bead, i.e. each allele. Results were
obtained as reporter median fluorescence intensity (MFI) per bead region and sample,
and exported from BioPlex Manager software into spreadsheets.
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4.3.8. Allele calling MOL-PCR
For each sample, the allelic state of each SNP was assessed with the following algorithm:
1. Bead counts > 40 beads per bead region
2. Allelic ratio (AR) < 0.4; ancestral allele called
3. Allelic ratio (AR) > 0.6; mutant allele called
4. MFI > threshold MFI (see below)
AR = MFImutantMFIH2Omutant
MFImutant
MFIH2Omutant
+ MFIancestralMFIH2Oancestral
MFI = median fluorescence intensity of reporter-dye (Alexa532) of the corresponding
allele / bead region
A threshold MFI for each allele/bead was used to exclude low signal calls and to avoid
SNP-calls for H2O signals (false-positives). This value was different for each SNP and
each allele (i.e. each bead region) and had to be calculated for each run, as we observed
significant differences of H2O signal levels between different runs, and occasionally H2O
signal levels higher than uncalled allele signals. The pragmatic approach that we used to
calculate the signal threshold for allele was the following. For each allele, the threshold
was set higher than each of the corresponding H2O values (a minimum of three H2O
samples per 96-well-plate were included). The threshold was then lowered so far that no
allele was called for any of the H2O-sample, which is made possible by the range of the
allelic ratio. Furthermore, an absolute minimal threshold value was used.
4.3.9. Assay description TaqMan PCR
TaqMan real-time PCR was originally described in 1991 (Holland et al., 1991) and was
since then optimized for commercial use. The PCR based method makes use of fluores-
cently labeled allele-specific probes, the 5’-3’-exonuclease activity of Taq polymerase and a
non-fluorescent quencher. During PCR amplification of the region of interest, fluorescence
is detected in a real-time PCR thermocycler.
55
4.3.10. SNP selection and probe design for TaqMan
Primers and probes for Lineage 2, Lineage 3 and Lineage 4 were described before (Ta-
ble 4.2). SNP for Lineage 1 was chosen from the list of lineage-specific SNPs recently
published (Comas et al., 2009b), and SNPs for Lineage 5 and 6 from the list of genome
sequences as described above. For the design of probes and primers, the software Primer
Express (Applied Biosystems, Carlsbad, USA) was used. As TaqMan assays were single-
plex, oligonucleotide design was less complex, as heterodimer formation is limited to the
two primers and two probes of one assay. Furthermore, the design of the primer pair can
be varied over a large sequence range.
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4.3.11. TaqMan real-time PCR
TaqMan real-time PCR was performed according to standard protocols (Applied Biosys-
tems, Carlsbad, USA). Briefly, in a 12 µL volume, 2 µL DNA sample were added to a
mix of 5 µL TaqMan Universal MasterMix II (Applied Biosystems), 5 µL H2O containing
forward and reverse primer (0.21 µM each; Sigma-Aldrich), probe A for ancestral allele
and probe B for mutant allele (0.83 µM each; Applied Biosystems). Primer and probe
sequences are listed in Table 4.2. Reactions were run in a StepOnePlus thermocycler
(Applied Biosystems; 60°C 30 sec; 95°C 10 min; 95°C 15 sec and 60°C 1 min for 40 cycles;
60°C 30 sec) and fluorescence intensity in the VIC and FAM channels measured at the
end of every cycle. Results were analyzed with StepOne software (Applied Biosystems)
and alleles called with the default algorithm.
4.3.12. Spoligotyping
43-spacer spoligotyping was performed following standard protocols on a membrane (Kamer-
beek et al., 1997).
4.3.13. PCR and sequencing of putative deletion in Rv3113
As we did not obtain MOL-PCR signal for the M. bovis / M. caprae-specific SNP for
two strains (N1007 and N1032, see Table S1), the locus was assessed for a potential
deletion in Rv3113. PCR was run in a 25 µL volume with 12.3 µL H2O, 2.5 µL PCR
buffer with MgCl2 (Roche), 5 µL GC buffer, 0.75 µL forward primer K-297 (10 µM,
Sigma-Aldrich, CCATGATGCTGGCAGAACTGA), 0.75 µL reverse primer K-298 (10
µM, Sigma-Aldrich, CCTGCGTACCTTCGTCGTCA), 0.5 µL dNTPs (10 mM, Qiagen,
Hombrechtikon, Switzerland) and 0.2 µL Fast Start Taq Polymerase (Roche). Reaction
was run in a standard thermocycler (96°C, 7 min; 35 cycles of 96°C 30 sec, 62°C 30 sec,
72°C 30 sec; 72°C 4 min). PCR product was analyzed using standard gel electrophoresis
and stained with ethidium bromide.
4.4. Results
Eight SNPs were used in the multiplexed MOL-PCR assay (Table 1). Six SNPs were
interrogated serially with TaqMan assays (Table 4.2). Forty-six MTBC strains were run
as a “training panel” (Table S1). Most samples were available as 10 ng / µL purified
genomic DNA (CTAB-method) and as crude lysates from 7H9 culture. Both methods,
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MOL-PCR and TaqMan, were run in parallel for all samples and all SNPs. Table S1
shows allelic state for each SNP for both purified DNAs and crude extracts, called by
MOL-PCR and TaqMan, respectively.
For MOL-PCR, 662 of 672 (98.6%) total data points (alleles) resulted in a successful
call of either the ancestral or the mutant allele (Table S1 and Table 4.3). Eight data
points, for which no allele call was obtained, involved crude lysates, and two were puri-
fied DNA samples. For two strains, N1007 and N1032, no allele was called for the M.
bovis / M. caprae-specific SNP, Rv3480645TG, for both crude and purified DNA. To test
for a potential deletion in the corresponding genomic region, we designed PCR primers
and amplified the region up- and downstream of this SNP. Gel electrophoresis showed an
expected amplicon length of approximately 250 bp for H37Rv, but no band for the two
strains in question, suggesting that this region was deleted in strains N1007 and N1032
(Figure S1).
For TaqMan PCR, 498 alleles of 504 (98.8%) total data points were successfully called
(Table S1 and Table 4.3). The remaining six data points without allele calls were two crude
lysates and four purified DNA samples. There was no case where TaqMan PCR failed to
call an allele for both purified and heat-inactivated sample. Both methods agreed 100%
in lineage assignment of the 36 strains comprising the training panel (excluding M. bovis,
M. caprae, M. microti and M. pinnipedi, as no SNP for M. bovis / M. caprae was used
in the TaqMan assay) (Table 4.4). Using the prototype spacer definitions (Kato-Maeda
et al., 2011a; Demay et al., 2012), spoligotyping data confirmed the lineage-assignments
of TaqMan and MOL-PCR for 39 of 42 strains (excluding M. microti / M. pinnipedii).
Of the three remaining strains, N0153 and N0051 could not be classified into any of the
known spoligotype families. Strain N1024 showed a “Beijing” spoligopattern and was
confirmed by TaqMan and MOL-PCR as a Lineage 3 (also known as CAS/Dehli) strain
(Table 4.3). The spoligotype of this strain was described as “Pseudo-Beijing” previously
(Fenner et al., 2011).
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Table 4.3.: Comparison of MOL-PCR and TaqMan for allele calling and lineage assignment.
MOL-PCR TaqMan
Training panel Total data points 672 (100%)1 504 (100%)1
Data points with allele call 662 (98.6%) 498 (98.8%)
Total number of strains 42 (100%)2 36 (100%)3
Strains assigned to a lineage 42 (100%) 36 (100%)
Congruence in lineage assignment 100%
Test panel Total data points 624 (100%) 78 (100%)
Data points with allele call 619 (99.2%) 78 (100%)
Total number of strains 78 78
Strains assigned to a lineage 76 (97.4%) 78 (100%)
Congruence in lineage assignment 100%
1 excluding N/A as indicated in Table S1
2 excluding M. microti, M. pinnipedi
3 excluding M. bovis, M. caprae, M. microti, M. pinnipedii
Next, we used a test panel of 78 clinical isolates from Nepal to validate our methods
(Table S2). These samples were mainly crude, heat-inactivated extracts, and no geno-
typing had been done before. To follow the procedure that would be used as routine
SNP-typing, we first performed MOL-PCR, as information for all SNPs is obtained in
parallel. Of a total of 624 data points (i.e. 78 strains and eight SNPs), 619 (99.2%) allele
calls were obtained (Table S2 and Table 4.3). The five data points with no calls were from
three strains (1671A, 3052B and 3074B). Thereof, two strains (1671A, 3074B) failed to
be assigned to a lineage by MOL-PCR (97.4% sensitivity in lineage assignment). Never-
theless, we obtained ancestral allele calls for seven (1671B) and six (3074B) other SNPs
for these strains. We then performed the corresponding TaqMan assay for each sample.
TaqMan called alleles for all 78 samples. Again, lineage-assignment was 100% congruent
between MOL-PCR and TaqMan.
To evaluate the signal detection limit of MOL-PCR, we used different DNA concen-
trations as input material. Samples with known DNA concentration were diluted appro-
priately for different amounts of input DNA. One strain of each lineage was used and
MOL-PCR performed with 60 ng, 10 ng, 1 ng, 0.1 ng purified DNA, and 4 µL of crude,
heat-inactivated extract. Figures S2-S8 show a decrease of signal intensities with de-
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creasing amount of DNA. Nevertheless, the use of 0.1 ng purified DNA (CTAB) or 4 µL
crude extract still resulted in signals high enough for allelic ratio determination. Signal
intensities of the complementary allele were constantly low.
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4.5. Discussion
Informative SNPs are valuable markers for deep phylogenetic typing of clinical MTBC
isolates (Schürch et al., 2012). Therefore, SNP-typing will likely play an important role
for genotype-phenotype association studies in the coming years. Even though routine
whole-genome-sequencing, i.e. “genometyping”, might replace most other typing methods
eventually, current limitations such as costs, bioinformatics capacity, the lack of user-
friendly software packages, and data storage has been hindering the broad implementation
of “genometyping” (Kato-Maeda et al., 2011b; Schürch et al., 2012). Nevertheless, thou-
sands of informative SNPs have become available from whole genome sequences, which
can be used for SNP-typing.
In this study, we presented 14 canonical SNPs, comprising two sets of markers for the six
main phylogenetic lineages of MTBC, the M. bovis / M. caprae clade and the “Beijing”
sublineage. In contrast to other published SNP sets (Gutacker et al., 2006; Filliol et
al., 2006), our SNPs were obtained from many whole genome sequences representing
the global diversity of MTBC, and thus do not suffer from phylogenetic discovery bias
(Pearson et al., 2004). Phylogenetic discovery bias occurs when SNPs used for subsequent
genotyping are initially identified by comparing only a few whole genome sequences (for
example when these genomes represent only a subset of all MTBC lineages). As a result,
strains belonging to lineages not represented in the initial genome set will falsely appear
as intermediates in the corresponding phylogenies (Smith et al., 2009). In additional
advantage of our SNP sets is that they also identify Mycobacterium africanum (Jong et
al., 2010) and discriminate between the West-African I and the West-African II subtypes
(i.e. MTBC Lineages 5 and 6). Moreover, the addition of a “Beijing”-specific SNP makes
the differentiation between this sublineage and other strains of Lineage 2 (East-Asian)
possible.
For the rapid typing of the SNPs described, we have successfully developed a multi-
plexed assay adapted from MOL-PCR (Deshpande et al., 2010). Our assay uses three
oligonucleotides per SNP instead of two, with the LPOs competing for annealing to the
template DNA. This allows an allele-call based on allelic ratio rather than signal-to-noise
ratio, which increases sensitivity. We further separated the hybridization/ligation from
the PCR step, which reduced unspecific signal. We compared the new MOL-PCR assay
with TaqMan real-time PCR which was used as standard SNP-typing method in our lab-
oratory. We found an agreement of 100% in classifying strains into the main phylogenetic
lineages and an allele-calling sensitivity of 98.6% and 98.8%, respectively, when typing
two panels of clinical MTBC strains.
MOL-PCR was sensitive enough to be used with low concentrations of DNA as well as
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heat-inactivated samples (crude extracts) (Figures S2-S8). We found that the detection
limit of MOL-PCR was as low as 0.1 ng of input DNA. Heat-inactivated samples resulted
in similarly high signal levels. This is especially valuable as performing MTBC cultures
and DNA extraction is laborious and time-consuming. Even though the signal levels of
H2O control reactions were at time relatively high (Figures S2-S8), the MFI threshold
determination we applied allowed us to control for this, and water samples could not be
called false-positive alleles. We recommend to include at least three water samples per
96-well plate, and to use a mean value for the calculation of allelic ratios. Additionally, we
always included H2O control samples for the PCR step to detect potential contamination.
We observed a putative deletion in the region of SNP Rv3480645TG, as we did not
obtain signal for neither allele for two samples (N1007 and N1032). To our knowledge,
no genomic deletion has been described to span this SNP (Tsolaki et al., 2004). PCR
amplification of this region resulted in no visible band for these two samples (Figure S1),
which suggested that there might be a deletion present in some Lineage 3 (CAS/Delhi)
strains. This highlights the fact that genomic deletions can affect a SNP call, even though
the corresponding gene was originally described as essential (Sassetti et al., 2003a; Sassetti
et al., 2003b). However, with MOL-PCR we always generated complete allelic information
for all other SNPs of the assay. As the canonical SNPs defining different MTBC lineages
are mutually exclusive (except Lineage 2 and Beijing), the lack of an allelic call for one
SNP can be neglected if the alleles at other loci are called successfully.
A limitation in the development of the MOL-PCR assay was the low efficiency of design
and validation of oligonucleotides. For each lineage, we had to design up to 5 sets of probes
targeting different SNPs, because many had to be rejected during validation, most often
because of unfavorable allelic or signal-to-noise ratios or lack of signal. The use of long
(i.e. 40-140 bp) oligonucleotides makes hairpin and homodimer formations likely, and
multiplexing probes adds a level of complexity due to a high combinatorial number of
possible heterodimer formations. We used different software for homo- and heterodimer
analysis, but still were not able to fully predict the success of probes. Recently, an
online tool for MOL-PCR specific oligonucleotide design and evaluation became available
(moligodesigner.lanl.gov) (Song et al., 2010), which could strongly facilitate the design
of such oligonucleotides. Furthermore, an oligonucleotide design tool for copy-number-
variation analysis of human, mouse and rat genomes with MLPA and MOL-PCR has
been described (Zhi et al., 2008; Zhi, 2010), and might be extended to SNP analysis and
bacterial genomes.
Four other methods have been described for multiplexed SNP-typing on the Luminex
platform, namely Direct Hybridization, Allele-Specific Primer Extension, Single-Base-
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Extension and Oligonucleotide Ligation (Dunbar, 2006; Lee et al., 2004). In contrast to
MOL-PCR, these methods use multiplex-PCR for amplification of template DNA. This
makes high multiplex-levels difficult, as a multiplex PCR is usually the limiting factor in
multiplexed assays. In our assay, 24 oligonucleotides of 48 to 80 bp lengths were included
for eight SNPs. A number of additional SNPs could be interrogated in the same reaction,
i.e. for sublineages, drug resistance mutations (Bergval et al., 2008) or outbreak-specific
SNPs (Schürch et al., 2010).
In addition to MOL-PCR, we also developed TaqMan SNP-assays for robust and rapid
singleplex-typing of all main MTBC lineages. TaqMan SNP-typing is a well-established
method for genotyping and available commercially. This facilitates the design and vali-
dation of probes, and provides standardized reaction conditions. Furthermore, criteria of
TaqMan primer and probe design are less strict than in MOL-PCR. TaqMan makes use of
quantitative PCR, which renders the method particularly sensitive. On the other hand,
multiplexing of TaqMan assays is demanding and the degree of multiplexing is limited.
Hence, we recommend using MOL-PCR for strain collections with no a priori information.
TaqMan SNP-typing, on the other hand, is most suitable for confirmation of MOL-PCR
results, or for strain collections for which previous information about genotypes is avail-
able.
Costs for reagents and consumables are another important consideration when imple-
menting a new technique. Similar to other methods, running costs of MOL-PCR per SNP
decrease with increasing number of multiplexed SNPs. We have estimated the minimal
reagent costs per SNP to be 0.8 Euro when run in a singleplex reaction. Reagent costs
drop to 0.15 Euro per SNP when running an 8-plex reaction. The cost of one TaqMan
reaction was estimated at 0.9 Euro per SNP. For both assays, the initial setup costs
are relatively high due to purchase of customized and labeled oligonucleotides. Further-
more, both methods require an expensive piece of equipment in form of a Luminex or a
real-time-PCR machine. However, both of these devices can be used for a wide variety
of applications in addition to SNP-typing (e.g. spoligotyping on the Luminex platform
(Cowan et al., 2004)), and many laboratories already have access to such equipment.
In conclusion, we propose a new set of canonical SNPs specific for the main phylogenetic
lineages of MTBC. When combined with multiplexed MOL-PCR or singleplex TaqMan
SNP-typing, these SNPs are ideal for phylotyping of strain collections from a small to a
large scale. These assays provide a new basis for phylogenetically robust classification of
clinical isolates.
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Figure S1. Agarose gel of PCR product of Rv3114 covering the SNP specific for M.
bovis / M. caprae (Rv3480645TG). H37Rv was used as positive control, whereas N1007
and N1032 were the samples that did not result in any signal in MOL-PCR. Ladder is
Hyperladder II (Bioline).
Figure S2 to S8. Dilution series of DNA from previously characterized clinical isolates
of Lineages 1 to 6, and M. bovis.
Table S1. MOL-PCR and TaqMan allele calls for the training panel of 46 well-characterized
MTBC strains.
Table S2. MOL-PCR and TaqMan allele calls for the test panel of 78 MTBC strains
with no previous genotyping information.
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5.1. Abstract
Background: High-throughput DNA sequencing produces vast amounts of data, with
millions of short reads that usually have to be mapped to a reference genome or newly
assembled. Both reference-based mapping and de novo assembly are computationally in-
tensive, often generating large intermediary data files. These types of analyses also require
bioinformatics skills that are often lacking in the laboratories producing the data. More-
over, many research questions and practical applications require only a small fraction of
the whole genome data of interest.
Results: We developed KvarQ, a new tool that directly scans fastq files for known vari-
ants, such as single nucleotide polymorphisms (SNP), bypassing the need of mapping
all sequencing reads to a reference genome and de novo assembly. Instead, KvarQ loads
“testsuites” that define specific SNPs or short regions of interest in a reference genome,
and directly synthesizes the relevant results based on the occurrence of these markers in
the fastq files. KvarQ has a versatile command line interface and a graphical user inter-
face. KvarQ currently ships with two “testsuites” for Mycobacterium tuberculosis, but new
“testsuites” for other organisms can easily be created and distributed. In this article, we
demonstrate how KvarQ can be used to successfully detect all main drug resistance muta-
tions and phylogenetic markers in 880 bacterial genome sequences. The average scanning
time per genome sequence was two minutes. The variant calls of a subset of these genomes
were validated with a standard bioinformatics pipeline and revealed >99% congruency.
Conclusions: KvarQ is a user-friendly tool that directly extracts relevant information
from fastq files. This enables researchers and laboratory technicians with limited bioin-
formatics expertise to scan and analyze raw sequencing data in a matter of minutes. KvarQ
is open-source, and pre-compiled packages with a graphical user interface are available at
http://www.swisstph.ch/kvarq.
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5.2. Background
Large scale whole genome sequencing (WGS) is revolutionizing microbiology and public
health (Olsen et al., 2012; Bertelli et al., 2013; Branco, 2013). Thanks to the latest
technological advances, bacterial genomes can now be sequenced in less than 48 hours
for less than e 100 per genome. New benchtop devices are providing WGS capability
to routine microbiological laboratories, and WGS is now becoming an important part
of clinical microbiology and molecular epidemiology. This emerging field of “genomic
epidemiology” (Robinson et al., 2013; Parkhill et al., 2011; Loman et al., 2012; Le et al.,
2013; Croucher et al., 2013; Gilmour et al., 2013; Gardy, 2013; Walker et al., 2013a)
already includes numerous studies that have evaluated the potential of WGS to trace
the transmission of pathogens such as Clostridium difficile, Pseudomonas aeruginosa,
Klebsiella pneumonia, Neisseria meningitidis, Staphylococcus aureus and Mycobacterium
tuberculosis (Didelot et al., 2012; Snyder et al., 2013; Snitkin et al., 2012; Lavezzo et
al., 2013; Köser et al., 2013; Castillo-Ramirez et al., 2012; Gardy et al., 2011; Bryant
et al., 2013b; Roetzer et al., 2013; Walker et al., 2013b). Moreover, WGS is playing an
increasing role in molecular drug susceptibility testing (DST) and the identification of
drug resistance mutations (Mather et al., 2013; Drobniewski et al., 2013; Chen et al.,
2013; Köser et al., 2013; Paterson et al., 2013; Zankari et al., 2013; Török et al., 2012). It
is expected that WGS will eventually replace all other genotyping methods (Pallen et al.,
2010).
In contrast to the increasing availability of WGS platforms, the capability to analyse
WGS data is lagging behind, partially because of the lack of rapid and user-friendly anal-
ysis tools. Extracting single nucleotide polymorphisms (SNPs), the most widely studied
form of genetic variation, from WGS data requires substantial bioinformatic expertise,
as well as dedicated bioinformatic analysis pipelines often based on customized scripts.
Moreover, this standard approach of analysing WGS data is time-consuming and compu-
tationally expensive (Stucki et al., 2013), and as a consequence, many biological questions
can often not be addressed by the people generating the data. Furthermore, large amounts
of data are produced when analyzing complete genomes, although often only a small pro-
portion of these data are actually relevant for the study question; this is particularly
true when screening for drug resistance determinants. Identifying individual SNPs of in-
terest usually requires mapping all sequencing reads in a fastq file to a given reference
genome, despite the fact that only a few nucleotide positions might be relevant. Tools
have been developed to speed up the extraction of relevant information. These include in
silico multi-locus sequence typing (MLST) from draft genomes or contigs, but all these
methods rely on previous assembly (Kruczkiewicz et al., 2012; Jolley et al., 2010; Inouye
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et al., 2012). One of these tools, SRST, facilitates the process by accepting fastq files for
a given typing scheme. SRST uses BWA and SAMtools and is highly configurable, but
is aimed at the bioinformatically skilled users and lacks a graphical interface. However,
a graphical interface is crucial for making these kind of genome analyses accessible to a
broader group of microbiologists, including the ones primarily interested in routine clinical
applications. Consequently, there is a need for software able to extract allelic information
directly from the raw sequencing reads without the need of previous mapping or de novo
assembly.
Here we present KvarQ, a software that enables rapid screening of short sequence reads
for mutations at multiple nucleotide positions of interest. KvarQ uses as input a fastq file,
and generates the output in form of a textfile in JavaScript Object Notation (json) format.
Using a completed bacterial genome sequence as a reference, KvarQ can interrogate any
single nucleotide position or short DNA sequence of interest for known or new mutations,
respectively.
KvarQ is universally applicable to any short read dataset and corresponding reference
sequence, and is highly adaptable with respect to target polymorphisms. Hence, KvarQ
may benefit many users, including clinical microbiological laboratories, where time from
generating data to results is crucial, as well as laboratories in resource-limited settings,
where access to both computational power and skilled staff remains limiting. Even ad-
vanced users will save time by avoiding the need for formal mapping or assembly to answer
specific questions, particularly when studying large numbers of genomes.
KvarQ is available for Linux, OS X and Windows, and runs on any portable or desktop
system. A command line interface and a simple graphical user interface are available.
We aimed at a self-explaining application, short run times (<20 minutes on a standard
workstation for a fastq file of 1000 MB) and a high flexibility for application to a variety
of organisms. KvarQ can be downloaded (source code as well as precompiled packages)
from www.swisstph.ch/kvarq.
5.3. Implementation
5.3.1. Overview
KvarQ analyzes a fastq file and detects the allelic state of known polymorphisms, and
compiles all the relevant information about the genome sequence. In contrast to current
genetic analysis software (Kruczkiewicz et al., 2012; Inouye et al., 2012), KvarQ extracts
the relevant information directly from the sequence reads, without the need to map every
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read to a reference genome (hence KvarQ is a “mapping free” tool). The software can
be used via the command line or the graphical user interface, and is split into one part
that scans the fastq files and saves the results to a json file, and a second part that
extracts and illustrates the information contained in the json file. Although results
reported in this article mainly use sequencing data from the Mycobacterium tuberculosis
complex (MTBC), the software can be used with any short read sequencing data from any
organism. Currently, KvarQ is optimized for haploid organisms, but could be extended to
analyze diploid data sets.
5.3.2. Algorithm and parameters
The following paragraphs describe the flow of information inside KvarQ from the fastq
files to the final results that are displayed to the user (Figure 5.1).
Before the scanning process, target sequences are generated from known mutations or
regions of interest. KvarQ uses a modular approach, where different “testsuites” (real-
ized as python modules) define known single nucleotide polymorphisms (SNPs) or small
regions of interest which harbour potential mutations (such as the Rifampicin Resistance-
Determining Region, RRDR, in MTBC (Ramaswamy et al., 1998)). The target genomic
sequence is extracted from a reference genome and flanked on both sides with additional
bases. This flanking increases the length of the sequence and thereby increases the cover-
age over the region of interest (see Figure 5.2). For each of these “target sequences”, the
corresponding base-sequence on the complementary strand is also generated.
The actual scanning algorithm is implemented in C and splits the fastq file into small
parts that are distributed to multiple threads and scanned simultaneously. First, every
read is trimmed by a user-specified minimum quality score. The trimmed part is then
shifted along each of the target sequences and every match (not exceeding a specified
number of single nucleotide differences) is recorded in the “hit-list” if a minimum overlap
is warranted. Currently, no indexing/caching is used for comparison of the reads with
the target sequences. This works fast enough for the short target sequences used in our
analysis. The scanning process continues until the whole file is scanned or a specified
minimum coverage is reached.
Next, the data gathered from the fastq files is translated into intermediary data struc-
tures (“coverages”). These data structures combine the reads from the original as well
as the complementary strand, position them within the genome, and summarize non-
matching bases in reads (these can be true mutations in the genome or sequencing errors).
Finally, the testsuites determine the results based on the information conveyed by the
intermediary data structures created in the last step. Currently, mutations are extracted
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                    TGTTCGTCCATACGACCTCGATGCCGCTGGTGATCGCGTCCTTACCGGTTCCG
          TTCGTCGGGGTGTTCGTCCATACGACCTCGATGCCG TGG
          -*+-2011//112/0122/0/21011210///0122**++
                      TTCGTCCATACGACCTCGATGCCG TGGTGATCGCGTCCT
                      ,,*-*/1/0221211110020021222122212/02-*-*
                                     TCGATGCCG TGGTGATCGCGTCCTTACCGGTTCCGGTGC
                                     -+-+//21200/202000121/02/1100102/2//1,-+
katG = DrugResistance('Isoniazid', Gene('katG', 2153889, 2156111))
Test(template=TemplateFromGenome( 2155167, 2155169), genotype=katG))
             ...CCTCGATGCCGCTGGTGATCGCGTCC...hypothetical ancestor
genome
definitionpreparation
scanning
synthesis
flank flank
G
G
G
target sequence
bases & PHRED score
.fastq reads
mutation, amino acid change
coverage
result
TV  V  E  I  G     T  I  A  D  K
Isoniazid resistance [2155168CG=katG.S315T]
resistance.py
testsuite
            
region of interest
Figure 5.1.: Simplified overview of scanning process and preparation. “Testsuites” are python
source files that define the SNPs of interest (or in this case a 3 base pair long region) as
well as other relevant genetic information (in this case the katG gene in which mutations
can confer isoniazid resistance). This information is used to extract a “target sequence” from
a reference MTBC genome: on both sides, additional bases (“flanks”) are concatenated to
avoid border effects within the sequence of interest. During the scanning process, every read
is trimmed depending on its PHRED score (in this case, a quality cutoff of Q=13 was defined
which corresponds to the ASCII character “/”). After the scanning, the part of the reads
that matched the target sequence and exceeded the minimum quality score (represented with
gray bars) are assembled to a “coverage” that indicates the overall coverage depth as well as
all detected mutations (green). In a further step, additional information is generated from
this coverage (such as the resulting amino acid sequence) and finally a short “result” string
is generated that summarizes the result of the scanning process.
by using a simple threshold that separates them from sequencing errors – this is possible
because KvarQ neglects bases that do not satisfy the minimum read quality requirements
set by the user. How this mutation information is processed further varies depending on
the various testsuites. For example, the phylogenetic testsuite we applied for MTBC uses
three phylogenetically informative SNPs for every lineage and imposes logical constraints
on sublineages. For example, any genome belonging to the MTBC “Beijing” sublineage
must also have the SNPs characteristic of “Lineage 2”. The resistance testsuite checks for
every mutation whether a change in amino acid sequence follows the nucleotide change
(non-synonymous mutations) and only reports those to the user. If the results have a low
confidence due to low coverage of the sequences, this is also added as a remark to the
result output.
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5.3.3. Data format and analysis
KvarQ uses fastq files with Solexa, Sanger and different Illumina quality scores as input
files. The quality format is determined by a heuristic search. Only one input file per
genome sequence is accepted, but paired-end data files can be merged into a single file. The
output is structured data in json format, a human readable file that contains information
about the scanning process (parameters used, fastq file size, statistics about read number,
length and quality, and scan time), the final results, and the intermediary data structures
that were used to calculate these results. The information contained in the json file can
be used to re-calculate the results without the need to re-scan the fastq file, because
most of the relevant information is contained in the intermediary data structures that are
saved along with the results in the json file.
To facilitate the extraction of relevant results, KvarQ provides data analysis tools to
inspect the data interactively from the command line or with a hierarchical menu-driven
graphical user interface. The “json explorer” shows the summarized test results for every
testsuite (KvarQ’s main goal is to be user-friendly) as well as detailed information about
the coverage of every target sequence that was used by the different testsuites (Figures 5.2,
5.3). The interactive exploration of this wealth of information is intended for the advanced
operator to get, for example, a better impression of the usefulness of newly designed target
sequences or the fastq quality. Additionally, the “json explorer” displays overall number
of reads in a fastq file and the length of the reads.
5.4. Results
We validated KvarQ with 880 fastq files of predominantly Mycobacterium tuberculosis
complex (MTBC) isolates, for which we interrogated 206 genomic positions where poly-
morphisms have been previously described (Additional Information 1 and 2 in Appendix
A.1).
In MTBC, single nucleotide mutations are reliable drug resistance markers, as most
phenotypic drug resistance is conferred by single amino acid changes (Ramaswamy et
al., 1998; Riska et al., 2000; Rodwell et al., 2013). Hence, molecular DST is becoming
increasingly widespread in the diagnosis of TB, and various genotyping platforms make use
of these markers. Moreover, SNPs are powerful phylogenetic markers in MTBC, because
similar to other genetically monomorphic bacteria, MTBC exhibits limited horizontal
gene exchange and as a consequence, SNP homoplasies are rare (Hershberg et al., 2008;
Comas et al., 2010). Hence, SNPs can be used to study the evolutionary history of
MTBC, as well as classify clinical strains associated with variable degrees of virulence or
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Figure 5.2.: Interactive inspection of “coverage”. This screenshot shows the coverage over a short
region of interest (3 basepairs within vertical red lines, corresponding to codon 315 in katG)
and the surrounding flanking sequence. Note the mutation in the middle of the three base
pair long sequence (in green, text description at bottom of window). The decrease of coverage
on both sides is due to the minimum overlap that is set to a value equal to the length of the
two flanking regions.
Figure 5.3.: Interactive inspection of json file. The upper pane of each window in these screenshots
shows the main categories of data contained in the json file. In the left window, the drug
resistance section is selected and the lower pane shows details about all target sequences
in this testsuite (the “+” in front of the “Isoniazide resistance” indicates a non-synonymous
mutation). In the right window, the phylogenetic section is selected, showing that all SNPs
for “lineage 2” and “beijing sublineage” were found.
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different clinical outcomes (Coscolla et al., 2010; Stucki et al., 2012). MTBC comprises
several phylogenetic lineages, and SNPs represent ideal markers to classify clinical MTBC
isolates into these lineages (Comas et al., 2013; Comas et al., 2009b).
In this study, we included 27 canonical SNPs as phylogenetic markers defining MTBC
lineages and sublineages, as well as 32 single nucleotide mutations and three genomic
regions (63 base pairs (bp) in gyrA, 81 bp in rpoB and 3 bp in katG) associated with
drug resistance for the detection of variants with KvarQ (Tables A.1 and A.2 in Appendix
A.1).
We tested KvarQ with a set of “in-house” generated whole genome sequences of clinical
MTBC isolates and additionally downloaded sequences from public sequence read archives
(Additional Information 2 in Appendix A.1). Different, overlapping subsets of fastq
files were used for i) the comparison of SNP-calls with a standard BWA-based mapping
pipeline (N=206), ii) detecting drug resistance mutations (N=19) and iii) comparison
of KvarQ phylogenetic classification with laboratory based classification (N=321)—see
Figure 5.4. In addition to these well-characterized genome subsets, we used a previously
published “blind” subset of 388 fastq files downloaded from a public source to extract
phylogenetic information and drug resistance mutations, which were not reported in the
original publication (Walker et al., 2013b).
5.4.1. KvarQ scanning times and overall performance
First, we applied KvarQ to all 880 fastq files and calculated scanning times for the set
of SNPs described. The scanning times were found to be correlated with the average
genome coverage (or the total base output) in the fastq file. A genome sequence file
with 100-fold coverage of the MTBC genome required approximately 2 minutes of KvarQ
scanning time, and increased linearly with sequence coverage (Figure 5.5).
To assess overall performance, we looked at phylogenetic classifications in all 880 fastq
files. These files included whole genome sequences generated on different sequencing
devices using different laboratory procedures (i.e. library preparations), and of unknown
quality (Additional Information 2 in Appendix A.1). Successful phylogenetic classification
was obtained for 865/880 fastq files (98.2%) (Figure 5.6). The remaining 15 included the
chimpanzee bacillus (Coscolla et al., 2013), Mycobacterium canettii and eight confirmed
non-MTBC isolates, for all of which no MTBC lineage classification would be expected.
For five other strains, no MTBC lineage-specific SNP was detected, which can be due to
low coverage or because isolates were not MTBC.
Furthermore, we compared the number of KvarQ hits per position with overall base out-
put in the fastq file (data not shown). The correlation varied strongly between positions
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Figure 5.4.: FastQ dataset used to validate KvarQ. A total of 880 whole genome sequences in fastq
format from various sources were used in this study. All 880 genome sequences were scanned
for phylogenetic classification and drug resistance mutation identification. Different, over-
lapping subsets were used to i) compare SNP calls obtained with KvarQ with SNP calls of
our standard SNP-calling pipeline based on BWA and SAMtools for 206 isolates, ii) compare
KvarQ phylogenetic classification of 321 MTBC isolates with previous phylogenetic informa-
tion, iii) compare KvarQ drug resistance mutations with previously identified drug resistance
associated mutations in 19 MTBC isolates, and iv) obtain additional information, i.e. phy-
logenetic classification and drug resistance mutations, from a "blind" set of 388 genome
sequences from a recent study (Walker et al., 2013b). More information can be found in
Additional Information 2 in Appendix A.1.
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Figure 5.5.: KvarQ scanning time for all 206 polymorphic positions with respect to average
sequence coverage of the MTBC genome per fastq file. Each dot represents one
isolate (i.e. fastq file). Scanning time was found to be 112 seconds / 100x coverage. Eleven
isolates of 880 were excluded due to variable read lengths (difficult calculation of total base
output). Three additional isolates isolates were excluded because of file sizes larger than 10
GB.
on the genomes and between fastq files, which indicates that the number of hits per SNP
depends on the SNP queried (i.e. the particular genomic region being interrogated) and
the quality of the base calls in the fastq file.
5.4.2. Comparison of SNP-calls with BWA calls
A subset of 206 fastq files was used to directly compare SNP-calls obtained with KvarQ
with SNP-calls generated with our standard pipeline using BWA, SAMtools, BCFtools
and custom scripts for filtering (Coscolla et al., 2013). For each of the 206 positions (single
nucleotide positions plus regions of interest), the BWA list of variants in the corresponding
genome was interrogated for presence of an alternative allele compared to the reference
genome (reconstructed hypothetical ancestor (Comas et al., 2010; Comas et al., 2013)).
With this, a direct comparison of all 206 positions in 206 strains was performed, resulting
in 42,436 total data points (Table 5.1).
A total of 782 mutations were called by both KvarQ and the BWA-pipeline (1.8% of
all data points). This corresponds to a sensitivity of 99.2% in mutation calling of KvarQ
(782/788) taking the BWA pipeline as the gold standard. Specificity was found to be
99.9% (41,615/41,648 positions).
Thirty-three mutations (0.08% of all data points) from 20 fastq files were called by
KvarQ, but no mutation was found in the corresponding BWA SNP-list. Upon manual
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lineage 1 : 8.5 % (75)
lineage 2 : 13.1 % (115)
lineage 3 : 22.0 % (194)
lineage 4 : 49.1 % (432)
lineage 5 : 2.0 % (18)
lineage 6 : 1.7 % (15)
lineage 7 : 0.5 % (4)
animal lineage : 1.4 % (12)
unknown : 1.7 % (15)
Figure 5.6.: Phylogenetic classification of all 880 isolates used in this study. This figure shows
the distribution of phylogenetic markers in all of the scanned genomes. For 865 isolates,
an MTBC lineage-specific SNP was found. In 15 isolates, no MTBC lineage-specific SNPs
were found, either because isolates were non-MTBC (10 were known to be non-MTBC), or
because coverage was low.
Table 5.1.: Comparison of SNP-calls at 206 polymorphic positions in 206 MTBC genome
sequence fastq files.
SNP in BWA mapping pipeline
yes no Total
N % N % N %
SNP in KvarQ 782 99.24 33 0.08 815 1.92
no SNP in KvarQ 6 0.76 41,615 99.92 41,621 98.08
Total 788 100 41,648 100 42,436 100
inspection, we found a successful SNP-call in the SAMtools pileup-list for each of the 33
mutations, but these mutations were filtered out in the subsequent heuristic filtering step
including the SAMtools varFilter command for unknown reasons despite good quality
and coverage.
We found three fastq files where KvarQ missed a single SNP and one file where KvarQ
missed 3 SNPs despite six calls in the BWA-pipeline. The BWA read depths for these six
calls (0.01% of all data points) were 5, 6, 21, 38, 64 and 77. Corresponding KvarQ number
of hits were 0, 1, 2, 3, 4 and 5, respectively. For strain MTB_erdman_SRR017677, when
the KvarQ quality cutoff was removed (all reads considered), the number of hits increased
to 57, 84 and 120, respectively. Subsequent FastQC analysis 1 showed poor fastq quality
over the whole read length (data not shown).
1http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
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5.4.3. Validation of phylogenetic classification
A subset of 321 isolates was used to compare the phylogenetic classification by KvarQ with
data obtained previously by various genotyping methods (molecular assays in our labora-
tory (Stucki et al., 2012)), data obtained from the collaborating laboratory that provided
DNA for WGS, or meta-data from the sequence read archive in the case of downloaded
files. The comparison included seven main phylogenetic lineages (Comas et al., 2013),
the animal-associated MTBC clade (M. bovis/M. caprae), the Beijing sublineage of Lin-
eage 2, and 10 non-MTBC isolates. In 309/321 (96.3%) isolates, KvarQ detected MTBC
lineage-specific SNPs that were in agreement with the previous classifications (Additional
Information 2 in Appendix A.1). The remaining 12 genome sequences for which no MTBC
lineage-specific SNP was found included eight non-MTBC, the chimpanzee bacillus andM.
canettii, for which no MTBC-lineage specific SNP was expected, and two isolates (0.6%)
with low KvarQ coverage and therefore no lineage-call.
5.4.4. Drug resistance associated mutations
KvarQ was applied to a subset of 19 strains harbouring known mutations associated with
drug resistance to validate the interpretation (annotation) of the mutations. The 19
strains overlapped with the 206 strains of the direct comparison described above, but the
resistance-associated mutations were identified with separate scripts from the annotated
SNP-list in the BWA pipeline. The 179 drug resistance associated genomic positions were
interrogated with KvarQ, including the 81 bp Rifampicin Resistance Determining Region
(RRDR) of rpoB, the 63 bp Quinolone Resistance Determining Region of gyrA (QRDR)
and 3 bp in the codon 315 of katG (Table A.2 in Appendix A.1).
Among the 19 strains, 16 (84.2%) had perfectly congruent drug resistance mutations
identified by KvarQ when compared to the BWA pipeline. For one strain (GQ1580),
one mutation in rpoC was not found by KvarQ. However, this mutation was not in the
list of target SNPs (Table A.2 in Appendix A.1). For one isolate, MTB_KZN_605, an
additional mutation in gyrA was found with KvarQ, and was not found with the BWA
pipeline due to low read depth and the presence of an alternative allele. For another
isolate, MTB_russia_ERR015616_1, six additional mutations in five genes were found
by KvarQ. All mutations in these two isolates were traced back to the filtering problem
discussed above, and were found in the pileup file.
In total, KvarQ detected 314 drug resistance associated mutations in 139/880 files
(15.8%) (Figure 5.7).
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Figure 5.7.: MTBC drug resistance associated mutations found in all 880 isolates. This figure
shows all 314 mutations that were found with KvarQ in 139 isolates with at least one mutation
in any of the drug resistance associated genes that were analysed (see Table A.2 in Appendix
A.1). Only mutations that were found in at least ten isolates are labeled.
5.4.5. “Blind” set of FastQ files from a public repository
Finally, a “blind” set of whole genome sequences was used to illustrate the added value
provided by KvarQ. We downloaded available sequences of a recent publication that used
whole genome sequencing for molecular epidemiology of MTBC transmission (Walker et
al., 2013b). This publication did not report drug resistance data or phylogenetic data.
We therefore analyzed all available sequences for phylogenetic SNPs and drug resistance
mutations. The original sample set consisted of 390 isolates, but two fastq files were not
found for download (http://www.sanger.co.uk, ERR192249 and ERR192250). Results
for 388 isolates were obtained in less than 12 hours. A total of 62 drug resistance mutations
were identified in 33 patient isolates from 11 patients (Figure 5.8). All paired isolates
(cross-sectional: paired pulmonary and extrapulmonary isolates from the same patients;
longitudinal: paired isolates from the same patient separated by at least 6 months; shown
as smaller dotted boxes in Figure 5.8) were found to harbour identical drug resistance
associated mutations, except for one patient (P000155), where an additional mutation
was found in two of three isolates. Isolates of one community transmission cluster (defined
by MIRU-VNTR), cluster 9, were found to harbour drug resistance associated mutations
(large box in Figure 5.8). Within cluster 9, all patient isolates harboured the same drug
resistance mutations, except for one patient (P000179) with three otherwise unidentified
mutations. Among the 388 isolates, we found a predominance of Lineage 4 (i.e. the Euro-
American lineage) in the sample set (65%), followed by Lineage 3 (24%) and Lineage 1
(6%) (Figure 5.9).
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Figure 5.8.: KvarQ identified 62 drug resistance associated mutations in 33 of 388 patient
isolates in a “blind” set of genome sequences fromWalker et al. (2013b). Each circle
represents one isolate (Patient number given as P-number, isolate given as ERR-number).
Only isolates with drug resistance associated mutation identified by KvarQ are shown. The 62
individual drug resistance mutations are shown as colors of pies. Phylogenetic lineages were
obtained with KvarQ and are shown as colored and dashed boxes. Group definitions were
obtained from the original publication (Walker et al., 2013b): cross-sectional isolates were
paired pulmonary and extrapulmonary isolates from the same patient, longitudinal isolates
were paired isolates from the same patient separated by at least 6 months, and genomic
cluster 9 was a large MIRU-VNTR defined cluster of transmission in the community. Paired
isolates (longitudinal and cross-sectional) as well as isolates of cluster 9 were found to harbour
the same mutations, except for P000179, where three otherwise not detected mutations were
found by KvarQ. For patient P000155, an additionally acquired mutation was found in two of
three isolates. Two of the 390 whole genome sequences in the original publication were not
found for download.
lineage 1 : 5.9 % (23)
lineage 2 : 2.6 % (10)
lineage 3 : 24.0 % (93)
lineage 4 : 65.5 % (254)
lineage 5 : 0.5 % (2)
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Figure 5.9.: Main MTBC phylogenetic lineage classification of the fastq set of Walker et
al. (2013b), consisting of 388 isolates. Successful lineage assignment was obtained for
388/388 (100 %) isolates. Figure includes all clustered isolates as well as longitudinal, cross-
sectional and household isolates.
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5.5. Discussion
In this article, we present a new approach to in silico SNP-typing from whole genome
sequence data. KvarQ scans fastq short sequence reads directly for known polymorphisms
instead of mapping or assembling the complete genome. This results in a massively
reduced computational time required compared to established WGS analysis tools. At
the same time, KvarQ offers a high degree of flexibility and is also very user-friendly.
This was achieved by developing an extended command-line interface together with pre-
compiled packages with a graphical user interface.
KvarQ was designed for bacterial genomes, but is applicable to any fastq sequence
data. The default parameters work best for the different Illumina machines, but can
easily be adapted to data from other manufacturers. For example, the Roche 454 reads
in our testset were scanned with a lower quality cutoff. Due to the lack of relevant data
from MTBC isolates, we were not able to test reads from Pacific Bioscience devices.
KvarQ currently takes a single fastq file as input. Paired-end data can be used as
well, but reads have to be concatenated before running KvarQ. Trimming of files is not
necessary, as KvarQ will accept only high-quality parts of the reads anyway.
Both the reference sequence and the interrogated polymorphisms can be changed or
extended. Changing the SNPs of interest can be achieved by template files, which are
lists of nucleotide positions screened by KvarQ. An extended documentation including
instructions for changing the target polymorphisms is distributed with the software and
available online2. Scanning parameters are adjusted by invoking a number of options in
the command-line interface or via the settings dialog in the graphical user interface.
Using our test set of 880 fastq files, we obtained KvarQ running times of less than
2 minutes on a high-performance computer (average running time 110 seconds) and less
than 20 minutes on a standard desktop computer (Figure 5.5). This important decrease
in time for analysis (when compared to the conventional pipeline in which the whole
genome sequence is first reconstructed) is crucial for the efficient treatment of data as
WGS becomes more widely available. The overall performance of KvarQ was high, as
reflected by 98.3% of genome sequences successfully assigned to a phylogenetic MTBC
lineage (Figure 5.6). By including phylogenetically redundant SNPs, the sensitivity of
classification was increased. Specifically, classifications were obtained if 2 of 3 redundant
SNPs were found mutant. The 96.3% congruence of lineage-assignment of KvarQ with
a priori lineage classification illustrates how WGS combined with a quick tool such as
KvarQ has the potential to replace previous genotyping methods.
2http://www.swisstph.ch/kvarq
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When comparing KvarQ SNP-calls with calls from our mapping pipeline using BWA and
SAMtools, we found a high sensitivity and specificity of 99.2% and 99.9%, respectively.
The three mutations that were called by the BWA pipeline but not by KvarQ were resolved
when lowering the quality cutoff parameter. FastQC3 confirmed the low quality of the
reads in these files.
Drug resistance mutations obtained with KvarQ and BWA in the 19 compared files
were nearly identical, but showed one limitation. Mutations conferring resistance to
pyrazinamide are found in any part of pncA, which is 561 bp long (Cole et al., 1998).
KvarQ was designed to scan short stretches of DNA, and we therefore excluded mutations
in pncA to avoid an increase in scanning time.
In the total set of 880 genomes, we found many additional drug resistance associ-
ated mutations (Figure 5.7) that could not be validated due to the lack of laboratory
DST data for many of the isolates and the complex genetic nature of drug resistance in
MTBC (Warner et al., 2013).
Successful KvarQ calls depended on the selection of suitable SNPs. Several SNPs had
to be replaced in the testing phase. Most SNPs that were replaced occurred in repetitive
regions, and these SNPs were also never called when using the BWA-pipeline. We therefore
recommend including only SNPs that were previously found to be in core genome regions,
in non-repetitive regions and where no deletions have been described.
With a “blind” set of genome sequences obtained from a recent publication (Walker
et al., 2013b), we were able to obtain lineage classifications and drug resistance calls
that had not been reported in the original publication in less than one day. Using the
clustering information of the publication, all isolates identified as drug-resistant by KvarQ
and from the same patient (paired isolates) or the same patient cluster shared the same
drug resistance mutations (except patient P000179, see Figure 5.8) and were assigned to
the same phylogenetic lineage, highlighting the consistency in mutation calling. The fast
generation of drug resistance and phylogenetic data illustrates the application of KvarQ
for quick targeted scanning of large public datasets.
KvarQ was designed to interrogate positions with known mutations. However, as some
regions (e.g. hot spot regions of drug resistance) can harbour several mutations in close
proximity, we included the capability to scan regions of interest for the presence of any
(new) mutation. These regions can be of any length, but the scanning time increases in
square with sequence length. The DST testsuite in the current version checks some short
regions known to harbour many different drug resistance associated mutations and reports
any new mutation that would result in a amino acid change of the associated gene. In
3http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
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future releases, KvarQ could be extended to scan for other genomic polymorphisms, such as
small insertions and deletions (InDels) as well as large sequence deletions or duplications.
5.6. Conclusion
In conclusion, KvarQ provides a user-friendly and highly flexible platform for rapid and
targeted analysis of fastq files. KvarQ will help overcome the hurdles of whole genome
sequence analysis in clinical microbiological laboratories and other settings where bioinfor-
matics capacity is limited. The short running times, the user-friendly graphical interface
and the high configurability at the command line level allows analysing hundreds of fastq
files in a short time.
5.7. Materials and methods
5.7.1. Informative SNPs for MTBC
We used known phylogenetic markers and drug resistance associated mutations of MTBC
to validate and benchmark KvarQ when scanning genome sequences of clinical MTBC
strains. Phylogenetically informative SNPs were selected from previous publications
(Stucki et al., 2012; Comas et al., 2009b). For each of the seven main phylogenetic
lineages of human-associated MTBC, plus the Mycobacterium bovis/M. caprae lineage,
we included three redundant canonical SNPs as markers for the corresponding lineage.
Previously published SNPs were complemented with SNPs obtained as described be-
fore (Stucki et al., 2012) for cases where less than three SNPs per phylogenetic clade were
available. The extraction of these additional SNPs was based on 172 genomes described
by (Comas et al., 2013). For Lineage 2, we additionally included known polymorphisms
to discriminate the so-called “Beijing” lineage from non-Beijing Lineage 2 strains. An
overview of the phylogenetically informative SNPs included in KvarQ is shown in Table
A.1 in Appendix A.1. We included drug resistance-mutations obtained from the Tuber-
culosis Drug Resistance Database (TBDReaMDB) (Sandgren et al., 2009), and addition-
ally compensatory mutations from (Comas et al., 2011a). High-confidence mutations for
the most important anti-tuberculosis drugs were selected (isoniazid, rifampicin, etham-
butol, streptomycin, fluoroquinolones and second-line injectable drugs). Pyrazinamide-
resistance conferring mutations were excluded. Mutations in TBDReamDB are listed as
codon changes, therefore we generated the corresponding nucleotide changes for inclusion
in KvarQ. For rifampicin- and fluoroquinolone-resistance conferring mutations, we included
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the rifampicin-resistance determining region (RRDR) (Ramaswamy et al., 1998) and the
quinolone resistance determining region (QRDR) (Takiff et al., 1994), respectively, rather
than specific positions. The codon 315 of katG was also treated as a region of three base
pairs. All included mutations and regions associated with drug resistance mutations are
listed in Table A.2 in Appendix A.1. All genomic positions given in this study refer to
the genome of the strain H37Rv (NC000962.3 / AL123456.3) (Cole et al., 1998; Camus
et al., 2002; Lew et al., 2011).
5.7.2. Short-read datasets
We used a test set of 880 bacterial whole genome sequences in fastq format to screen for
mutations with KvarQ. This set represents a global and diverse collection of clinical isolates
of MTBC, and includes drug-resistant strains from patients and from in vitro evolution
experiments, as well as non-MTBC bacterial genome sequences. Additionally, the genome
sequences were chosen to represent a technically diverse collection (Illumina HiSeq 2000,
GAIIx and MiSeq). In addition to the genome sequences generated in-house, the test
set contains fastq files downloaded from www.sanger.ac.uk, the European Nucleotide
Archive (ENA; http://www.ebi.ac.uk/ena/) and the Sequence Read Archive (SRA;
http://www.ncbi.nlm.nih.gov/sra). More information on the fastq files including
accession numbers can be found in Additional Information 2 in Appendix A.1.
5.7.3. Mapping data for comparison with KvarQ
To compare KvarQ SNP calls with SNP calls obtained from conventional mapping of
fastq short sequencing reads to a reference, we used a previously published computational
pipeline (Coscolla et al., 2013). In brief, all short reads were mapped to a hypothetical
reconstructed ancestor with BWA, reads were piled up with SAMtools and variants called
with BCFtools (Li et al., 2009). Filtering for low quality calls was done with customized
Perl scripts. The 206 positions that were used in KvarQ for allele detection were extracted
with a Python script and compared to the KvarQ calls in the corresponding sequence.
Discrepant results were manually checked with Artemis (Rutherford et al., 2000).
5.7.4. KvarQ parameters used
All KvarQ results were generated using default parameters, i.e. a quality cutoff of 13, a
minimum read length of 25, a minimum overlap of 25, a minimum coverage of two reads
for allele calls and a maximum of two errors per read. Parameters were adjusted for fastq
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files with low coverage or low quality values, and are reported in Additional Information
2 (Appendix A.1). In case of paired-end sequencing files, only one of two read files was
used. Files were manually concatenated in case of low coverage (reported in Additional
Information 2 in Appendix A.1).
5.7.5. Hardware specification
KvarQ runs on any system that runs Python and has a POSIX threads implementation
(this includes notably Windows, OS X and Linux). Analyses in this study were performed
on a Red Hat Enterprise Linux Server release 5.9 (Tikanga) with four six-core AMD
Opteron CPUs and 132 GB RAM, using 8 threads.
5.8. Availability and requirements
Project name: KvarQ: Targeted and Direct Variant Calling from FastQ Reads of Bac-
terial Genomes
Project home page: http://www.swisstph.ch/kvarq
Operating systems: platform independent; requires Python 2.7, POSIX thread library;
pre-compiled packages for OS X (10.6.8 and later) and Windows (7 and later)
Programming Language: Python/C
Licence: GNU GPL v3
88 5. KvarQ: in silico SNP-typing
6. Tracking a tuberculosis outbreak
over 21 years: strain-specific single
nucleotide polymorphism-typing
combined with targeted whole
genome sequencing
David Stucki 1,2,§, Marie Ballif 3,§, Thomas Bodmer 4,5, Mireia Coscollà 1,2, Anne-Marie
Maurer 6, Sara Droz 4, Christa Butz 7, Sonia Borrell 1,2, Christel Längle 4, Julia Feld-
mann 1,2, Hansjakob Furrer 8, Carlo Mordasini 7, Peter Helbling 9, Hans L. Rieder 10,11,
Matthias Egger 3,12, Sebastien Gagneux 1,2,∗, Lukas Fenner 1,2,3,∗
1 Swiss Tropical and Public Health Institute, Basel, Switzerland
2University of Basel, Switzerland
3 Institute of Social and Preventive Medicine, University of Bern, Switzerland
4 Institute for Infectious Diseases, University of Bern, Switzerland
5 labormedizinisches zentrum Dr Risch, Bern-Liebefeld, Switzerland
6 Cantonal Health Authorities, Canton of Bern, Switzerland
7 Bernese Lung Association, Bern, Switzerland
8Department of Infectious Diseases, Bern University Hospital and University of Bern, Switzerland
9 Federal Office of Public Health, Bern, Switzerland
10 International Union Against Tuberculosis and Lung Disease
11 Institute of Social and Preventive Medicine, University of Zürich, Switzerland
12 School of Public Health and Family Medicine, University of Cape Town, South Africa
§ Contributed equally
∗ Corresponding authors
This paper was accepted for publication in The Journal of Infectious Diseases in 2014.
90 6. Transmission of MTBC in an outbreak
91
6.1. Abstract
Background. Whole-genome sequencing (WGS) is increasingly used in molecular-epi-
demiological investigations of bacterial pathogens, despite cost- and time-intensive anal-
yses. We combined strain-specific single-nucleotide polymorphism (SNP) typing and tar-
geted WGS to investigate a tuberculosis cluster spanning 21 years in Bern, Switzerland.
Methods. On the basis of genome sequences of three historical outbreak Mycobacterium
tuberculosis isolates, we developed a strain-specific SNP-typing assay to identify further
cases. We screened 1,642 patient isolates and performed WGS on all identified cluster
isolates. We extracted SNPs to construct genomic networks. Clinical and social data were
retrospectively collected.
Results. We identified 68 patients associated with the outbreak strain. Most received
a tuberculosis diagnosis in 1991–1995, but cases were observed until 2011. Two thirds
were homeless and/or substance abusers. Targeted WGS revealed 133 variable SNP po-
sitions among outbreak isolates. Genomic network analyses suggested a single origin of
the outbreak, with subsequent division into three subclusters. Isolates from patients with
confirmed epidemiological links differed by 0–11 SNPs.
Conclusions. Strain-specific SNP genotyping allowed rapid and inexpensive identifica-
tion of M. tuberculosis outbreak isolates in a population-based strain collection. Subse-
quent targeted WGS provided detailed insights into transmission dynamics. This com-
bined approach could be applied to track bacterial pathogens in real time and at high
resolution.
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6.2. Introduction
Tuberculosis transmission has traditionally been investigated using contact tracing and
molecular typing (Cook et al., 2012; McElroy et al., 2003). However, social contact data
are often hard to obtain retrospectively, especially in high-risk groups such as home-
less individuals and substance abusers, who are difficult to trace (Anderson et al., 2014;
Asghar et al., 2009; Burki, 2010; Lambregts-van Weezenbeek et al., 2003). Moreover,
classical molecular epidemiological techniques such as IS6110 restriction fragment-length
polymorphism (RFLP) analysis and mycobacterial interspersed repetitive unit – variable
number of tandem repeat (MIRU-VNTR) analysis interrogate only a small proportion of
the mycobacterial genome and therefore suffer from limited resolution (Kato-Maeda et al.,
2011b).
More recently, whole-genome sequencing (WGS) of Mycobacterium tuberculosis has
been used to investigate tuberculosis outbreaks (Walker et al., 2013a). Known as “ge-
nomic epidemiology” (Gardy, 2013), this emerging field uses WGS to detect unknown
transmission events, identify superspreaders, and exclude or confirm epidemiologically
suspected transmission links (Bryant et al., 2013b; Gardy et al., 2011; Roetzer et al.,
2013; Walker et al., 2013b). Moreover, WGS can also be used to detect drug resistance
mutations (Köser et al., 2013). Even though routine WGS has the potential to replace
classical genotyping (Walker et al., 2013b; Diep, 2013), analyzing WGS data remains
resource-intensive and requires further standardization to meet public health needs, par-
ticularly for tracking ongoing outbreaks in real time (Walker et al., 2013a).
In 1993, a tuberculosis outbreak was reported in the Canton of Bern, Switzerland
(Genewein et al., 1993). Twenty-two cases were involved, and theirM. tuberculosis isolates
shared identical IS6110 RFLP patterns. As in other affluent countries (Abubakar et
al., 2012; Bamrah et al., 2013), this outbreak involved mainly homeless individuals and
substance abusers. In 2012, we studied the molecular epidemiology of tuberculosis in
Switzerland. We used the classic methods of spoligotyping and MIRU-VNTR to genotype
520 M. tuberculosis isolates from patients in whom tuberculosis was diagnosed between
2000 and 2008 (12.3% of all culture-confirmed tuberculosis cases in Switzerland during
the study period) (Fenner et al., 2012b). Among 68 isolates from the Canton of Bern,
two were identified as belonging to the same outbreak described in 1993, indicating that
this particular strain was still circulating in the area.
In the present study, we used a combination of single-nucleotide polymorphism (SNP)
typing and targeted WGS to track the spread of the outbreak over two decades. Using rep-
resentative isolates from the historical outbreak, we first developed a novel strain-specific
SNP-typing assay to rapidly and inexpensively identify all tuberculosis cases caused by
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this strain in the Canton of Bern between 1991 and 2011. We then applied targeted WGS
to all cluster isolates identified by the screening assay to study the outbreak dynamics in
relation to social contact information.
6.3. Methods
6.3.1. Study setting and sample set
We subcultured 1,642 patient isolates available from the M. tuberculosis strain collection
at the Institute for Infectious Diseases (Bern, Switzerland). These isolates were all col-
lected between 1991 and 2011 and correspond to 84.6% of all 1,940 tuberculosis cases (all
forms) notified in the Canton of Bern during the same period (Figure 6.1). Subcultures
were performed on Löwenstein-Jensen slants according to international laboratory stan-
dards. Purified DNA for WGS was obtained using the CTAB extraction method after
subculturing a single colony in 7H9 liquid medium (Embden et al., 1993). Bulk extracts
(i.e. without single colony selection) were available for four isolates.
The collection included the 22 historical outbreak isolates reported by Genewein et al.
(1993). One strain isolated in 1987, before systematic collection was started in 1991,
was also included (P028, originally termed “patient 1” (Genewein et al., 1993)). Finally,
for one outbreak patient from 1991, we identified an additional strain isolated in 1988
(P006A, originally termed “patient 2”; Figure 6.1).
6.3.2. Cluster strain-specific SNP-typing assay and screening of
strain collection
We performed WGS on one historical outbreak isolate from 1992 (Genewein et al., 1993)
and two isolates from 2005 and 2008 with the same MIRU-VNTR and spoligotyping
patterns (Fenner et al., 2012b) associated with the so-called “Bernese cluster”, as described
below. We also performed WGS on two isolates with the same spoligotyping pattern
(isolation years 2001 and 2004) but a different MIRU-VNTR pattern (three and four
different loci, compared with the outbreak isolate), one additional Lineage 4 isolate from
another study, and the reference strain H37Rv (Figure 6.2). The three outbreak isolates
shared 118 SNPs not observed in any of the control isolates (Figure 6.2). We used one of
these outbreak-specific SNPs (878,174 GA; position in reference to H37Rv) to develop a
real-time polymerase chain reaction (PCR) SNP-typing assay (TaqMan, Life Technologies,
Switzerland), as described previously (Stucki et al., 2012). All 1,642 available isolates were
screened for the presence of that SNP. For confirmation, we subjected all isolates with
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All TB cases notied in the Canton
of Bern during 1991 and 2011 (n=1940)
1,642 single patient isolates
available for SNP-typing
68 single patient isolates 
identied as Bernese cluster isolates
69 isolates for
whole genome sequencing
Mycobacterium tuberculosis isolates 
available for 84.6% of cases
3 false-positive 
isolates excluded
Screening for Bernese cluster isolates
with real-time PCR based SNP-typing
1 additional patient isolate
pre-dating the systematic 
isolate collection (P028, 1987)
1 serial isolate of
the key patient (P006A, 1988)
Figure 6.1.: Overview of patient isolates and whole genome sequences generated. A total of
1,642 isolates collected between 1991 and 2011 were available for single-nucleotide polymor-
phism (SNP) genotyping. Three isolates showed ambiguous SNP-typing results and were
excluded. One additional patient isolate (P028; isolated in 1987) reported in the original
publication (Genewein et al., 1993) and predating the systematic collection of isolates in
1991 was included in the study. For the key patient, a second isolate (P006B; isolated in
1991 (Genewein et al., 1993)) was available and was included in the genomic analyses.
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118 SNPs
outbreak 1
outbreak 2
outbreak 3
control 1
control 2
control 3
H37Rv
92
100
93
100
50
Figure 6.2.: Initial neighbor joining phylogeny of Mycobacterium tuberculosis isolates. Three
whole-genome sequences from the historic outbreak and four control isolates were used to
identify single-nucleotide polymorphisms (SNPs) specific to the outbreak genotype. Node
support was assessed by bootstrapping over 1000 pseudo-replicates and is indicated as a
percentage.
a mutation at this position to a second, phylogenetically redundant SNP-typing assay
(981,565 CT). Both SNPs were selected to be synonymous and located in genomic regions
suitable for primer and probe design.
6.3.3. WGS and phylogenetic analyses
All isolates identified by the screening assay and the additional serial isolate from patient
P006 were subjected to Illumina WGS at GATC Biotech (Konstanz, Germany), with a me-
dian nucleotide coverage of 157.3 reads (range, 29.1–8 96.9 reads). Sequence read mapping
and SNP calling was done as previously described (Coscolla et al., 2013). We considered
SNPs with a coverage of at least 10 sequencing reads and a value of 20 in the Phred-scaled
quality score. SNPs in genes annotated as “PE/PPE/PGRS”, “maturase”, “phage”, “inser-
tion sequence”, or “13E12 repeat family protein” were removed. Additionally, positions
with missing nucleotide calls in at least three isolates were excluded. We used a second
short-read alignment tool (SMALT, Wellcome Trust Sanger Institute, United Kingdom)
to obtain SNP calls. Only positions called by both methods after filtering for the criteria
mentioned above were included for further analysis. A subset of 28 SNPs was confirmed
by Sanger sequencing (Supplementary Materials in Appendix A.2).
A genomic network with all variable positions was generated using Fluxus Network
Software (available at: www.fluxus-engineering.com) and the Median Joining algo-
rithm. Arlequin 3.5.1.12 (Excoffier et al., 2005) was used to calculate genetic distances
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and fixation indices (FST) to estimate population separation between genomic subclusters.
Statistical significance was calculated with permutations.
Raw sequencing data are available under accession number PRJEB5925 (European
Nucleotide Archive).
6.3.4. Clinical and socio-demographic data collection
We collected clinical and sociodemographic data for all patients identified as belonging
to the cluster. Treating physicians, hospital archives, the Bernese Lung Association, and
the Cantonal health authorities collected the data, using standardized questionnaires.
We also collected contact tracing information for confirmed or presumptive links among
cluster patients. The National Tuberculosis Surveillance Registry (Federal Office of Public
Health) provided basic demographic data (age, sex, birth place, and disease site) for all
tuberculosis cases notified in the Canton of Bern between 1991 and 2011.
6.3.5. Definitions
We categorized patients as having new tuberculosis, recurrent tuberculosis, or an unknown
previous treatment status, according to international definitions (Rieder et al., 1996).
Links between cases were considered confirmed for contacts named in the contact tracing
information. Links between cases were considered presumptive when contacts were not
clearly named but were strongly supported by other contact tracing information (i.e.
visiting common hotspots of transmission, shared housing, and shared place of work).
Alcohol abuse was defined as daily consumption of alcohol, and smoking was defined as
past or current smoking. We defined “milieu” as a combined variable capturing high-risk
populations (substance abusers and/or homeless individuals) and/or patients frequenting
high-risk settings (i.e. drug injection places, methadone distribution places, and homeless
shelters).
6.3.6. Statistical analyses
We used χ2 tests or Fisher exact tests to assess differences between groups in binary
variables and the Wilcoxon rank sum test for analysis of continuous variables. We inves-
tigated differences between (1) the characteristics of patients in the Bernese cluster and
all other notified tuberculosis cases in the Canton of Bern between 1991 and 2011 and (2)
patients in the genomic subclusters.
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6.3.7. Ethics statement
Ethics approval for this study was obtained from the ethics committee of the Canton of
Bern. The treating physicians sought written informed consent from study participants.
In most cases, however, informed consent could not be obtained because the patient
could not be located or was known to have died. We therefore obtained permission from
the Federal Expert Commission on Confidentiality in Medical Research to use the data
provided by the treating physicians.
6.3.8. Role of the funding sources
The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the article.
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6.4. Results
6.4.1. Identification of Bernese cluster isolates by strain-specific
SNP typing
Using the strain-specific real-time PCR SNP-typing assay, we screened 1,642M. tuberculo-
sis single patient isolates for the Bernese cluster–specific SNP (878,174 GA) and identified
71 of 1,642 (4.3%) isolates as belonging to this cluster. All isolates but three were con-
firmed by use of a second, phylogenetically redundant SNP (981,565 CT). These three
isolates with ambiguous results were excluded from further analysis, as subsequent WGS
revealed mean pair-wise distances of 91, 148, and 174 SNPs to the other cluster isolates.
In contrast, all other cluster isolates were separated by ≤19 SNPs (Supplementary Table 1
in Appendix A.2). This corresponds to a specificity of 99.8% (three false-positive results
out of 1,574 noncluster isolates), when considering our screening results based on only
the first strain-specific SNP. All 22 historical isolates described in 1993 (Genewein et al.,
1993) were correctly identified by both SNP-typing assays (sensitivity, 100%) as having
Bernese cluster genotype. Hence, we identified a total of 68 patients linked to the cluster
strain (Figures 6.1 and 6.3).
For one patient, two isolates (P006A and P006B, isolated in 1988 and 1991, respectively)
were available, and we included both for further analyses because of the central role of
this patient described in the original study (originally termed “patient 2” (Genewein et al.,
1993)). Hence, we included 69 cluster isolates in the WGS analyses (Figure 6.1).
To illustrate the strengths of our novel combined approach, we compared the costs,
advantages, and disadvantages of the different methods used in outbreak investigations
of tuberculosis (Table 6.1). Our strain-specific SNP assay to screen 1,642 isolates was
approximately 15 times less expensive than the current gold standard based on MIRU-
VNTR. A combination of the SNP assay and targeted WGS for 69 cluster isolates was
approximately 20 times less expensive than performing WGS of the entire collection.
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Figure 6.3.: Epidemic curve of the 68 patients identified as tuberculosis cluster cases. Gray
boxes indicate patients associated with the social milieu (homeless individuals and/or sub-
stance abusers). One additional patient isolate ((P028, isolated in 1987) reported in the
original publication (Genewein et al., 1993) and pre-dating the systematic collection of iso-
lates in 1991 was included in the study. For one patient from 1991 (Genewein et al., 1993),
a second isolate (P006A, isolated in 1988) was available and was therefore backdated.
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6.4.2. Description of the tuberculosis cluster over 21 years
Of the 68 patients in the Bernese cluster, 55 (80.9%) received their diagnosis during
1998 or earlier, and 13 received their diagnosis between 1999 and 2011 (Figure 6.3).
The characteristics of the 68 cluster patients, compared with characteristics of all other
tuberculosis cases diagnosed in the same region and period, are presented in Table 6.2.
Cluster patients were more likely to be male (79.4% vs 57.3%; P < 0.001), born in
Switzerland (83.8% vs 47.4%; P < 0.001), and to have pulmonary tuberculosis as opposed
to extrapulmonary tuberculosis (94.1% vs 75.1%; P < 0.001). The median age of the
cluster patients was 41 years (interquartile range [IQR], 34–53 years), compared with 44
years (IQR, 29–71 years) for all other patients with tuberculosis (P = 0.12). Most (67.6%)
of the cluster patients were part of the local injection drug scene and/or homeless milieu.
Among cluster patients, 19.1% were infected with human immunodeficiency virus (HIV;
HIV information was unavailable for noncluster patients). Four particular hotspots of
tuberculosis transmission were identified within the milieu: a short-term homeless shelter,
a long-term social integration home, a meeting point for injection drug and methadone
supply, and a bar where substance abusers met. The distribution of cluster patients
among these four transmission hotspots, the social milieu, and the general population are
presented in Figure 6.4.
Contact investigation provided information on potential patient-to-patient links (Figure
6.4). Fourteen of 68 patients (20.6%) had confirmed epidemiological links (Figure 6.4).
Confirmed links were more frequent between patients sharing transmission hotspots, in-
dicating the large degree of social interaction in these settings. Only one confirmed link,
between a father and his daughter (P040-P041), was identified in the general population.
6.4.3. WGS of Bernese cluster isolates
A total of 133 variable positions were identified among the 69 cluster isolates (Supple-
mentary Table 2 in Appendix A.2). We generated a Median Joining network using these
133 variable positions (Figure 6.5). Despite identical MIRU-VNTR and spoligotyping
patterns (Supplementary Table 3 in Appendix A.2), 52 of 69 isolates (75.4%) were dis-
criminated by at least one SNP from their most closely related neighbor. The maximum
number of SNPs between any two isolates was 19 (Supplementary Table 1 in Appendix
A.2), and the mean pair-wise distance (±SD) between all isolates was 6.0 ± 2.9 SNPs.
Patient isolates with confirmed epidemiological links differed by 0–11 SNPs (Supplemen-
tary Table 1 in A.2). No drug resistance–associated mutation was detected among the 69
cluster isolates (Supplementary Materials in Appendix A.2).
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Table 6.2.: Characteristics of cases confirmed to be in the tuberculosis cluster, compared
with all other notified tuberculosis cases in the Canton of Bern between 1991 and
2011
Characteristic Bernese cluster cases All other cases P-value
Total 68 (100) 1,872 (100)
Age at TB diagnosis (median, IQR) 41 (34-53) 44 (29-71) 0.12
Sex
Male 54 (79.4) 1072 (57.3)
Female 14 (20.6) 800 (42.7)
Birth region <0.001
Switzerland 57 (83.8) 888 (47.4)
Europe (without Switzerland) 10 (14.7) 398 (21.3)
Sub-Saharan Africa 0 227 (12.1)
Asia 1 (1.5) 284 (15.2)
Caribbean and Latin America 0 31 (1.7)
Other regions 0 36 (1.9)
Unknown 0 8 (0.4)
Tuberculosis site <0.001
Pulmonary 64 (94.1) 1,406 (75.1)
Extra-pulmonary 4 (5.9) 466 (24.9)
Tuberculosis category
New case 54 (79.4)
Recurrent 7 (10.3)
Unknown 7 (10.3)
Imprisonment within 2 years of diagnosis 9 (13.2)
Diabetes 3 (4.4)
Alcohol abuse 39 (57.4)
Smoker 41 (60.3)
Injection drug user 18 (26.5)
Homeless 21 (30.9)
HIV positive 13 (19.1)
Homeless/substance abuser milieu 46 (67.6)
Residence
Bern City 37 (54.4)
Outside Bern City 29 (42.6)
Unknown 2 (2.9)
TB, tuberculosis
IQR, interquartile range
Data are no. (%) patients or median (interquartile range).
Data for some characteristics were missing for the other cases notified to the Canton of Bern.
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Figure 6.4.: Distribution of tuberculosis cluster patients in the milieu of substance abusers
and homeless people. The four main hotspots of transmission that were identified by
social contact tracing are shown (a short-term homeless shelter, a long-term social integration
home, a meeting point for substance abusers and a bar). Milieu patients are associated with
a particular social milieu (homeless, substance abuser scene). Red lines indicate confirmed
epidemiological links, blue lines indicate suspected social links. Presumptive individual links
between milieu patients are not shown because these patients are highly interlinked.
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Figure 6.5.: Median Joining network using 133 variable single nucleotide positions (SNP)
among whole genome sequences of Mycobacterium tuberculosis cluster isolates of
the “Bernese cluster” outbreak. Branch lengths correspond to number of SNPs. Circle
sizes correspond to number of isolates, median vectors (mv) are hypothetical genotypes. Po-
sition of “mv6” is the root of the network. A. Network showing the four identified subclusters.
Darker circles in each subcluster indicate patients that were associated with the particular
social milieu (homeless, substance abuser scene), lighter circles are patients in the non-milieu
population. Underlined labels represent isolates that were identified in the original publi-
cation (Genewein et al., 1993). B. Network colored according to time period when the M.
tuberculosis strains were isolated. C. Network showing patients associated with a particular
hotspot.
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Figure 6.5 continued.
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6.4.4. Subclusters and key patient
The genomic network revealed three independent star-like structures, suggesting (1) an
early divergence of a shared ancestor strain into three subclusters (Figure 6.5) and (2)
the presence of one or several superspreaders. A fourth, more distantly related subcluster
was separated by nine SNPs from the nearest isolate (P006A; Figure 6.5). In contrast,
subclusters 1 and 2 were separated by one SNP, and subclusters 1 and 3 were separated
by two SNPs. The average pairwise distance within each subcluster was 4.2 (subcluster
1), 3.1 (subcluster 2), 5 (subcluster 3), and 9.3 SNPs (subcluster 4). All corresponding
SNP distances were larger between subclusters than within subclusters (4.8 SNPs between
subclusters 1 and 2, 6.8 SNPs between subclusters 1 and 3, 12.2 SNPs between subclusters
1 and 4, 7.3 SNPs between subclusters 2 and 3, 12.6 SNPs between subclusters 2 and 4,
and 14.6 SNPs between subclusters 3 and 4). Pairwise fixation indices (FST) between
subclusters were between 0.24 (subcluster 1 and 2) and 0.67 (subcluster 2 and 4; P <
0.005 for all comparisons), further supporting the subcluster distinction.
The central position of subcluster 1 was occupied by the first isolate from the key
patient, patient P006 (P006A; isolated in 1988) together with isolate P010. The second
isolate from the key patient (P006B; isolated 1991) was found in the central position of
subcluster 2. This suggests a second tuberculosis episode in patient P006, generating
further secondary cases. Seven other isolates were genomically clustered with P006B and
could also be the source of transmission in subcluster 2. However, patient P006 was
a homeless substance abuser who was known to have interrupted treatment and had a
history of treatment failure, and a key role for this patient in the outbreak was already
suspected in 1993.
The central position of subcluster 3 remained unoccupied (i.e. no isolate was available
with this hypothetical genotype). This could be explained by an unsampled strain variant
from patient P002 (i.e. from a mixed infection of microevolved strains) that had been
transmitted to other subcluster 3 patients. Such a variant would have been missed as
a result of the single colony isolation step preceding WGS. Manual inspection of the
corresponding Sanger sequence trace files generated from a separate DNA preparation
without the single colony isolation step revealed a double peak at the SNP separating
P002 from the hypothetical node mv2 (genomic position 2,156,041) in the bulk isolate of
P002, indicating the presence of a mixed population in P002. Alternatively, an unsampled
patient isolate (reported as “A”, “B”, and “C” by Genewein et al. (1993)) might correspond
to the central position of subcluster 3.
When plotting the period of isolation of M. tuberculosis strains in the genomic network
(Figure 6.5B), we found no evidence that the different subclusters were associated with
107
specific periods.
Finally, we compared the patient characteristics between the subclusters, excluding
subcluster 4 (genetically distant, epidemiologically unrelated) and patient P006, whose
isolates belonged to both subclusters 1 and 2. We found that HIV infection was more
frequent in subcluster 1 (7 of 17 [41.2%]) than in the other subclusters (3 of 30 [9.7%] in
subcluster 2 and 3 of 17 [17.6%] in subcluster 3; P = 0.04). All three subclusters included
a majority of individuals from the social milieu (12 of 17 [70.6%] in subcluster 1, 17 of 30
[56.7%] in subcluster 2, and 14 of 17 [82.4%] in subcluster 3; P = 0.19). Subcluster 3 was
associated with two particular transmission hotspots: a long-term social integration home
(1 of 17 [5.9%] in subcluster 1, 0 of 30 in subcluster 2, and 7 of 17 [41.2%] in subcluster
3; P < 0.001; Figure 6.5C), and a meeting point for methadone supply (1 of 17 [5.9%] in
subcluster 1, 1 of 30 [3.3%] in subcluster 2, and 5 of 17 [29.4%] in subcluster 3; P = 0.02).
6.5. Discussion
Using a novel combination of a rapid and inexpensive strain-specific SNP screening assay
and targeted WGS, we tracked a tuberculosis cluster spanning 21 years and revealed the
transmission dynamics among the outbreak patients.
Our study demonstrated the feasibility and advantages of tracking a tuberculosis out-
break by using a strain-specific SNP-based screening assay in a large population-based
collection of M. tuberculosis isolates. We subsequently performed targeted WGS on the
69 identified cluster isolates, which, combined with social contact data, enabled us to
retrace transmission dynamics at high resolution. The combined cost of six initial whole-
genome sequences used to design the SNP-typing assay and the subsequent population-
wide screening by real-time PCR was low (approximately US$ 4900), compared with the
cost of screening all isolates with any other genotyping method. Additionally, the time
required for screening was substantially reduced, making this a powerful approach for
identifying and tracking tuberculosis outbreaks in real time. Even though our study was
retrospective, our approach could be used to screen isolates prospectively.
Our results indicate that the sensitivity and specificity of this approach are nearly 100%.
However, we could only estimate the technical test characteristic, because WGS data were
not available for the entire collection. Importantly, the performance of a strain-specific
SNP-typing assay depends on the selection of SNPs, and the selection of SNPs depends on
the isolates initially sequenced. For the successful design of such an assay, we recommend
the following: (1) select at least two known clustered isolates for WGS, (2) include at
least two control isolates with genotyping patterns closely related to but different from
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those of the clustered isolates (e.g. MIRU-VNTR), (3) identify SNPs specific to all clus-
tered isolates and absent in the control isolates, (4) exclude SNPs in genes known to be
associated with drug resistance, (5) select SNPs suitable for probe and primer design,
and (6) use at least two SNPs for the screening of isolates, as the specificity of each SNP
might vary.
Using our combined approach and linking it to clinical and contact tracing data, we
found that the tuberculosis cluster continued to propagate in Bern, mainly in particular
transmission hotspots and in the originally described high-risk populations of substance
abusers and homeless people (Genewein et al., 1993). This is consistent with previous
reports from other low-incidence settings (Anderson et al., 2014; Bamrah et al., 2013;
Mitruka et al., 2011; Zenner et al., 2013). The outbreak involved a key patient who
caused numerous secondary cases, which corresponds to superspreader behavior. Most
outbreak cases occurred between 1991 and 1995, followed by 16 years of sporadic cases,
the majority of which were likely cases of reactivation tuberculosis. The cases in the early
1990s coincided with known peaks of heroin abuse in Switzerland. However, 32.4% of all
cluster cases involved the nonmilieu population, possibly reflecting transmission from the
milieu to the wider community.
In retrospect, more secondary cases could have been identified if our novel screening
method had been available in the 1990s. Indeed, strain-specific SNP typing would have
provided an inexpensive method to identify outbreak cases more rapidly. Furthermore,
targeted WGS would have identified superspreaders in a context where contact tracing
is particularly difficult. Such superspreader behavior could have then been targeted with
intensified control measures to interrupt transmission.
The targeted WGS analyses of all cluster isolates identified by strain-specific SNP typ-
ing shed new light on the transmission dynamics of the outbreak, compared with tradi-
tional genotyping methods. Whereas MIRU-VNTR and spoligotyping showed identical
genotyping patterns, WGS revealed distinct genotypes for 76.5% of the Bernese cluster
isolates. In particular, we identified four genomic subclusters not revealed by classical
genotyping, likely reflecting concomitant but independent clusters of a common ancestral
strain. However, the genetic distances between subclusters were small (one, two, and
three SNPs between subclusters 1, 2, and 3), and therefore the definition of “subcluster”
may be debatable. The subclusters were, however, supported by FST values indicating
separation of these populations.
Two sequential isolates from the key patient, isolated in 1988 and 1991, occupied the
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central positions of subclusters 1 and 3, respectively. This suggests that two disease
episodes of this patient led to two independent star-like patterns in the genomic network,
indicating superspreader behavior (Gardy et al., 2011; Roetzer et al., 2013; Walker et al.,
2013b). The central role of this patient was already suspected in the original description
of the outbreak (Genewein et al., 1993). Hence, WGS analyses indicated that this patient
likely caused more secondary cases than previously assumed.
Despite the many advantages of WGS, our results also showed that interpreting WGS
data has limitations. For example, nearly 25% of cluster isolates were genomically indis-
tinguishable from at least one other isolate. This emphasizes the need to include repetitive
regions of the genome that are currently excluded because of technical limitations (Bryant
et al., 2013a; Copin et al., 2014). Furthermore, there is increasing evidence that bacterial
populations within patients are heterogeneous as a consequence of ongoing microevolu-
tion, further complicating the interpretation of transmission events (Pérez-Lago et al.,
2014). In our study, genomes were generated from single colonies for most isolates. Yet,
considering potential clonal variants that were randomly excluded from the sequencing
process could influence the way transmission events are inferred. With improving se-
quencing technologies, future studies should sequence bulk isolates rather than single
colonies and consider within-host heterogeneity in bacterial populations. Mutations can
also arise during laboratory culture; these could be avoided by performing WGS directly
from sputum (Blainey, 2013).
In conclusion, our strain-specific SNP-based screening approach offers a rapid and in-
expensive way of tracking tuberculosis outbreaks retrospectively and prospectively. This
novel screening method, combined with targeted WGS, can be used to guide control inter-
ventions by rapid and inexpensive screening, revealing transmission hotspots and missing
links in transmission chains. Future studies could use this approach in real time to track
ongoing outbreaks of tuberculosis and other infectious diseases in hospital settings, as
well as population-wide.
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7.1. Abstract
Tuberculosis has been co-evolving with humans for 70,000 years. Today, seven main phy-
logenetic lineages of the Mycobacterium tuberculosis complex (MTBC) are found among
human isolates, each associated with particular human populations. An “out-of-Africa”
scenario was proposed to explain the present-day phylogeographic distribution. The
“Euro-American” lineage, also known as “Lineage 4”, has likely emerged as one of three
“modern” lineages of MTBC around 46,000 years ago. Despite the hypothesized expansion
in Europe, Lineage 4 has been observed on all continents, and is also the main cause of
TB in the Americas. The reasons for this apparent “success” of Lineage 4 are unclear.
Lineage 4 comprises various “subtypes”, but whether these are homogeneously distributed
in the world is unknown. We hypothesized that European explorations (starting with the
Age of Discovery in the 15th century) and European colonialism in Africa, Asia and the
Americas at least partially account for the prevalence of the “European” genotype on all
continents. We aimed at inferring the evolutionary history of Lineage 4.
We first used 72 whole genome sequences of Lineage 4 isolates to define 10 sublineages
and to extract sublineage-specific phylogenetic markers. We developed a new single nu-
cleotide polymorphism (SNP)-genotyping assay based on the Luminex platform, which
we used to screen 3,366 isolates for sublineage classification. Plotting isolate sublineage
against patient place of birth revealed a phylogeographically structured population of
Lineage 4 sublineages. Five of the 10 sublineages were not observed among 228 isolates
from European patients, and were locally restricted to particular geographical areas (L4.2,
L4.4, L4.7, L4.8, L4.9). These included three sublineages only seen in Africa (L4.2, L4.8,
L4.9). Three sublineages were found frequently in Europe and, at the same time, partic-
ularly widespread globally (L4.3, L4.5, L4.10). Each of these three global sublineages was
observed in more than 40 of the 100 countries represented in this study.
Next, we focused on the most frequent of the globally distributed sublineages, L4.5 (also
known as the “Latin-American Mediterranean” (LAM) family), using 150 whole genome
sequences from MTBC isolates from all continents. Analysis of 12,256 SNPs resulted in
a phylogeny with five genetically distinct clades among the LAM sublineage. Maximum
Parsimony and Bayesian reconstruction of ancestral characters supported a hypothetical
ancestor of LAM isolates in Europe with 100% and 66% probability, respectively. We also
found that LAM isolates from TB patients in Europe harboured significantly more genetic
diversity than isolates from Africa and the Americas, and that the average nucleotide
diversity of these isolates decreased with the geographic distance from Lisbon.
Our data show that Lineage 4 is a globally prevalent lineage with a remarkably struc-
tured phylogeography. The fact that five MTB Lineage 4 sublineages do not appear to
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occur in Europe points at an early dispersal of Lineage 4 genotypes, preceding the intro-
duction of Lineage 4 into Europe. The three sublineages most frequently seen in Europe
and also occurring on all other continents support a (perhaps more recent) dispersal from
Europe. In particular, our data are consistent with the notion that the global distri-
bution of the L4.5/LAM sublineage reflects global waves of European exploration and
colonization. However, the relatively weak negative correlation of genetic diversity with
geographic distance, as well as the lack of phylogenetic clustering by geography, indicates
that LAM genotypes have also been circulating globally, perhaps as a consequence of
increasing globalization.
115
7.2. Introduction
Tuberculosis (TB) is estimated to have caused more than one billion human deaths in the
last two centuries. Today, TB still causes 8.6 million new cases and 1.3 million deaths a
year (Selgelid, 2008; WHO, 2013). Evolutionary studies of the causative agent, Mycobac-
terium tuberculosis (MTB), suggest that MTB has co-evolved with humans for thousands
of years and spread globally with human migrations (Hershberg et al., 2008; Wirth et al.,
2008; Comas et al., 2013). Seven main human-associated phylogenetic lineages of MTB
are found today; these are associated with particular geographic regions and human pop-
ulations (Gagneux et al., 2006b; Jong et al., 2010; Pareek et al., 2012; Fenner et al., 2013;
Firdessa et al., 2013; Comas et al., 2013). Over recent years, there has been increasing
evidence that strain variation in MTB influences the outcome of TB (Coscolla et al., 2010;
Click et al., 2012; Caws et al., 2008). MTB Lineage 4, also called the “Euro-American”
lineage, is one of three phylogenetically “modern” lineages of the Mycobacterium tuber-
culosis complex (MTBC), and has likely evolved from a common ancestor of Lineages
2, 3 and 4 around 46,000 years ago in the Eastern Mediterranean region, spreading to
Europe subsequently with human migrations (Wirth et al., 2008; Comas et al., 2013).
Today, MTB Lineage 4 is the predominant cause of TB in Europe as well as in North-
and South-America (Gagneux et al., 2006b). But Lineage 4 has repeatedly also been de-
scribed in high proportions in Africa (Ani et al., 2010; Wampande et al., 2013), and with
varying prevalence in Asia (Panel A in Figure 7.1) (Nahid et al., 2010; Li et al., 2011).
Reasons for the global distribution and broad “success” of MTB Lineage 4 are unknown.
The global prevalence of Lineage 4 was proposed to have its origin in the explorations
and migrations of Europeans to the world in the past centuries (Hershberg et al., 2008).
The huge historic burden of TB in Western Europe (a mortality of up to 1% between the
18th and 19th century (Murray, 2001)), the exponential population growth in the last
centuries (Panel B in Figure 7.1) and the subsequent migrations from Europe to other
continents may have shaped the global population structure of Lineage 4. However to
date, no comprehensive study adressing the evolutionary scenario of MTB Lineage 4 us-
ing genomic data has been performed.
Various subgroups or sublineages of MTB Lineage 4 (strain/genotype families) have
been described. Among them are the well-known families known as “H” (Haarlem), “X”,
“T” and “LAM” that were originally defined based on IS6110-RFLP and spoligotyping
(Brudey et al., 2006; Comas et al., 2009b). Using early genomic approaches, sublineage-
specific large sequence polymorphisms were identified (Gagneux et al., 2006b), and are
now used as sublineage-specific markers (Anderson et al., 2013; Rindi et al., 2012). Later,
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Figure 7.1.: Today’s global phylogeography of the MTBC, and the TB mortality in Europe
during the last thousand years. A. Strains of the “Euro-American” lineage, also called
MTB Lineage 4, were reported to be the predominant cause of TB in Europe, North and
South America, but are also highly prevalent in Africa, and partly in Asia. Dots indicate
predominant phylogenetic lineages per country; colors correspond to lineage colors in 1.4.
Modified from Gagneux et al. (2006b). B. The European population has exponentially grown
in the last 1000 years. In parallel, the mortality due to TB in Western countries was up to
1000 times higher between the 17th and 20th century than today. European explorations
and colonizations of other continents potentially spread particular “European” genotypes of
the MTBC globally. Mortality data from Murray (2001), population data from Feuerwerker
(1990). Population data point for 2009 from www.worldpopulationstatistics.com.
single nucleotide polymorphism (SNP)-schemes were developed for the classification of
clinical isolates (Baker et al., 2004; Filliol et al., 2006; Abadia et al., 2010; Bergval et al.,
2012; Homolka et al., 2012). All classification schemes, however, were either based on
suboptimal markers (Comas et al., 2009b), or suffer from discovery bias (Achtman, 2012),
and therefore provide an incomplete picture. Furthermore, the various molecular markers
and genotyping schemes have lead to confusing strain definitions and nomenclatures. In
the last years, large-scale whole genome sequencing (WGS) has become widely available
and allows generating unambiguous and robust phylogenies of MTBC (Comas et al.,
2009b; Achtman, 2012). A robust phylogenetic framework for MTB Lineage 4, based on
a large representative collection of isolates and WGS data, is now needed to be able to
compare between studies.
One sublineage of Lineage 4, the “Latin American Mediterranean” (LAM) family, has
been described as particularly widespread (Lazzarini et al., 2007; Brudey et al., 2006;
Gibson et al., 2008; Ignatova et al., 2006; Casali et al., 2012; Lanzas et al., 2013). The
genotype “Latin-American Mediterranean” was named in 2001 based on spoligotyping and
VNTR data after the regions where it was first observed (Sola et al., 2001). Thousands of
LAM isolates have been reported since then, with particular subtypes of LAM dominating
in different regions (Gibson et al., 2008; Demay et al., 2012). The evolution and global
distribution of LAM strains has been the subject of ongoing discussions (Mokrousov et
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al., 2014). Interestingly, strains of the LAM family were described to be the predomi-
nant genotypes in Southern Europe (Lopes et al., 2013), but also in Sub-Saharan Africa
(particularly in the coastal regions) (Pillay et al., 2007; Viegas et al., 2010), in South
America (Gibson et al., 2008; Lanzas et al., 2013; Gomes et al., 2012; Lopes et al., 2013),
and in some countries of South-East Asia (Demay et al., 2012). We hypothesized that
the LAM genotype, potentially representative for the whole MTB Lineage 4, was dis-
tributed from (Southern) Europe to other continents by early Spanish and Portuguese
explorations starting in the 15th century, colonization of the Americas, and imperial colo-
nialism in Africa and Asia (Lehning, 2013; Barr et al., 2014). We asked the question if the
phylogenetic structure seen today supports the origin and dissemination from a European
origin, or, if more recent and increasing migrations and trade have lead to a “everything-
is-everywhere” situation of the LAM genotype. Specifically, assuming an “export” of the
LAM sublineage from Europe, we expected a phylogeny structured by geographic region
and a higher genetic diversity of LAM strains in Europe compared to all other continents
(due to bottlenecks and clonal expansion in the “receiving” regions) compared to Europe.
To test these hypotheses, we used population genomic methods to infer the evolutionary
trajectory of MTB Lineage 4. First, we used a reference collection of 72 MTB Lineage 4
whole genome sequences to define evolutionary robust sublineages of MTB Lineage 4.
We then used SNP-typing with sublineage-specific SNPs to classify 3,366 clinical isolates
and to estimate the frequencies of Lineage 4 sublineages in different regions of the world.
Finally, we applied targeted whole genome sequencing to 150 global LAM isolates, and
used population diversity estimates to test the hypothesis of global dissemination of the
LAM sublineage from Europe.
7.3. Methods
7.3.1. MTBC isolates and DNA extraction
All MTBC isolates were obtained from existing strain collections, where ethics approval
was obtained in the original study.
For the definition of Lineage 4 sublineages, we aimed at covering maximal diversity of
MTB genotypes, i.e. selected isolates based on spoligotyping data, large sequence poly-
morphisms and diverse geographical origins. For the total of 72 whole genome sequences,
we included all MTB Lineage 4 genome sequences and representative strains of other main
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phylogenetic lineages from Coscolla et al. (2013) and Comas et al. (2013), and additionally
generated WGS of selected isolates from various ongoing studies. For the latter, purified
DNA was obtained with the CTAB method (Embden et al., 1993).
For the screening of clinical isolates for sublineage-classification, we used 2,763 MTB
Lineage 4 DNA isolates from 100 countries (country of birth of the patient) and vari-
ous ongoing studies. All isolates were previously identified as MTB Lineage 4 isolates
by SNP-typing, RD-typing or spoligotyping. Purified DNA or crude, heat-inactivated
extracts were obtained as previously described (Stucki et al., 2012), or with comparable
protocols. All 2,763 isolates were randomly selected. Additionally, we obtained sublineage
data for 156 isolates from a collection of strains from Uganda, in which the L4.8/“Uganda”
genotype had been previously identified (Wampande et al., 2013). To correct for the pro-
portion of L4.8/“Uganda” isolates in the same time period, we estimated the corresponding
proportion of L4.8/“Uganda” genotype in Uganda based on reported data (Wampande et
al., 2013) and added 447 data points of L4.8 for the sublineage phylogeography. These
data were not included for the frequency figures (Figure 7.6). Including isolates from
Uganda, we therefore used sublineage classification data for 3,366 isolates with known
country of birth of the patient. Approximately one third of these isolates were from pa-
tients immigrated to Switzerland or to the US (1,106; 32.9%), where we used country of
birth of the patient as a proxy for country of infection with the MTB strain, as previously
done (Fenner et al., 2012b; Anderson et al., 2013; Gagneux et al., 2006b). Two thirds
of the isolates (2,260; 67.1%) were from countries where both country of isolation and
country of birth were identical.
For the set of 150 “LAM” strains used for WGS, we included previously sequenced strains
and added selected isolates identified during the sublineage-SNP-typing. Additionally, we
downloaded genome sequences from Lanzas et al. (2013) and Coll et al. (2014). The
reference strain H37Rv and one isolate of L4.6 were included as the outgroup.
7.3.2. Whole genome sequencing, SNP calling and diversity
analyses
Whole genome sequencing was performed using Illumina chemistry (GAIIx and HiSeq,
paired end or single end). We used a pipeline as previously described for the mapping
of short sequencing reads to the reference genome (a hypothetical MTBC ancestor strain
(Comas et al., 2010)) with BWA (Coscolla et al., 2013)(and Chapter 6). As a difference
to the previous pipeline, we used a dynamic minimum reads threshold for SNPs to be
kept, corresponding to 10% of the mean coverage over the whole genome. SNPs with a
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quality of less than 30 (QUAL field in VCF files), and SNPs with a coverage of more than
double the average genome coverage were excluded. Illumina MiSeq-generated sequencing
reads were clipped for Illumina adapters with Trimmomatic (Bolger et al., 2014) before
mapping. All SNPs were then annotated using H37Rv reference annotation (AL123456.1)
with Annovar (Wang et al., 2010) and customized scripts. SNPs in regions annotated as
“PE/PPE/PGRS”, “maturase”, “phage” and “insertion sequence” were removed. The final
alignment of polymorphic positions in all strains was imported into MEGA5 (Tamura
et al., 2011). Phylogenetic trees were built using Maximum Likelihood. Positions with
gaps in more than 90% of sequences were ignored. Pairwise SNP distances were calculated
using the “Compute pairwise distance” function in MEGA5. Genetic diversity (nucleotide
diversity pi, the average pairwise distance between two DNA sequences per site) and fixa-
tion indices (FST; an estimation of population separation) were calculated using Arlequin
3.5 (Excoffier et al., 2005) and DnaSP v5 (Librado et al., 2009). Populations were defined
according to country of birth of the patient, either as continents or large geographic re-
gions according to the United Nations definition1. The presence of large deletions (large
sequence polymorphisms, LSP, according to Gagneux et al. (2006b)) was assessed by
manually inspecting BAM alignment files from BWA mappings in Artemis (Rutherford
et al., 2000) for the presence of reads at the genomic regions with described deletions. For
the definition of MTB Lineage 4 sublineages, we performed principal component analy-
sis (PCA) with Jalview2, using the alignment of all variable positions extracted from 72
whole genome sequences of Lineage 4 isolates.
7.3.3. Identification of sublineage-specific SNPs
The alignment of all SNPs from the initial 72 MTB Lineage 4 strains was converted to
NEXUS format and imported into Mesquite (Maddison et al., 2011), in parallel with
the phylogenetic tree generated from the same data in MEGA5. We then used the
“Trace Character History” module of Mesquite to map polymorphisms to clades. The
full dataset of reconstructed positions was exported to an OpenOffice spreadsheet, and
sublineage-specific SNPs were extracted as nucleotide differences between internal nodes
of the phylogeny.
1https://unstats.un.org/unsd/methods/m49/m49regin.htm
2http://www.jalview.org
120 7. Global spread of MTB Lineage 4
7.3.4. SNP-typing to screen for MTB Lineage 4 sublineages
We developed a new SNP-typing assay to screen clinical isolates for the defined sublin-
eages. For this, we selected one canonical SNP per sublineage using previously defined
methods and criteria. Oligonucleotides were designed for a 10-plex MOL-PCR assay
based on the Luminex xTag platform (Luminex, Austin, USA) (Stucki et al., 2012) (Fig-
ure 7.2 and Table 7.1). DNA extracts from clinical MTB isolates (previously confirmed as
MTB Lineage 4 isolates) were screened with i.) the new MOL-PCR assay, ii.) standard
PCR amplification plus subsequent Sanger sequencing of the region up- and downstream
of the sublineage-specific SNP (isolates from New Zealand and Canada; PCR primers
in Table 7.2), iii.) a real-time PCR melting curve assay using the same SNPs (isolates
from China), or iv.) the MassARRAY platform (Sequenom, San Diego CA, USA) using
phylogenetically redundant SNPs (samples isolated in San Francisco).
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7.3.5. Reconstruction of ancestral geographical origin of LAM
strains
The software RASP (Yu et al., 2010) was used to reconstruct the hypothetical geographic
origin of the MTBC LAM ancestor genotype. As input, the alignment of all 12,256
SNPs among 150 LAM strains plus the two outgroup strains was used. Both Maxiumum
Parsimony (S-DIVA) as well as Bayesian Binary Method were used.
7.3.6. Genetic diversity of LAM strains compared to geographical
distances
To analyze the association between genetic diversity of LAM strains and distance from a
reference point, we used great circle distances between capitals of each country and the
reference point (Lisbon, Mexico City or Brasilia) as geographical distances. For each large
geographical UN region (see above), we calculated within-population nucleotide diversity
(pi). In parallel, we calculated for each isolate the geographical distance between capitals
of the countries of origin and the reference point. We plotted the mean geographical
distance against the nucleotide diversity. One LAM strain was excluded as the patient
place of birth was unknown. The single isolate from the Oceania region (a patient from
Australia) was also excluded. GraphPad Prism (GraphPad Software, La Jolla, USA) was
used for statistical analyses and figures.
7.3.7. Estimation of MTB Lineage 4 prevalence
To estimate the proportion of MTB Lineage 4 among all MTBC isolates, we used the
“Online Tools”/“Clade Distribution” function of the SITVITWEB database on http://
www.pasteur-guadeloupe.fr:8081/SITVIT_ONLINE/index.jsp and extracted data for
each country separately. Spoligotyping families with either of the text strings “LAM”,
“S”, “H”, “MANU”, “T” or “X” were categorized as MTB Lineage 4; spoligotypes with
text strings “EAI”, “PINI”, “AFRI”, ,“BOV”, “CAS” or “BEIJING” as non-Lineage 4, and
“ZERO” and “UNKNOWN” as “unknown” (referring to Coscolla et al. (2010) and Comas
et al. (2009b)). Orphan spoligotypes are not included in the “Clade Distribution” function
of the SITVITWEB database. A total of 49,799 data points were used.
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7.4. Results
7.4.1. Definition of 10 MTB Lineage 4 sublineages
We first aimed at defining sublineages within MTB Lineage 4. We started with 72 MTB
Lineage 4 whole genome sequences. A total of 9,455 genomic single nucleotide positions
were variable among these 72 strains, and used to generate a Maximum Likelihood phy-
logeny. The overall topology of this phylogeny was congruent with previously published
topologies (Comas et al., 2013). Based on the Lineage 4 phylogeny (Figure 7.2), we ini-
tially defined sublineages by the branching depth of the topology (dashed line in Figure
7.2), indicating in 9 sublineages. We further subdivided one clade into L4.8 and L4.9, as
these two sublineages had been previously defined based on specific regions of difference
(RDs) (Gagneux et al., 2006b) and spoligotyping data (Niobe-Eyangoh et al., 2003; Nie-
mann et al., 2002), and the definitions have been widely used in various typing schemes
(“Uganda” family, RD724-deleted, historically known as M. africanum subtype II (Jong
et al., 2010), and “Cameroon” family, RD726-deleted). We continued our study based on
10 defined sublineages.
To validate our definitions, we used five different approaches. First, we performed
principal component analysis (PCA) using the complete SNP alignment of 9,455 SNPs.
PCA showed a clear separation of seven sublineages (L4.1, L4.2, L4.3, L4.4, L4.5, L4.6,
L4.10; Figure 7.3). Sublineages L4.7, L4.8 and L4.9, however, were less clearly separated,
likely mirroring the (intended) subdivision of the initial sublineage into these two “sub-
sublineages” (see above). L4.8 and L4.9 (“Uganda” and “Cameroon”) are part of a larger
clade including three additional isolates from Ethiopia.
Second, we calculated pairwise SNP distances between and within the defined sublineages.
Whereas the mean pairwise SNP distance between any two of all 2,556 pairs (72 isolates)
was 564 SNPs, the distance between pairs within the defined sublineages was significantly
lower than between pairs between sublineages (242 SNPs vs. 601 SNPs, p < 0.0001, Table
7.3), supporting our sublineage definitions.
Third, we calculated sublineage-pairwise fixation index values (FST). FST values are
a concept from diploid organisms and indicate the degree of separation between two
populations based on nucleotide differences, and range from 0 (“panmixis”, i.e.
no population separation) to 1 (completely separated populations). All FST values (Table
7.4) between our defined sublineages were found to be larger than 0.33, indicating good
population separation, i.e. a reasonable definition of sublineages.
Fourth, we compared the genetic diversity among all 72 isolates with the genetic di-
versity within each sublineage. We used nucleotide diversity pi, the mean number of
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Table 7.3.: Mean pairwise SNP distances within and between isolates of defined sublineages.
Distance within sublineages Distance to other sublineages
L4.1 325 621
L4.2 26 622
L4.3 162 600
L4.4 323 656
L4.5 274 605
L4.6 330 556
L4.7 321 608
L4.8 220 554
L4.9 136 589
L4.10 307 596
Mean 242 601
nucleotide differences per site, between any two DNA sequences of a population (in our
case the sublineages). The nucleotide diversity was found lower within each sublineage
than among all 72 isolates, indicating a valid level of sublineage definition (Figure 7.4).
However, for L4.4, the difference to the nucleotide diversity among all isolates was not
statistically significant (overlapping confidence intervals). Differences between sublineages
were not significantly different except for sublineages 4.2 and 4.3.
Last, to further support our definitions and to make a comparison with other studies
possible, we mapped previously reported markers, i.e. SNPs and RDs, onto our genome-
based phylogenetic tree (Sreevatsan et al., 1997; Gagneux et al., 2006b; Filliol et al.,
2006; Abadia et al., 2010; Homolka et al., 2012) (Supplementary Figure 7.5). Many
of the markers overlapped and therefore supported our definitions. However, the figure
also revealed that previous sets of markers were incomplete, and that no comprehensive
RD/SNP set had been defined hat would include all our sublineages. In particular, no
markers had been reported for sublineages L4.4 and L4.6. So far, no marker has been
identified that was not covered by our definitions, indicating the completeness of our set
of 10 defined sublineages.
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Figure 7.2.: Maximum likelihood phylogeny of 72 whole genome sequences of Lineage 4 strains
and 9455 SNPs. Bootstrap values are indicated. On the right side of the tree and colored
are the newly defined sublineages of Lineage 4. Previously reported markers from other
publications are mapped to the same tree in Figure 7.5.
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Figure 7.3.: Principal component analysis of 9455 SNPs in 72 Lineage 4 strains. Each dot
represents one of 72 MTB Lineage 4 strains. Colors correspond to Figure 7.2.
Table 7.4.: Pairwise FST values between MTB lineage 4 sublineages. Numbers in brackets are
values with p>0.05. All other values were statistically significant.
L4.1 L4.2 L4.3 L4.4 L4.5 L4.6 L4.7 L4.8 L4.9 L4.10
L4.1 0
L4.1 0
L4.2 0.408 0
L4.3 0.432 0.683 0
L4.4 0.387 0.448 0.527 0
L4.5 0.510 0.631 0.630 0.413 0
L4.6 0.417 (0.57) 0.590 0.330 0.430 0
L4.7 0.471 (0.63) 0.649 0.387 0.500 0.389 0
L4.8 0.486 0.679 0.660 0.414 0.510 0.411 0.471 0
L4.9 0.523 (0.67) 0.692 0.455 0.563 0.471 0.509 0.508 0
L4.10 0.487 0.588 0.594 0.429 0.482 0.389 0.437 0.427 0.499 0
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Figure 7.4.: Nucleotide diversity (per polymorphic site) of MTB Lineage 4 sublineages, cal-
culated with Arlequin software. A total of 8,872 polymorphic sites were used. Error
bars indicate confidence intervals.
7.4.2. Phylogeographic distribution of Lineage 4 sublineages
We then aimed at extracting informative, sublineage-specific SNPs as markers for the
newly defined sublineages. Using the 9,455 variable positions among the 72 MTB Lin-
eage 4 strains, we found between 51 and 277 SNPs specific for the corresponding sublin-
eage. Suitable markers were extracted and globally representative clinical isolates screened
for sublineage classification. We obtained sublineage-classification data for 3,273 (97.2%)
of a total of 3,366 SNP-typed isolates. The remaining 93 (2.8%) isolates failed during
SNP-typing. A total of 92/3,273 (2.8%) isolates were found to harbour the reference
allele for all 10 sublineages (i.e. not classified into any of the ten sublineages), but were
confirmed to be Lineage 4 isolates, and potentially representing additional sublineages.
Each of the remaining 3,181 isolates was classifed into one of the ten defined sublineages.
Sublineage L4.5 (“LAM”) was the most frequent sublineage with a global proportion of
22.9% among all sublineages, followed by L4.10 (14%), L4.3 (11.6%), L4.1 (11%), L4.9
(10.4%) and L4.6 (10.7%) (Panel A in Figure 7.6). However, frequencies were likely bi-
ased by the unequal distribution of isolates among countries (Panel B in Figure 7.6).
We therefore plotted the relative frequencies of sublineages in each country (country of
birth of patient) to a global map. Figure 7.7 shows that MTB Lineage 4 sublineages are
phylogeographically structured, i.e. were found in unequal proportions between countries,
and different sublineages were found to be predominant in different geographic regions
of the world. Strikingly, individual sublineage ‘heat maps” (Figure 7.8) revealed sublin-
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Figure 7.5.: Phylogenetic tree of 72 whole genome sequences as in Figure 7.2, with previously
reported Lineage 4 sublineage specific markers mapped. Boxes on branches represent
large sequence polymorphisms (LSP), also known as regions of difference (RD), as defined by
Gagneux et al. (2006b) and used by Lazzarini et al. (2007). Circles are clade-specific SNPs
previously defined by Sreevatsan et al. (1997), Filliol et al. (2006), Abadia et al. (2010) and
Homolka et al. (2012).
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Figure 7.6.: Sublineage L4.5 of MTB Lineage 4 (“LAM”) was the most frequent sublineage in
our dataset. A. Pie chart showing global frequencies of sublineages. Data of 2763 isolates
were used (excluding data from Uganda, see above). B. Bar chart showing isolates by country
of birth of the patients, stratified by sublineages. Category “others” includes countries with
less than 20 isolates. Colors correspond to sublineage colors in panel A.
eages that were present globally, and sublineages that were locally restricted. Sublineages
L4.3 (Haarlem), L4.5 (LAM) and L4.10 (PGG3) were found globally. Sublineages L4.2
(Ghana), L4.4 (Ural), L4.7, L4.8 and L4.9 were restricted to specific geographical regions.
Sublineage L4.1 (X) was observed in the Americas and in lower proportions in few coun-
tries of Southern Africa, Asia and Europe. L4.6 was seen in high proportions among
isolates from Asia, and in lower proportions among isolates from few countries in Africa,
Europe and the Americas.
Each of the three global sublineages (L4.3, L4.5, L4.10) were found in more than 45
countries (Figure 7.9). The L4.5/“LAM” sublineage was found with a proportion of 30-
100% in 47 countries in which it was observed (Figure 7.9).
Five of the 10 sublineages were not observed among patients born in Europe. Among
the other five sublineages, L4.3 (Haarlem), L4.5 (LAM) and L4.10 (PGG3) were found
frequently in Europe and in high proportions. L4.1 and L4.6, on the other hand, were
observed only in four and five European countries, respectively, and in low proportions.
Importantly, the three sublineages most frequent in Europe were also observed globally.
7.4.3. Discovery of new diversity
We generated whole genome sequences of 17 of the 92 isolates (18.5%) that were not
classified into any of the 10 defined sublineages i.e. harbouring the ancestral allele for
all 10 SNPs). The resulting phylogenetic tree (Supplementary Figure 7.10) showed the
same topology as in Figure 7.2, but revealed that the 17 isolates (plus the previously
uncategorized 3 isolates clustering with L4.8 and L4.9) branched off towards to root of
tree compared to the branching points of the defined sublineages. Interestingly, these
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Figure 7.7.: Lineage 4 sublineages were found globally distributed, but proportions of sub-
lineages varied depending on the country and the geographical region. Pie charts
show proportions of the 10 sublineages among all MTB Lineage 4 isolates per country. Circle
sizes correspond to number of isolates per country. Data obtained from screening 3,366 MTB
Lineage 4 isolates with sublineage-specific SNPs.
strains did not form a distinct new sublineages; instead they were spread across the
phylogeny.
7.4.4. Reconstruction of the global dispersal of LAM strains by
whole genome sequencing
To address the evolutionary scenario of MTB Lineage 4, we focused on the presumably
most “successful” sublineage, L4.5/“LAM”, and generated whole genome sequences of 150
isolates. We found 11,352 SNPs separating the 150 LAM isolates (12,256 SNPs including
the outgroup). The mean pairwise distance between two LAM isolates was 387 SNPs
(range 6-581; standard deviation 97). The resulting Maximum Likelihood phylogeny
showed several sub-groups which we labelled subgroups A to E (Figure 7.11); we also
included the previous definitions of RDRio/RD174 (Lazzarini et al., 2007) and RD115
(Gagneux et al., 2006b).
We first tested the hypothesis that the phylogeny reflects a LAM strain population
structured by geography, i.e. that particular LAM sub-clades are associated with geo-
graphical regions. To that end, we mapped the strain origin (patient place of birth) of
each LAM strain to the phylogeny (colored tree tips by continent in Figure 7.5). Overall,
the four continents were heterogenously distributed among all subgroups (Figure 7.11),
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Figure 7.8.: Heat maps of the proportions of the different sublineages reveal “global” versus
“local” sublineages. Sublineages L4.1 (X), L4.3 (Haarlem), L4.5 (LAM), L4.6 and L4.10
(PGG3) were found in higher proportions globally spread, whereas sublineages L4.2 (Ghana),
L4.4 (Ural), L4.7, L4.8 and L4.9 were restricted to certain geographical regions. Intensity
of red indicates proportion of the sublineage among all Lineage 4 isolates. Countries with
less than three isolates in total are shown as “no data” and are filled white. A total of 3,366
isolates was used. The scale for red intensity is the same for all sublineages (and indicated
at L4.9) except for the L4.2 sublineages (separate scale shown).
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Figure 7.9.: Isolates of five sublineages of MTB Lineage 4 (L4.1, L4.3, L4.5, L4.6, L4.10)
were found in more than twenty countries. Three sublineages were found in more
than 45 countries each (L4.3, L4.5 and L4.10). One of those sublineages, L4.5 (“LAM”), was
found with a proportion of 30-100% in more than 50% of the countries of occurrence. The
differences in proportions among sublineages were statistically significant (p=0.001, χ2 test).
but some regions were overrepresented in particular clades (Table 7.5). In subgroup A,
a subclade of the well-described RDRio family, 43% and 38% of isolates were from the
Americas and Europe, respectively, and less than 10% from Africa or Asia. By contrast in
subgroup C, no isolate from the Americas was detected. Most remarkable, 100% (19/19)
of the isolates in subgroup B1, also part of RDRio (named after its first description in
Brazil), were from Africa.
However, irrespective of the varying proportions of the different subgroups, we did not
identify any clade that branched off ancestrally and was represented by isolates from a
single continent only.
We continued by reconstructing the most likely geographical origin of the hypothetical
LAM ancestor genotype. Both Maximum Parsimony (100% probability) and Bayesian
(66% probability) approaches predicted “Europe” as the most likely character state of the
LAM ancestor (Figure 7.12). When we split Europe into Southern Europe and the rest of
Europe (following the hypothesis that LAM was mainly spread with early migrations from
Portugal and Spain), the signal for Europe was lost in the Bayesian approach (and com-
bined Central America and Africa was obtained as most likely origin; data not shown),
but remained strong for combined Southern and other Europe in the Maximum Parsi-
mony reconstruction (specific combinations of regions can not be defined in the Bayesian
approach, but can be defined in the Maximum Parsimony approach).
Next, we tested the hypothesis that the genetic diversity of LAM strains was highest
in Europe if the LAM sublineage originated in Europe. The “export” to other continents
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Figure 7.10.: Lineage 4 isolates that were not classified into any of the 10 defined sublineages
branch off more ancestrally compared to the ancestral node of the defined sub-
lineages. The phylogenetic tree was generated with all Lineage 4 isolates as in Figure 7.2
(collapsed branches), plus 17 newly sequenced isolates that were not classified into any of
the 10 sublineages. Colored, collapsed clades represent sublineages as shown in Figure 7.2.
Bootstrap values are indicated.
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Table 7.5.: Proportions of isolates from each continent in the subgroups of the LAM-
phylogeny as defined in Figure 7.11.
LAM group Europe Africa Asia Americas others
A 8 (38.1%) 2 (9.52%) 1 (4.76%) 9 (42.86%) 1 (4.76%)
B 7 (18.92%) 22 (59.46%) 2 (5.41%) 6 (16.22%) 0 (0%)
B1 0 (0%) 19 (100%) 0 (0%) 0 (0%) 0 (0%)
C 3 (42.86%) 2 (28.57%) 2 (28.57%) 0 (0%) 0 (0%)
D 8 (38.1%) 8 (38.1%) 0 (0%) 5 (23.81%) 0 (0%)
E 11 (17.46%) 17 (26.98%) 3 (4.76%) 27 (42.86%) 5 (7.94%)
E1 2 (9.09%) 7 (31.82%) 2 (9.09%) 11 (50%) 0 (0%)
would have represented population bottlenecks (followed by clonal expansion), in sum
reducing the genetic diversity in the non-European regions. Nucleotide diversity analysis
was indeed found significantly higher in Europe than in Africa and the Americas (ANOVA
p<0.0001 in Panel A in Figure 7.13). LAM strains in Asia were found to harbour a similar
level of diversity; however, only 12 isolates were included from Asia.
Finally, we assessed if the genetic diversity of LAM strains decreases with the distance
from Europe. Indeed, we found a weak correlation (R=-0.22, p=0.142) between distance
from Lisbon and nucleotide diversity (Panel B in Figure 7.13). In contrast, when we used
Mexico City or Brasilia as reference points, this correlation was lost (-0.05<R<0.05, n.s.).
7.4.5. Global prevalence of MTB Lineage 4
In order to estimate the TB burden caused by MTB Lineage 4 in different geograph-
ical regions of the world (in relation to all main phylogenetic lineages), we calculated
country-specific proportions of Lineage 4 among all phylogenetic lineages using data from
the SITVITWEB database (Demay et al., 2012). Knowing the limitations of phyloge-
netic classification using spoligotyping, we used data from 49,799 MTB strains from 76
countries in the SITVITWEB database, and found MTB Lineage 4 globally prevalent
with proportions between 0% (Singapore) and 100% (Dominican Republic) (Figure 7.14).
As expected, markedly different proportions of Lineage 4 were found between continents.
In the Americas, all countries were found to harbour more than 45% Lineage 4 isolates;
in Africa, all countries except Sudan had more than 30% Lineage 4 isolates, with many
countries more than 70%. In South-East Asia, on the other hand, no country was found
to harbour more than 35% Lineage 4 isolates. Interestingly, countries in Northern and
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Figure 7.11.: Maximum likelihood phylogeny of 150 isolates of the L4.5/“LAM” family of
MTB Lineage 4. H37Rv and one isolate of sublineage L4.6 were used to root the tree. A
total of 12,256 SNPs separated isolates. Bootstrap values are indicated in small font. Boxes
with “RD” designations indicate branches with the particular region deleted, identified by a
lack of sequencing reads mapping to the corresponding genomic region. The scale bar shows
number of substitutions (SNPs) per site.
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Figure 7.12.: The most likely geographical origin of the LAM ancestor genotype was found to
be Europe by both Maximum Parsimony and Bayesian estimations. Maximum
likelihood tree as in Figure 7.11 and known patient place of birth were used as input for
RASP software (Yu et al., 2010). Colors of circles show patient place of birth of the corre-
sponding MTB isolate (small circles) or the likely geographical region for the internal nodes
(large circles). Colors are indicated in the legend and differ between panels. Transpar-
ent circles indicate undetermined character state. A. Reconstruction of ancestral character
states (continent of origin) using the “Statistical Dispersal Vicariance Analysis” (S-DIVA)
algorithm of RASP, a Maximum Parsimony approach. Combinations of continents were
allowed for Northern, Central and South America (combinations of B, C and D). The LAM
ancestor, indicated with an arrow, had a 100% probability of Europe as reconstructed an-
cestral state. B. Reconstruction of ancestral states (continent) using the Bayesian Binary
Method, for which combinations of populations can not be given a priori, but are defined
by the algorithm.
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Figure 7.13.: Genetic diversity of LAM isolates per continent and world region. A. The ge-
netic diversity of LAM isolates, measured as nucleotide diversity per site (pi), was found
to be highest in Europe and Asia/Melanesia. Mean nucleotide diversity was significantly
different across all four continents (ANOVA, p<0.0001). Error bars indicate 95% confidence
intervals. B. A regression coefficient of R2=0.22 (dashed line, linear regression) indicates
that the genetic diversity (pi) decreases with geographical distance from Portugal, indicating
an origin of the LAM genotype in Europe (largest diversity due to origin) and subsequent
introduction to other continents (bottlenecks and clonal expansion leading to lower diver-
sity). Abbreviations are: WAF, Western Africa; SE, Southern Europe; EAF, Eastern Africa;
AM, Asia Melanesia; SAF, Southern Africa; CAM, Central America and Carribean; NAM,
Northern America; SAM, South America; MAF, Middle Africa; NAF, Northern Africa;
NWE, Northern, Western and Eastern Europe. The software DnaSP (Librado et al., 2009)
was used for nucleotide diversity calculations, using 10,120 of a total of 12,256 variable sites
without gaps. Mean great circle distances were used for geographical distance. For each
geographical region, we calculated the distance between Lisbon and the capitals of all coun-
tries of origin of the isolates, and used a mean value of the distance to be plotted against
genetic diversity. Error bars indicate confidence intervals of the population mean.
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Figure 7.14.: Proportion of Lineage 4 among all isolates (all lineages) shown by country.
Dark red color indicates a high proportion of MTB Lineage 4 among all isolates, blue color
low proportion of Lineage 4. Data was extracted from SITVITWEB (Demay et al., 2012)
using 49,799 MTB strains with known country of isolation and known spoligotypes, as
accessed on 22 April 2014. Percentages shown are Lineage 4 isolates among all isolates
of the corresponding country dataset, including unknown or uninterpretable spoligotyping
families. No data or less than 10 isolates is shown as white filled countries.
Western Europe showed a Lineage 4 prevalence of less than 50%, likely reflecting a large
proportion of immigrants among TB cases, who were infected with a non-Lineage 4 strain
from their country of origin (Gagneux et al., 2006b).
7.5. Discussion
MTB Lineage 4, previously called the “Euro-American” lineage, is geographically the most
widely distributed lineage of MTB. To better understand the distribution and evolution
of MTB Lineage 4, we defined 10 sublineages and found a spatially structured global
population with 5 locally restricted and 5 globally distributed sublineages. Remarkably,
the three sublineages observed frequently in Europe were also frequent globally. Zooming
into the most frequent and most widespread sublineage, the L4.5/LAM family of strains,
we used 150 WGS and found phylogenetic evidence that the origin of the LAM family
might have been in Europe. Additionally, the genetic diversity of LAM strains was found
highest in Europe and decreasing with distance from Europe.
As a first in the MTB strain genotyping era, we were able to comprehensively define
robust sublineages of MTB Lineage 4 based on whole genome data. These sublineages
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included all major, previously reported definitions using SNPs and LSPs (Supplementary
Figure 7.5), and also the most important spoligotyping families. Our definitions, though,
were more complete and included sublineages not defined before. To the best of our
knowledge, no SNP markers has been described to include all genotypes of our sublineages
L4.4 and L4.5. We recommend that future typing schemes should consider the complete
diversity of MTB Lineage 4, as data might otherwise suffer from discovery bias (Achtman,
2008). One objective of our study was to provide a framework for unambiguous MTB
Lineage 4 strain classification.
Our SNP-screening of clinical isolates demonstrated that more than 95% of MTB Lin-
eage 4 isolates can be categorized into one of our 10 sublineages. Furthermore, not a single
isolate of totally 3,366 was found with two simultaneously mutant sublineage-specific al-
leles, once more underlining the clonal population structure of MTBC (Comas et al.,
2009b). However, we found 3% of isolates with all 10 sublineage-specific SNP position
showing the ancestral allele. This indicated the presence of additional sublineages. Se-
quencing of a subset of these isolates identified them as taxa branching off ancestrally in
the phylogeny rather than forming genetically distinct new sublineages. However, we only
sequenced 17 of 92 (18.5%) of those isolates, and additional strains might indeed reveal
new sublineages. The constantly growing phylogeny shows that sublineage definitions are
not static and closing definitions, but working definitions that will change with increasing
coverage of the diversity. The reduction of branch lengths by adding taxa questions the
definitions of sublineages or “families” in the long run, and will push strain classification
from a categorical to a more continuous, dynamic process revealed by, and manageable
only using the high resolution of WGS.
We conclude that our iterative process of using WGS-defined clades and WGS-extracted
markers for subsequent SNP-screening of large isolate collections, and the subsequent se-
quencing of uncategorized isolates, is a successful strategy to uncover genetic diversity in
MTBC.
The global phylogeography of MTB Lineage 4 sublineages revealed a pronounced struc-
ture. Five sublineages were found in less than 20 of 100 countries included in the study,
and were locally restricted. Three of these sublineages, L4.2/“Ghana”, L4.8/“Uganda”
and L4.9/“Cameroon”, were found exclusively in sub-saharan Africa, except for anecdotal
cases in immigration countries. This finding is particularly interesting in the light of a
postulated European origin of MTB Lineage 4, and at least two alternative explanations
could account for this geographic restriction. On the one hand, L4.2, L4.8 and L4.9 might
have existed in Europe in low frequencies before, and were introduced by European ex-
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plorations somewhere along the coasts of Africa likely after 1471 (Diffie et al., 1977). A
scenario of clonal and spatially restricted expansion in Africa and the simultaneous ex-
tinction in Europe would then explain today’s distribution. It is tempting to speculate
that these sublineages are less virulent than other Lineage 4 genotypes and were therefore
extinct in Europe, but persisted in Africa as they were still more transmissible than My-
cobacterium africanum (Jong et al., 2010). M. africanum consists of two “ancient” lineages
of MTBC (Lineage 5 and Lineage 6) and was associated with a longer latency period and
a putative lower virulence as an adaption to low host-densities (Jong et al., 2008; Gag-
neux, 2012). As an alternative explanation, if an ancestral Lineage 4 strain originated in
Africa rather than Europe or the Middle East, these three sublineages would represent
the “ancient” sublineages that never migrated out of Africa. However, the complete lack
of these genotypes in the Americas despite the large population migrations from Africa to
the Americas make this scenario unlikely. Furthermore, the three sublineages L4.2, L4.8
and L4.9 do not form a monophyletic group in the phylogeny.
Sublineages L4.4 and L4.7 were found in large proportions in Eastern Europe and Asia.
These sublineages potentially represent “ancient” MTB Lineage 4 sublineages that di-
verged from a common MTB Lineage 4 ancestor preceding the introduction of MTB
Lineage 4 in Europe. Consistent with this finding is the recent description of up to 45.9%
non-“Beijing” isolates (but mainly MTB Lineage 4) in China (Li et al., 2011), mainly
in Western China. However, these two sublineages do not form a monophyletic group,
and we therefore conclude that strains from at least two independent branching events
of MTB Lineage 4 have migrated from a common ancestor eastwards. Consistently, the
branching point of L4.4/“Ural” was found to be the most ancestral of all sublineages.
Sublineages L4.1 and L4.6 were inconclusive. Sublineage L4.1/“X” was found mainly
in Northern America, but in smaller proportions also in South America, Africa and Asia.
Interestingly, a “sub-sublineage” of L4.1 (RD183 deleted) has recently been found to be
associated with genotypic clustering in San Francisco (Anderson et al., 2013). This po-
tential hypertransmissibility could be associated with host genetic factors and/or social
factors. Isolates of L4.6 (including the “S” spoligotyping family) were observed in higher
proportions in East and South-East Asia, partly in Africa and the Americas and almost
absent from Europe. This also indicates a dispersal preceding the introduction into Eu-
rope.
Sublineages L4.3/“Haarlem”, L4.5/“LAM” and L4.10/“PGG3” were found in more than
40 countries each, and had been described frequently by others (Durmaz et al., 2007;
Homolka et al., 2008; Demay et al., 2012; Rindi et al., 2012; Traore et al., 2012; Lopes
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et al., 2013). This finding is consistent with a global distribution from Europe. The
LAM sublineage was additionally present with a frequency of more than 30% among
all MTB Lineage 4 strains in more than 50% of the countries in which it occurred, po-
tentially reflecting hypertransmissibility or other factors contributing to its global success.
Concluding on the phylogeography of MTB Lineage 4 sublineage, we provide a solid
basis for future studies looking at clinical and biological differences between sublineages
of MTB Lineage 4, and for evolutionary studies. Lineage 4 was found globally prevalent
despite its original name “Euro-American”. However, the absence of at least five of the 10
sublineages from Europe speaks against the hypothesis that the complete MTB Lineage 4
dispersed from (Central/Southern) Europe. A more complex evolutionary scenario is
therefore expected and needs further research using increased sample numbers especially
from the Eastern Mediterranean and Central Asian regions.
We acknowledge that the proportions we calculated represent proportions among all
MTB Lineage 4 isolates, not among all MTBC isolates (all lineages). The global frequen-
cies of MTB Lineage 4 overall, however, indicated that Lineage 4 isolates are frequent
throughout the world (Figure 7.14).
To investigate the evolution of MTB Lineage 4 in more detail, we focused on the
L4.5/“LAM” sublineage. A total of 150 LAM whole genome sequences revealed again
a genetically structured, but geographically less clearly separated population. Overall,
we did not observe LAM isolates phylogenetically clustering by continent, except for the
subgroup B1 (part of the RDRio group) that harboured exclusively isolates from sub-
saharan Africa. Such a grouping indicates a single introduction of an ancestral genotype
in Africa and a subsequent clonal expansion. Interestingly, the RDRio genotype was
otherwise described as a cosmopolitan genotype, with a predominance in Brazil (Dalla
Costa et al., 2013) and New York (Weisenberg et al., 2012), but is also known to have
caused cases of multi- and extensively drug resistant TB in South Africa in case of the
KwaZuluNatal genotype (KZN) (Pillay et al., 2007).
As expected, isolates from Europe were found in all subgroups of the LAM phylogeny,
consistent with a global dissemination from Europe. However, we note that also isolates
from other continents were found in all subgroups.
As a more powerful method, we used phylogenetic reconstruction of character states
(continent of origin) and inferred Europe as the most likely continent for the geographical
origin of the LAM-ancestor. When splitting Europe into Southern and Northern Europe,
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the signal disappeared and other continents were found as more likely ancestral origin
in the Bayesian approach. This might indicate that the spread of LAM strains was not
exclusively originating from Southern Europe, but also from other (coastal) regions of
North-Western Europe. The sample size of North-Western European isolates, however,
was low (n=14) and most of the isolates were from Switzerland, likely not representative
of North-Western European LAM isolates. Further studies are required to investigate the
diversity of LAM strains, historically as well as contemporary, in Europe. The presence
of LAM-related genotypes in Northern UK in the 13th to 14th centry AD was recently
shown (Muller et al., 2014). Also, reports of the genetically distinct LAM-RUS subfamily
in Eastern Europe, Russia and Central Asia in relevant frequencies today (Mokrousov
et al., 2014) indicate that the LAM sublineage has been present in North-Eastern Europe
and Central Asia for a long time.
Our data also showed that the genetic diversity of LAM strains is highest in Europe
and decreases with the distance from Europe, as would be expected if the LAM genotype
diversified for the longest time in Europe and was introduced to other continents going
through population bottlenecks. However, the weak signal for diversification by distance
stands in contrast with data for all seven main phylogenetic lineages, for which 77% of
genetic variation was explained by distance from the likely cradle of the MTBC, Ethiopia
(Comas et al., manuscript in preparation). Possibly, the L4.5/LAM genotype might
represent a “generalist” that has been distributed in the last centuries as an “emerging”
genotype, and as a consequence of globalization is found in a globally mixed population
today. We speculate that MTB Lineage 4 was transmitted globally by Europeans before
the “Beijing” genotype / MTB Lineage 2 spread with increasing migrations from Asia and
a selective advantage associated with drug resistance, and has now become an emerging
pathogen (Cowley et al., 2008). Interestingly, MDR-TB cases were recently found at
higher rates in both “LAM” and ‘Beijing” strains than in other strains (Mokrousov et al.,
2012).
We hypothesize that the massive historic and contemporary migrations to and from
Europe lead to a “cosmopolitan” population structure, and to MTB Lineage 4 strains also
transmitting “allopatrically” on all continents (if “sympatry” was interpreted as MTB Lin-
eage 4 strains infecting primarily Europeans and Americans). These migration patterns
will likely continue to impact the MTB population structure. Historic samples from old
strain collections, or ancient DNA, will allow inferring the historically prevalent genotypes
in different parts of the world.
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7.5.1. Limitations
We acknowledge that the definition of the term “sublineage” as well as the number of
sublineages is arbitrary to a certain extent. We chose a level of discrimination that resulted
in 10 sublineages, but could have defined only 5 sublineages by moving the dashed line
in Figure 7.2 towards the root of the tree. We selected the level to be most compatible
with existing genotyping schemes and known molecular markers. Therefore, sublineage
markers from other studies using LSPs or SNPs are covered by our definitions (Figure
7.5), except for the group defined by SNP 4314642G>A that defines SNP cluster groups
(SCG) 5 and 6.
A potential weakness of our study is the sample selection. We used, on the one hand,
convenience samples from different countries, that might not be representative for the
whole country. Additionally, particular countries were overrepresented (Figure 7.6). On
the other hand, many countries were not included in this study. Also, we used immigra-
tion collections from Switzerland and the US. Place of birth of TB patients has in several
studies proven to be a valid proxy for place of infection (Baker et al., 2004; Gagneux et al.,
2006b; Fenner et al., 2013), but we can not exclude that patients were infected with a
circulating strain of their country of immigration. To be as conservative as possible, we
excluded all strains previously identified as part of a transmission cluster from the LAM
analysis. Overall, we are confident that the signal that we observe for the MTB Lineage 4
strains population structure would rather become stronger with a population-based sam-
ple. Obtaining globally representative collections of MTB (Lineage 4) isolates from 100
countries, as in our study, would be very difficult, hence our approach. One region that
future studies should particularly seek strains from is the Eastern Mediterranean and
Central Asia, which were underrepresented in our collection. These regions could be key
to study the phylogeography of the sublineages absent from Europe and likely having
diverged from a MTB Lineage 4 ancestor in that region.
We used “country” as a geographical origin rather than geographical coordinates, which
means, in the case of large countries, we might have lost signal due to the prevalence of
different predominant genotypes in different regions (such as Southern versus Northern
Brazil). However, obtaining geographical coordinates was nearly impossible for the large
and diverse sample collection we used, and the more detailed geographical information
should rather increase the signal.
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Figure 7.15.: Our findings support a scenario in which the “LAM” family of MTB Lineage 4
was dispersed to other continents from Europe, most likely starting with the
age of discovery in the 15th century. At least two other sublineages, L4.3 and L4.10,
might have followed the same path. Numbers in grey boxes indicate the time of coalescence
of MTBC lineages as proposed by Comas et al. (2013).
7.5.2. Conclusions
With this study, we provide the first comprehensive MTB Lineage 4 classification scheme
based on a large collection of whole genome sequences. We recommend to consider the
full genetic diversity of MTB Lineage 4 and to apply robust markers for future studies.
Applying the sublineage-screening to a large clinical collection, our data shows that
strains of MTB Lineage 4 are globally present, but with varying proportions of the 10
sublineages between geographical regions. The phylogeographic structure and the ab-
sence of five sublineages from Europe indicate that the evolution of MTB Lineage 4 did
not follow a simple “out-of-Europe” scenario, but is more complex. A proposed scenario is
indicated in Figure 7.15. Several sublineages are restricted to Asian and African regions
and might represent “ancient” genotypes that emerged in the Eastern Mediterranean /
Central Asian region. Strikingly, the three sublineages observed as frequent in Europe
were also observed as globally frequent.
The most frequent MTB Lineage 4 sublineage, the L4.5/“LAM” family, was found to
be globally distributed and at a high proportion in many countries. The results of the
phylogenetic reconstruction, as well as the elevated genetic diversity in Europe, support
our initial hypothesis that the L4.5/“LAM” sublineage (potentially representative also for
L4.3 and L4.10) has expanded dramatically with human populations in Europe and was
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dispersed to other continents with European migrations. Further studies, including the
dating of the phylogeny, ideally with ancient DNA, are necessary to gain more detailed in-
sights in the evolution of the globally important MTB Lineage 4. Clearly, the designation
“Euro-American” should to be abandoned.
8. General discussion
The completed genome sequence of H37Rv in 1998 (Cole et al., 1998) has revolutionized
TB research. It was not until 2010, however, that 21 whole genome sequences and the
first WGS-based phylogeny of the MTBC lead to the appreciation of the extent of genetic
diversity of MTBC (Comas et al., 2010). Nearly 10,000 SNPs were discovered with these
21 genomes. In the last four years, more than 3,000 (draft) genome sequences have been
generated (Stucki et al., 2013). For the first time, we are now able to obtain complete
sets of phylogenetically informative, clade-specific SNPs from comprehensive WGS data.
With these molecular markers, we can screen large collections of MTBC isolates.
The aim of this study was to develop and apply combinations of SNP-screening and
targeted whole genome sequencing to delineate micro- and macroevolutionary events in
a transmission cluster and on the global diversity scale. We have successfully developed
two laboratory and one in silico SNP-typing assays. With these assays, we provide a
robust framework for MTBC strain classification. Using a combination of WGS and
SNP-genotyping, we were able track the transmission of a single genotype causing a TB
outbreak in Bern, Switzerland, over two decades. This was possible in a time and cost
frame that would not have been possible with classical genotyping assays. Expanding
our perspective from micro-evolution to macro-evolution, we were able to delineate the
historical origin and map the likely spread of MTB Lineage 4 from Europe to the rest
of the world. Both the characterization of a TB outbreak as well as the evolutionary
reconstruction of the particularly successful MTBC Lineage 4 highlight the potential that
the “era of genomics” can bring to TB research and control.
In this chapter, we summarize the main findings and discuss the future applicability of
WGS and SNP-typing in molecular epidemiology and TB research.
8.1. The role of SNP-typing and whole genome
sequencing
Obtaining genomic information has become a daily task in basic and clinical TB research.
In this study, we present different approaches to extract SNP data directly from DNA in
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the laboratory, and from WGS data. These approaches show the complementary nature
but also the rapid evolution of methods.
In 2010, when this study started, WGS was available only for selected isolates and
was still expensive. First studies using WGS for molecular epidemiological purposes were
just being published (Schürch et al., 2010; Gardy et al., 2011). Multiplexed, barcoded
libraries only became available during the course of the study, and sequencing prices de-
creased with the roll-out of new DNA sequencing devices. While SNP-genotyping had
been expected to be widely used, WGS has gained strong momentum and is now in reach
for routine application on complete MTBC collections. WGS will likely replace all other
genotyping methods in the future, as molecular epidemiological as well as drug resistance
and phylogenetic information can be easily extracted. This “ultimate barcode” of a clini-
cal isolate is of great value and will allow comparability and exchange across laboratories.
Nevertheless, the challenges of implementing cutting-edge technologies, particularly in
resource-limited settings, where control of TB is most urgent, should not be underesti-
mated. Until robust, Xpert-like devices become available (ideally battery-powered) that
can be operated by any lab personnel (Lawn et al., 2013), established genotyping methods
including SNP-typing will continue to play a major role. Furthermore, the data analy-
sis and storage capacities are often limited, meaning that useful information can not be
obtained quickly (although tools are now becoming available for simplified analysis, such
as the software KvarQ described in Chapter 5 of this thesis.) SNP-genotyping, on the
other hand, is - depending on the protocol - very robust, and can be implemented in any
laboratory that has access to a PCR machine (Hillemann et al., 2005).
Almost four years after the beginning of this PhD thesis, the price of WGS per MTBC
genome has massively decreased (http://www.genome.gov/images/content/cost_per_
megabase.jpg), and is now almost comparable to standard 24-loci MIRU-VNTR analysis
(MIRU commercially available for approximately EUR 50; MiSeq libary and sequencing
costs of around EUR 100). First public health authorities, particularly in the U.K., are
starting to implement WGS as a close-to-routine method (Walker et al., 2014). Despite
the great value added, targeted WGS with previous screening of informative SNPs can
be more cost-effective and faster, also in high-income countries. Likewise, in our last two
chapters, we show that SNP-typing and WGS are perfectly complementary.
8.2. Technical and analytical limitations of WGS
From a technical aspect, there are several limitations in our study. WGS of MTBC isolates
was performed with different generations of Illumina devices. We obtained sequencing
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read lengths of between 36 and 250 bp. This range of read length is in general too short
to extract repetitive regions such as the PE/PPE/PGRS genes or insertion sequences.
Therefore, we excluded approximately 10% of the genome, corresponding to potentially
10% of SNPs that remain undetected. Considering a potential excess of diversity in
these genes (Copin et al., 2014; McEvoy et al., 2012), the actual number of mutations
in these regions could be higher than expected. Ten percent of SNPs might be less
relevant for phylogenetic purposes such as the ones described in Chapter 7. But the
improved resolution by (potential) additional SNPs might allow discriminating the so
far indistinguishable 25% of the outbreak isolates described in Chapter 6. Furthermore,
longer sequencing reads would also allow the extraction of an in silico MIRU-VNTR
pattern with e.g. the KvarQ software, allowing the comparison with existing MIRU-VNTR
data and databases. A first approach of extracting MIRU-pattern has been made using
read depth and paired-end mapping (Ragheb et al., 2013), but needs further validation
for clinical isolates (an in vivo mutation model with MTBC Erdman strain was used in
that study). Longer reads might overcome the need for coverage-based MIRU-extraction,
but reads will need to be at least 500 bp long (each MIRU repeat unit is between 51
and 111 bp long (Supply et al., 2006)). Sequencing technologies achieving these lengths
are available, albeit not cost-effective for small prokaryotic genomes. On the other hand,
future sequencing platforms such as Nanopore sequencing promise to deliver longer reads
(Loman et al., 2012).
Another source of potentially missed diversity, i.e. molecular resolution, are insertions
and deletions (InDels). These were so far ignored due to technical difficulties in analysing
such genomic regions (Albers et al., 2011). Although 90% of the diversity in MTBC is
likely represented by SNPs (Comas et al., 2010), InDels are another important source of
genomic plasticity.
The third analytical difficulty are SNPs that had to be excluded due to “heterozygous”
SNP calls, i.e. positions with more than two alleles (e.g. reference and at least two alter-
native alleles). These calls can occur due to the presence of two or more alleles in the
genomic DNA (either a microevolutionary event or a “true” mixed infection with different
strains; sequencing errors or alleles occurring with a low frequency of only few reads are
ignored by the SNP-calling software). On the other hand, calls with ambiguous allele fre-
quencies (“AF1” field between 0 and 1 in the variant call format (VCF) file), were excluded
in our pipeline if a polymorphisms at that genomic position occurred only in one strain.
Again, this is likely negligible for phylogenetic purposes as described in Chapter 7, but
potentially harbouring additional information for transmission detection. In the “Bern
outbreak” dataset, one ambiguous position in one isolate was detected (as another isolate
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harboured the same mutation, otherwise it would have been missed) and confirmed by
subsequent Sanger sequencing to be an additional allele rather than a sequencing artefact.
These limitations also highlight the need for standardized and validated WGS data
analysis pipelines, as well as guidelines on how to generate WGS data. First guidelines
to ensure a high WGS data quality have been published by the Centre of Disease Control
(CDC) (Gargis et al., 2012), but these now need to be implemented. This is particularly
important with regards to future clinical assays using WGS, where software packages
and variant calling/filtering criteria must be clearly defined. Criteria to filter-out false-
positive SNP-calls lead to a trade-off between excluding a portion of true-positive calls (by
keeping only high-confidence calls) and keeping false-positive calls, and thresholds should
be validated before analysis. In the “Bern outbreak” dataset, 37 polymorphic positions
were excluded due to low quality or gaps, but these could potentially harbour additional
information. Manual confirmation of such positions as well as further research regarding
analysis software is therefore necessary.
An upcoming discussion for the near future will be the comparability of WGS data
between laboratories. How can a particular strain (e.g. the outbreak strain described
in Chapter 6 be identified by other researchers in their database (the key patient was
known to have travelled across Europe)? Current data compatibility would likely require
MIRU-VNTR or spoligotyping data, but WGS data as of today can often not easily
be reconciled. Recently, WGS-adapted multi-locus sequence typing schemes have been
developed for bacteria in general (Jolley et al., 2010; Jolley et al., 2012), and as a “core
genome multi-locus sequence type” (cgMLST) approach for MTBC (Kohl et al., 2014),
which extracts allelic information for 3,041 genes and transfers the SNP diversity into an
allele numbering system, which can easily be exchanged.
8.3. Future improvements of WGS
In addition to all analytical challenges, innovations are needed on the sequencing device
side, if WGS is to be used widely, particularly in countries with a large TB burden. On
the one hand, devices need to be smaller and more robust, thereby avoiding the need
for highly equipped laboratories and highly skilled personnel. The Nanopore sequencing
platform is a promising platform (Gut, 2013; Ying et al., 2013; Liang et al., 2014). On
the other hand, library preparation must be simplified (Tan et al., 2013), which could
be implemented in a lab-on-a-chip device (Sackmann et al., 2014). More down-to-earth,
a decrease in sequencing costs is still necessary. Indeed, sequencing prices for a mega-
basepair (Mbp) of (human) DNA have fallen to around 0.1 $ (around 1000 $ per human
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genome; http://www.genome.gov/images/content/cost_per_megabase.jpg), but due
to the large data redundancy and the low levels of multiplexing currently achieved for
bacteria, the corresponding costs for MTBC sequencing per Mbp are still orders of mag-
nitude higher. Only recently, smaller benchtop devices have become available that allow
more flexible and cost-effective sequencing of small genomes.
Last, for future studies it will be desirable to perform WGS directly from sputum
samples to investigate the within-host diversity, ideally in the form of single-cell sequencing
(Blainey, 2013; Gole et al., 2013; Lasken, 2012).
8.4. Micro-evolutionary aspects
The retrospective identification of a TB outbreak in a large, population-based study with
more than 1600 isolates collected over two decades was for the first time possible in such
a short time and at such a low cost (around 3 hours for 96 isolates; reagent costs of $ 4800
including the genome sequencing; Chapter 6). In the current era of transition between
classical genotyping methods and routine WGS, we have shown that a combination of
both (SNP-typing as the “classical method”) can be most appropriate and successfully
applied to identify outbreak isolates. Realizing that the outbreak continued to propagate
mainly in the same population of substance abusers and homeless, we emphasize the need
for continuous intervention in that population, particularly to identify the patients most
likely to cause secondary cases, i.e. the so-called “super spreaders”. In the Canton of
Bern, further outbreaks have been described already in 1993 (Genewein et al., 1993), but
never investigated. We note that the only study so far that has compared TB clusters
by WGS (Walker et al., 2013b) has identifified different topologies of genomic networks,
depending on the setting and the population. These varied from a star-like topology
in cluster 5 to a more linear topology in cluster 7. WGS of all clustered isolates in the
“Bernese outbreak” between 1991 and 2011 might reveal similar differences. By comparing
patient characteristics between genomic clusters of different topologies, the question could
be addressed if only social factors or also biological differences between MTBC strains
contribute to the different transmission patterns. From a public health perspective, the
topology could potentially inform public health staff where an targeted intervention is
most urgent, if e.g. if a “super spreader” can be identified in a star-like topology.
It is interesting to note that most of the previous reports studying TB outbreaks with
WGS have reported ”super-spreader” topologies (Roetzer et al., 2013) (Walker et al.,
2013b) (Gardy et al., 2011). Super-spreader behaviour has been identified by social con-
tact tracing (McElroy et al., 2003), but has not been possible with classical molecular
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epidemiological methods, urging for the need to implement prospective WGS-screening of
TB cases (Walker et al., 2013b).
Also, the described oubreak needs to be followed up, as new cases might still appear
many years later (the last case associated with the Bern outbreak described in Chapter
6 was identified in 2011). We hypothesized that the isolates post-dating 1998 resulted
from re-activation of infection during 1991 and 1995. Assuming that the 13 cases after
1998 (one child excluded) represent only the 10% of infected persons ever progressing
to active TB in their lifetime (Barry et al., 2009) (but potentially more in this highly
susceptible population), we would except a higher number of latently infected persons
in the population, and TB reactivation cases could potentially develop in the years to
come. From a research point of view, these re-activation cases might also be a unique
opportunity to study micro-evolutionary events in the dormant stage of MTBC. It has
recently been shown that MTBC mutation rates in latently infected macaques were com-
parable to MTBC during active disease (Ford et al., 2011), but no study was so far able
to investigate micro-evolutionary events in humans rather than in animal models.
Interestingly, looking at the “Bernese outbreak cluster” from a macro-evolutionary per-
spective, on a side note, the causative MTB strain belongs to the L4.6 sublineage of MTB
Lineage 4 (“S” spoligotype). In Chapter 7, this sublineage was observed mainly in patients
from Asian countries. An early transmission event from an Asian immigrant to the first
patient in the outbreak (pre-dating 1987) would explain the “allopatric” sublineage.
8.5. Macro-evolutionary aspects
Using a total of 239 whole genome sequences and SNP-genotyping data of 3,366 clinical
MTBC isolates, we showed for the first time that the previously called “Euro-American”
Lineage 4 is globally dispersed and more diverse than previously acknowledged, and that
the geographic origin of at least 3 sublineages with Lineage 4 was most likely Europe. In
a broader context, the distribution from Europe would be compatible with an origin of
MTBC in Africa (Wirth et al., 2008; Comas et al., 2013) and a subsequent migration via
Levant into Europe. The detailed migratory paths of humans and the MTBC to Europe,
however, are complex and need further investigation. Presumably, MTB Lineage 4 could
have paralleled the evolutionary pathway described for the Lineage 2 (“East Asian” lin-
eage, including the “Beijing” sublineage), with a population increase during the Neolithic
transition, which started around 10,000 years ago in Central China as well as in the Fertile
Crescent (Diamond et al., 2003).
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Despite the focus on the “Beijing” family and its association with drug resistance, HIV
co-infection and hypervirulence (e.g. De Beer et al., 2014; Duong et al., 2009; Fenner
et al., 2012a; Middelkoop et al., 2009; Klopper et al., 2013), future studies should also
explore the phenotypic characteristics of MTB Lineage 4 and its sublineages. This was
previously hindered by a confusion of genotyping families, which were based on suboptimal
markers. Indeed, with this study, we do not only provide an evolutionary scenario of MTB
Lineage 4, but also a robust classification scheme (including SNPs as ideal markers) for
unambiguous classification of MTB Lineage 4 isolates. An important study by Rindi et al.
(2012) had already shown that spoligotyping families are not always concordant with RD-
defined sublineages due to the large degree of homoplasy, and recommended therefore not
to use spoligotyping data for MTB Lineage 4 classifications. And although RD definitions
are phylogenetically robust, we have now shown that the RD-defined sublineages do not
represent the complete phylogenetic diversity of Lineage 4.
8.6. Evolutionary dating
For both micro- and macro-evolutionary aspects (Chapters 6 and 7), the dating of the
phylogeny might reveal the time of the coalescent points of subclusters and sublineages.
The feasibility of dating the origin of an outbreak has recently been shown using tip-
dates (isolation dates) (Roetzer et al., 2013). However, we would like to note that in the
“Bernese outbreak cluster” (chapter 6), the numbers of SNPs between isolates was very
low. Single SNPs might skew the estimated mutation rates significantly, and thus, the
complete within-patient diversity, as discussed above, needs to be taken into account. Fur-
thermore, culture-derived mutations also need to be excluded. Ideally, sequencing should
be applied to the bulk MTBC population isolated from the patient sputum sample.
Dating the MTB Lineage 4 phylogeny could be done with an estimated date of an
internal node, as recently shown with the complete MTBC phylogeny (Comas et al.,
2013) and the coalescent time of the human L3 mitochondrial haplogroup 70,000 years
ago. Three alternative dates were used and scenarios compared. The scenario of 70,000
years was consistent with an expansion of the effective population size during the Neolithic
transition starting 10,000 years ago. Such an approach might be difficult to apply to a
single MTBC lineage, as the time of emergence of MTB Lineage 4 might be more difficult
to link to a particular event in human evolutionary history. More promising would be
to use whole genome data from ancient DNA (aDNA). Two studies have reported WGS
data from MTBC aDNA recently, but both date back only to the late 19th century (St.
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George’s Church Crypt, England) and 1797 (Vàc, Hungary) (Bouwman et al., 2012; Chan
et al., 2013). Assuming 46,000 years since the emergence of MTB Lineage 4, 100 to 200
years will likely not lead to an accurate estimation of mutation rates. We are confident,
however, that in the future more studies using aDNA will reveal sequencing data from
older specimens. Clearly, the combination of WGS data from contemporary isolates with
data from historical isolates has a great potential to unravel the evolutionary history of
MTBC.
8.7. Public health relevance
With this study, we provide molecular markers and assays for the classification of MTBC
isolates. These low-cost assays can be implemented in any laboratory in high-burden
as well as low-burden TB settings to study phenotypic and epidemiological differences
between MTBC lineages and sublineages. Such studies can potentially reveal MTBC
strain differences that will be relevant for TB product design and treatment.
With KvarQ, we reduce the gap between the massive amounts of WGS data that are
being generated, and the lack of analysis capacity. This is today mainly of interest for
research applications, but if WGS becomes a routine “genotyping” method in the near
future, any lab personnel will be able to extract e.g. genotypic drug resistance information
with KvarQ.
WGS in general will likely change our understanding of TB transmission in general. Our
retrospective analysis of a TB outbreak in Switzerland has shown that an epidemiologically
suspected “super spreader” can be confirmed with WGS data. This was not possible
with previous genotyping methods. The identification of super-spreaders is most crucial
for public health responsibles in high-income countries, as these persons are potentially
causing a large number of clustered cases. Furthermore, if a “super spreader” person
shall be isolated (as a public health intervention), strong molecular evidence will help
supporting the action.
As long as routine WGS of all isolates is not practicable and not affordable, the SNP-
screening can inform public health staff which isolates should be subjected to WGS, as
shown in the case of an outbreak. Indeed, in most settings, routine (classical) molecular
typing of all MTBC isolates is not performed so far, and WGS will likely also not be an
option. There, epidemiologically suspected outbreaks could be tracked by an approach as
we have described it in Chapter 6.
The role of WGS in high-burden TB countries is so far unclear. On the one hand, the
costs of WGS are high, and the analytical capacities limited. On the other hand, it is also
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unclear if - with a higher force of infection - WGS will still provide enough discriminatory
power to resolve transmission chains. Studies are therefore needed to evaluate the benefit
of WGS in these countries, where the burden of TB is highest and most cases could be
prevented. In any case, only a selected number of isolates can probably be sequenced.
Our study contributes a SNP-screening approach to rationally narrow down the number
of isolates to be sequenced (e.g. only clusters), and that approach is equally suited for
high-burden as well as low-burden settings.
8.8. Conclusions
TB remains a major public health concern. The diversity of the pathogen and its diversity
is one aspect of TB control. The first part of this thesis has provided new markers and
tools for robust strain classification. SNP-typing allows low-cost genotypic classification
in virtually any laboratory and can nicely complement targeted WGS, which is so far only
available in high-income countries.
The second part of this thesis indicated the need for screening efforts and targeted
interventions for TB control in particular populations, as shown with the example of a
low TB-burden country such as Switzerland. The approach of combined SNP-screening
and WGS applied here can be implemented at larger scales to identify outbreaks in real-
time. Compared to classical molecular markers that suffered from a lack of discrimination
power, WGS was able to resolve a majority of isolates.
The third part of this thesis has found an “out-of-Europe” evolutionary scenario of
Lineage 4 of the MTBC. We found substantial genetic information within Lineage 4 and
also within one sublineage, the “LAM” family. However, Lineage 4 is only one lineage of
the MTBC, and the focus on other lineages might reveal similarly interesting evolutionary
pathways of this important pathogen.
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Table A.1.: SNP markers used to identify main MTBC phylogenetic lineages in KvarQ.
Phylogenetic Lineage Position
Genome
H37Rv
Ancestral
Allele
Mutant
Allele
Lineage 1 3920109 G T
Lineage 1 3597682 C T
Lineage 1 1590555 C T
Lineage 2 1834177 A C
Lineage 2 3304966 G A
Lineage 2 2711722 T G
Lineage 3 301341 C A
Lineage 3 4266647 A G
Lineage 3 157129 C T
Lineage 4 3326554 C A
Lineage 4 2154724 A C
Lineage 4 648856 C T
Lineage 5 1377185 C G
Lineage 5 801959 C T
Lineage 5 2859147 C T
Lineage 6 2427828 G C
Lineage 6 378404 G A
Lineage 6 4269522 G A
Lineage 7 14806 T C
Lineage 7 1663221 T G
Lineage 7 497126 G A
animal associated MTBC (M. bovis / M. caprae) 3480645 T G
animal associated MTBC (M. bovis / M. caprae) 1427476 C T
animal associated MTBC (M. bovis / M. caprae) 3624593 C T
“Beijing” sublineage of Lineage 2 2112832 A C
“Beijing” sublineage of Lineage 2 3587446 G A
“Beijing” sublineage of Lineage 2 1849051 C T
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A.2. Appendix to Chapter 6 (Transmission of MTBC in
an outbreak in Bern)
Supplementary Materials in the submission format (Supplementary Information, Supple-
mentary Tables and Supplementary Figures) is shown below.
Supplementary Information „Transmission of MTBC in an outbreak“ p. 1 
SUPPLEMENTARY INFORMATION 
 
MIRU-VNTR and Spoligotyping 
MIRU-VNTR analysis for 24 loci was performed according to standard protocols (Genoscreen, Lille, 
France). Spoligotyping patterns were obtained from WGS with SpolPred [1] and confirmed with bead-
based spoligotyping [2]. 
Sixty-four of 69 (92.8 %) isolates (68 single patient isolates plus the additional isolate of the key 
patient P006) were found identical by MIRU-VNTR pattern. Three isolates showed a double-band, 
which likely reflects technical issues, and two isolates had a different number of repeats at one locus 
each. 
Spoligotyping patterns were identical for all isolates except P073, for which two additional spacers 
were found absent. The “consensus” spoligotyping pattern was identified as “S” family, a sublineage of 
the Euro-American lineage of M. tuberculosis (Supplementary Table 3, see below). 
 
Excluded SNP calls 
Thirty-seven additional SNPs were excluded with gaps in more than three strains (i.e. no base call) or 
that had ambiguous SNP-calls, identified upon manual verification. 
 
Sequencing replicates 
As controls, we included four biological replicates for WGS (independent DNA extraction, sequencing 
library preparation and WGS) and did not detect any discrepant SNPs between replicates. To control 
for sequencing errors, we sequenced twice the same genomic library of three isolates and obtained 
identical SNP-calls.   
Supplementary Information „Transmission of MTBC in an outbreak“ p. 2 
Sanger sequencing for SNP confirmation 
To validate SNP-calls from WGS, we performed PCR and Sanger sequencing on a subset of 28 
mutations identified by WGS in the corresponding strain with the mutation identified by WGS. All WGS-
identified mutations were confirmed by Sanger sequencing. 
 
Drug resistance results  
We used the Bactec MGIT 960 system (Becton Dickinson Diagnostic Systems, Sparks, MD, USA) for 
semi-quantitative drug-susceptibility testing (DST) to first-line drugs as previously described [3]. No 
phenotypic drug resistance was detected in the 68 single patient isolates and the second isolate of the 
key patient P006 that were included in the genomic analyses. However, three additional isolates were 
available from recurrent tuberculosis episodes of patient P006, including the isolate P006C (“2R” in the 
original figure, isolated 1992, described as isoniazid mono-resistant in the article of Genewein et al. 
[4]), and the isolates P006D (patient “2”, isolated 1992, described as resistant to isoniazid and 
rifampicin), and P006E (isolated 1993, also resistant to isoniazid and rifampicin). For all isolates, we 
confirmed the resistance patterns described in 1993 [4]. Of note, despite the multiple tuberculosis 
episodes of the key patient over four years, none of the isolates with the evolved drug-resistant 
mutations was transmitted. 
We found mutations associated with resistance to isoniazid (katG S315N, 2155168CT), rifampicin 
(rpoB D435Y, 761109GT) and ethambutol (embB Q497P, 4248003AC) in the last two of the serial 
isolates of patient P006 (P006D and P006E) [5]. Phenotypic isoniazid mono-resistance was identified 
in the third isolate of patient P006 (P006C), as originally described by Genewein et al. [4]. The 
corresponding katG S315N mutation was only found in the DNA extracted from the DST culture 
directly, but not in the DNA extracted from the routine subculture and used for WGS. This indicates a 
mixed population of sensitive and resistant variants in the original isolate, and the selection for the 
resistant isolate in the DST.  
No other genotypic or phenotypic drug resistance was found in any other isolate. All drug 
resistance associated mutations were excluded for analyses of the genomic network. 
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